<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2026-02-16 09:43:59 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena L. Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature Medicine</td>
          <td>103</td>
          <td>48</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, Sara Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>5</td>
          <td>135</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Veres, Colin J. Chu, Anita Gola, R. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, J. Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>52</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="Sepsis is a life-threatening condition arising from a dysregulated host response to infection, characterized by a complex interplay between pro-inflammatory and anti-inflammatory immune mechanisms. B cells, that are key components of humoral immunity, are essential for antibody production, antigen presentation, and immune modulation. Sepsis is commonly associated with B cell lymphopenia, particularly in severe cases, as evidenced by a marked reduction in circulating B cells in both adult and pediatric patients. However, the mechanisms driving this depletion have not been completely understood, particularly in pediatric sepsis. In this study, we employed single-cell RNA sequencing (scRNA-seq) to profile peripheral blood leukocytes from pediatric patients with sepsis (three with mild and three with severe condition) alongside four healthy controls. Our analysis revealed a broad depletion of immune cells in sepsis, with B cells showing the most pronounced reduction and the strongest capacity to discriminate between mild and severe disease states. Subset-level analysis identified significant loss and transcriptional reprogramming of natural killer-like B cells (ΝΚΒ), MHC IIhighnaïve, and MHC IIlownaïve B cells in severe sepsis, accompanied by signatures indicative of intrinsic and extrinsic apoptosis, disrupted differentiation, and enhanced migratory potential. Importantly, we identified and validated the population of NKB cells in both pediatric and adult cohorts, broadening the known landscape of B cell phenotypes in human sepsis. We also explored intercellular communications, focusing on B cell-neutrophil interactions, given the notable neutrophilia observed, revealing potential crosstalk that may contribute to the overall immune dysregulation in sepsis. Collectively, these findings offer new insights into the cellular and molecular drivers of immune dysfunction in pediatric sepsis, shedding light on B cell depletion as a central feature of disease severity. This work lays the foundation for future diagnostic and therapeutic strategies targeting B cell-mediated immunity in septic children. The study was registered on ClinicalTrials.gov (NCT04103268), with registration date on 2019-09-23, before the first patient was enrolled.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bce54efd110fde03077139b1afa9c1f4e6856c6b" target='_blank'>
              Single-cell analysis of B cell dysregulation in pediatric sepsis stratified by disease severity
              </a>
            </td>
          <td>
            Fahd Alhamdan, Stefano Gianoli, Koichi Yuki, S. Koutsogiannaki
          </td>
          <td>2025-12-31</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/046a4759f61fd2ed00479ddd2426526fb3c7aa64" target='_blank'>
              Myeloid reprogramming by poly(I:C) recruits progenitor-exhausted CD8+ T cells and sensitizes rhabdoid tumors to PD-1 blockade
              </a>
            </td>
          <td>
            Valeria Manriquez, Sofia Cavada-Silva, Kévin Beccaria, L. L. Niborski, Amaury Leruste, W. Richer, Mathias Vandenbogaert, Zhi-Yan Han, C. Sedlik, Jordan Denizeau, Jeremy Mesple, Zoé Fusilier, L. Laëtitia Lesage, Jérémie Goldstein, Yohan Gerber-Ferder, Stéphanie Fitte-Duval, Federico Marziali, R. Mena-Osuna, Jimena Tosello-Boari, Rachida Bouarich-Bourimi, Maria Florencia Pacini, Y. Missolo-Koussou, Mylène Bohec, Sylvain Baulande, Philippe Benaroch, J. Helft, Hélène D Moreau, J. Waterfall, Franck Bourdeaut, Eliane Piaggio
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5984ff16cfe613f763f0430e61d72c3b4c0bbf01" target='_blank'>
              The breast tumor microenvironment exploits eosinophil plasticity to suppress their anti-tumor activity
              </a>
            </td>
          <td>
            Zofia Varyova, M. Pohin, Gracie J. Mead, Libby K. Jennings, Valeria da Costa, Sarah Spear, I. McNeish, A. Schwenzer, Adrian L. Harris, Audrey Gérard, Kim S. Midwood
          </td>
          <td>2026-01-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Background Resistance to immune checkpoint inhibitors represents a major therapeutic challenge, as less than 50% of patients with melanoma achieve long-term response to immune checkpoint inhibitor therapy. One mechanism of acquired resistance involves somatic mutations, such as loss of beta-2 microglobulin (B2m), that enable tumor cells to evade T cell-mediated killing. Methods This study used single-cell RNA-seq, flow cytometry, and ex vivo functional assays to characterize tumor-infiltrating immune cells in antigen presentation-deficient tumors. Tumor-bearing mice were treated with anti-PD-1 or CD40 agonist antibodies and cell depletion or cytokine blocking antibodies to define mechanisms of action. Analysis of published human RNA-seq datasets was performed to dissect the contributions of inflammatory monocytes to patient outcomes. Results We found an increase in immunosuppressive macrophages in B2m-null tumors. We hypothesized that repolarizing myeloid cells may restore control of tumor growth. Treatment with CD40 agonist antibody, which promotes differentiation of monocytes and macrophages towards a proinflammatory phenotype, reduced tumor growth and improved survival in B2m-null melanoma and colorectal cancer models. Unexpectedly, both CD8+ T cells and NK cells, but not CD4+ T cells, were required for the efficacy of CD40 agonist, even though CD8+ T cells cannot directly recognize antigen presentation-deficient tumor cells. Instead, these lymphocytes control tumor growth via secretion of IFNγ, as depletion of IFNγ inhibited the therapeutic effect of CD40 agonist. IFNγ receptor (Ifngr1) expression was required on host cells, not tumor cells, for CD40 agonist-mediated tumor control. Single-cell analysis identified a distinct population of inflammatory monocytes that were enriched for an IFNγ response signature in CD40 agonist-treated tumors, suggesting that these cells may be important for tumor control. Analysis of human bulk and single-cell RNA-seq datasets demonstrated that an inflammatory monocyte signature derived from our data was associated with improved patient outcomes and response to immune checkpoint inhibitors. Conclusions These data demonstrate that CD8+ T cells contribute to tumor control even in the absence of direct antigen presentation by tumor cells. More broadly, our work suggests that strategies to activate the effector functions of inflammatory monocytes may limit tumor growth and overcome acquired resistance to immune checkpoint inhibitors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/79afd1aea19402a4b7a5a69392d7d65d05f5b091" target='_blank'>
              Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 Immunotherapy
              </a>
            </td>
          <td>
            Matthew P. Zimmerman, Amy C Huang, Emily K Cox, Rose Al Abosy, Wan Lin Chong, Alexander G Bastian, Katherine J. Vietor, Yacine Choutri, Jenna L Collier, Vasyl Zhabotynsky, Haiyang Wang, Megan E Fung, Sarah A. Weiss, Emily J. Robitschek, Jia-Ren Lin, Tuulia Vallius, Shishir M. Pant, P. Sorger, Willy Hugo, Debattama R. Sen, W. Haining, Arlene H. Sharpe, Brian C. Miller
          </td>
          <td>2026-02-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Triple-negative breast cancer (TNBC) has high rates of recurrence despite chemotherapy and immune checkpoint blockade (ICB). Tumor-associated macrophages (TAMs) can either suppress or support anti-tumor immunity, but the mechanisms governing these states and therapeutic targets remain unclear. Here, integrating public scRNAseq datasets with TNBC cohorts, we identify a prognostic myeloid signature defined by CXCL9hi/C1Qlow TAM programs, associated with improved survival and increased lymphocyte activation pathways. Using immunocompetent p53-null syngeneic TNBC models spanning basal-like (2153L) and claudin-low (T12) subtypes, we show that immunomodulatory cyclophosphamide (CTX) reprograms hematopoiesis toward the monocytic lineage and induces an interferon (IFN) conditioned tumor milieu that supports CXCL9⁺ monocyte-derived macrophages (Mo.Macs) in basal-like disease. Combining CTX with the next generation MERTK-selective inhibitor UNC2371 (MRX-2843) drives complete remissions in both models, but durable long-term responses occurred selectively in the basal-like subtype model. The expansion of antigen-presenting CXCL9⁺ Mo.Macs and reduction of C1q⁺ phagocytic TAMs are observed in responding tumors. Mechanistically, MERTK inhibition relieves MAPK/SOCS1 mediated restraint of IFN signaling driving a positive feedback loop of IRF7/STAT1/IRF1 driven CXCL9 induction. Functionally, tumor control requires CXCL9-CXCR3 dependent CD4⁺ T cell recruitment, accumulation of stem-like memory CD4⁺ T cells, and germinal center like immune organization in tumor-draining lymph nodes. PD-1 blockade further increases durability, preventing recurrence in most treated basal-like tumors. Together, these findings define an IFN licensed, MERTK regulated myeloid checkpoint that can be therapeutically targeted to convert suppressive TNBC microenvironments into durable adaptive immunity, supporting clinical translation of CTX + MRX-2843 based combinations in basal-like TNBC. Significance Suppressive myeloid programing limits effective adaptive immune engagement in TNBC usually resulting in ICB treatment resistance and tumor recurrence. This study identifies a therapeutically actionable myeloid interferon checkpoint in which MERTK inhibition stabilizes CXCL9⁺ monocyte-macrophage programming to promote CD4⁺ T cell dependent immune memory and durable tumor control in basal-like TNBC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0786ff42326517ac1785fc16c7607185faf2d978" target='_blank'>
              MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancer
              </a>
            </td>
          <td>
            Alex J. Smith, Zachary Schrank, Nan Guan, Diego A. Pedroza, Sebastian J. Calderon, Xueying Yuan, Na Zhao, Zoe Gabriel, Yang Gao, C. Rivas, Fengshuo Liu, J. Serody, C. Perou, H. Earp, Jeffrey M. Rosen, Carolina-Chapel Hill. C.M.P
          </td>
          <td>2026-02-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>65</td>
        </tr>

        <tr id="Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4⁺ T-cells, and CD8⁺ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads. Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS–ICOSL pathway, and are enriched for ICOS⁺ Th1-like CD4⁺ T cells and ICOSLhigh cDC1s. CD8⁺ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon-γ–responsive program that sustains CD8⁺ T-cell function and prevents dysfunction. Functionally, ICOSL⁺ cDC1s are required for tumor eradication in vivo. In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c6a060eabfcbbb0a36b483e2912054f711b0272" target='_blank'>
              Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
              </a>
            </td>
          <td>
            Mehdi Chaib, M. Aminu, Shelley M Herbrich, Mahshid Arabi, Yue Xuan, Akshay V. Basi, Anna Casasent, Marc D. Macaluso, Kenneth H. Hu, Matthew M. Gubin, Xi Chen, James J. Mancuso, Sreyashi Basu, Sonali Jindal, Jared K. Burks, S. Watowich, Jia Wu, James P. Allison, Padmanee Sharma
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>58</td>
        </tr>

        <tr id="Glioblastoma (GBM), the most frequent and aggressive primary brain tumor, remains refractory to all current therapies including surgical resection, chemotherapy, radiotherapy and immunotherapy. Immunosuppressive mechanisms in the GBM tumor microenvironment contribute to the lack of anti-tumor adaptive immunity. We found that a subset of tumor associated macrophages (TAMs) can be repolarized into an anti-tumor phenotype via agonist stimulation of the retinoic acid-inducible gene I (RIGI), a cytosolic double-stranded RNA pattern recognition receptor (PRR). In silico analysis of adult GBM datasets available in the public domain revealed that RIGI expression by a subset of activated TAMs positively correlated with patient survival. Studies in syngeneic mouse models of GBM showed that intratumoral delivery of stem-loop RNA 14 (SLR14), a RIG-I agonist, improved the efficacy of chemotherapy, radiotherapy and immunotherapy treatments, beyond the effects of other nuclei acid sensor agonists. We found that RIGI+ macrophages are the main drivers of SLR14 effect, combining activation of TAMs and priming of functional cytotoxic CD8+ T lymphocytes and NK cells. The anti-GBM effect of SLR14 is opening a significant new avenue for adult GBM treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1342f808c2fd345588c30c0266370e6a04636995" target='_blank'>
              RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastoma
              </a>
            </td>
          <td>
            Han Xu, Sungwoon Lee, Felipe Leser, Olga Fedorova, Peiwen Lu, Eric Song, Mehdi Touat, Anne Eichmann, Akiko Iwasaki, A. Pyle, Jean-Leon Thomas
          </td>
          <td>2026-01-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Improving responses to cancer immunotherapies requires deeper insight into the cellular mechanisms governing T cell-mediated anti-tumor immunity. TMEM33 is an endoplasmic reticulum-resident transmembrane protein enriched across multiple tumor types, with reported functions in anti-viral immunity as well as calcium and lipid homeostasis, yet its role in tumor immunosurveillance remains unknown. Using murine genetic models, we demonstrate that host TMEM33 constrains anti-tumor CD8+ T cell responses. Constitutive Tmem33-/- mice exhibited delayed melanoma tumor growth and increased CD8+ T cell infiltration. Antigen-specific CD8+ compartments in tumors of Tmem33-/- mice showed TCF-1+PD-1+ progenitor-exhausted cell (Tpex) enrichment, elevated effector function and reduced exhaustion, alongside improved effector memory expansion and T-bet expression in draining lymph nodes. We highlight that TMEM33 functions intrinsically within the T cell compartment, as TMEM33 deletion (1) enhanced polyclonal activation of naive CD8+ T cells ex vivo, (2) promoted preferential Tpex accumulation among adoptively transferred naive OT-I cells in B16F10-OVA tumors and draining lymph nodes, and (3) improved the potency of ex vivo-expanded OT-I cells in controlling tumor growth during adoptive cell therapy. Finally, in a large, prospectively recruited metastatic melanoma cohort, lower TMEM33 expression in patient CD8+ T cells significantly correlated with improved survival and elevated TCF-7 (encoding TCF-1). Collectively, our findings define TMEM33 as a formerly unrecognized intrinsic determinant of tumor-directed CD8+ T cell fate that limits Tpex maintenance, and restrains cell therapy responses, suggesting that its modulation may strengthen immunotherapeutic efficacy. One sentence summary TMEM33 intrinsically limits progenitor exhausted CD8+ T cells, scales anti-tumor responses and predicts melanoma patient survival.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b5c85fa3ccdffaf374a3f09dd7d217b43c30d4c" target='_blank'>
              TMEM33 deletion potentiates anti-tumor CD8+ T cell immunity
              </a>
            </td>
          <td>
            M. T. Jackson, Tianming Zhao, G. Milotay, I. Pedroza-Pacheco, Yanshu Cai, Claire Willis, S. Phyu, Bruno Beernaert, Jamie TW Kwon, Hala Estephan, Vinnycius Pereira Almeida, Maria Aggelakopoulou, Silvia Panetti, Christian Zierhut, Tim Elliott, Eleni Adamopoulou, J. Rehwinkel, Malcolm JW Sim, Amit Grover, Dmitry I. Gabrilovich, Benjamin P. Fairfax, E. Honoré, D. Withers, John C. Christianson, Eileen E. Parkes
          </td>
          <td>2026-01-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c11565e00df96d730b6130fa5ba4b31516b47635" target='_blank'>
              PI3Kδ promotes T cell effector differentiation and plasticity during chronic infection
              </a>
            </td>
          <td>
            Andrea C. Pichler, J. Cannons, Dominic P. Golec, Julie M. Reilley, Dan Corral, Eduard Ansaldo, Qin Xu, Subrata Paul, Paul Schaughency, Francisco A. Otaizo-Carrasquero, Stacie M. Anderson, Anshu Deewan, Dorian B. McGavern, Pamela L. Schwartzberg
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="Multiple myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence and/or treatment sensitivity remains unclear. We developed an Immune Atlas of MM by generating profiles of 1,397,272 single cells from the bone marrow (BM) of 337 newly diagnosed participants and characterized immune and hematopoietic cell populations. Cytogenetic risk-based analysis revealed heterogeneous associations with T cells of BM, with 17p13 deletion showing distinct enrichment of a type 1 interferon signature. The disease progression-based analysis revealed the presence of a proinflammatory immune senescence-associated secretory phenotype in rapidly progressing participants. Furthermore, signaling analyses suggested active intercellular communication involving a proliferation-inducing ligand and B cell maturation antigen, potentially promoting tumor growth and survival. Lastly, using independent discovery and validation cohorts, we demonstrated that integrating immune cell signatures with known tumor cytogenetics and individual characteristics significantly improves stratification for the prediction of survival. Pilcher et al. present a single-cell transcriptomics-based immune atlas of participants with newly diagnosed multiple myeloma, reporting on the association of cell types, gene expression and intercellular interactions with disease progression phenotypes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6f88dd8011aa8686433c4d02b3a0e4dfd59a9255" target='_blank'>
              A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
              </a>
            </td>
          <td>
            William C. Pilcher, Lijun Yao, Edgar Gonzalez-Kozlova, Yered H. Pita-Juárez, Dimitra Karagkouni, Chaitanya R. Acharya, Marina E. Michaud, Mark Hamilton, Shivani Nanda, Yizhe Song, Kazuhito Sato, Julia Wang, Sarthak Satpathy, Yuling Ma, Jessica Schulman, D. D’souza, R. Jayasinghe, Denis J Ohlstrom, Katherine E. Ferguson, Giulia Cheloni, Mojtaba Bakhtiari, Nick Pabustan, K. Nie, J. Foltz, Isabella Saldarriaga, Rania Alaaeldin, Eva Lepisto, Rachel Chen, M. Fiala, Beena E. Thomas, April Cook, Junia Vieira Dos Santos, Chiang I-ling, Igor Figueiredo, J. Fortier, Michael Slade, Stephen T. Oh, Michael P. Rettig, Emilie I. Anderson, Ying Li, Surendra Dasari, Michael A. Strausbauch, Vernadette A. Simon, , I-ling Chiang, N. Kalavros, Jennifer Rogers, T. Dawson, Brian H. Lee, G. Kelly, Laura A Walker, Nicolas F. Fernandez, John Leech, Jarod Morgenroth-Rebin, K. Angeliadis, Matthew A. Wyczalkowski, Song Cao, Omar Ibrahim, Roderick Lin, T. Fehniger, Andrew J. Houston, E. Radkevich, Adeeb Rahman, Zhihong Chen, A. Laganà, John F. DiPersio, J. Rosenblatt, S. Kim-Schulze, S. Lonial, Shaji K. Kumar, Swati S. Bhasin, T. Kourelis, M. Dhodapkar, Ravi Vij, D. Avigan, H. Cho, George Mulligan, Li Ding, Sacha Gnjatic, Ioannis S. Vlachos, Manoj K. Bhasin
          </td>
          <td>2026-01-01</td>
          <td>Nature Cancer</td>
          <td>0</td>
          <td>112</td>
        </tr>

        <tr id="Natural killer (NK) cells are integral to the innate immune system, playing a crucial role in immune surveillance and the rapid response to virally infected and tumor cells. Epigenetic gene expression regulation significantly influences NK cell function and differentiation. Using a high-throughput small-molecule drug screening approach, we identified bromodomain and extra-terminal domain (BET) inhibitors (BETi) as potent modulators of NK cell function, reducing proinflammatory cytokine secretion while increasing markers of NK cell maturation and cytotoxicity. During NK lineage specification from hematopoietic stem cells, we demonstrated that BETi reduced NK cell fate and promoted increased myeloid cell differentiation. Moreover, differentiated NK cell types had more functionally differentiated gene expression programs. Thus, BET proteins are crucial for both mature NK cell functions and controlling NK cell lineage development from progenitors in the bone marrow. These findings suggest that BETi can fine-tune NK cell responses, offering promising therapeutic potential for cancer immunotherapy and the treatment of inflammatory and autoimmune diseases. Our study underscores the critical role of BET inhibitors in regulating NK cell function and opens new avenues for targeted immune modulation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e1b914c2c6315017334ad728068ea592de3c5137" target='_blank'>
              Bromodomain and extra-terminal protein inhibitors modulate natural killer cell function and differentiation
              </a>
            </td>
          <td>
            Eric S. Geanes, Gage Greening, Maria Aggelakopoulou, Linh-Huyen Truong, Santosh Khanal, C. LeMaster, Marc Herman, Rebecca McLennan, P. Borrow, Todd Bradley
          </td>
          <td>2026-01-03</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>72</td>
        </tr>

        <tr id="Abstract Introduction Mismatch repair-deficient (dMMR) colorectal cancers (CRCs) exhibit variable clinical responses to immune checkpoint inhibitors (ICIs) despite their high immunogenicity. Methods To investigate the molecular and spatial determinants of this heterogeneity, we analyzed five metastatic sites (colon, liver, peritoneum, left ovary, and right ovary) from a dMMR CRC patient treated with pembrolizumab using bulk and single-cell RNA sequencing combined with multiplex immunohistochemistry. Results Responsive lesions were characterized by enriched cytotoxic and interferon-γ signatures, greater CD8+ T-cell infiltration, and close spatial proximity between programmed death-ligand 1(PD-L1)+ tumor cells and M1-like macrophages. In contrast, resistant lesions demonstrated reduced effector cell presence and were enriched in immunosuppressive programs, including SPP1+ and CD163+ macrophages, noncanonical WNT5A/B signaling, and TGF-β–mediated matrix remodeling. Conclusion Collectively, these findings highlight the importance of spatial immune architecture and macrophage polarization in shaping ICI responses in dMMR CRC and underscore the need for spatial profiling to guide immunotherapy strategies in metastatic disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e7dee5edb3a5c46063fed969eabd6424ae6c3c71" target='_blank'>
              Comprehensive spatial and immune profiling of metastatic mismatch repair–deficient colorectal cancer reveals response to immunotherapy
              </a>
            </td>
          <td>
            Ilkyu Park, Hari Kang, Se-Hee Kim, YunJae Jung, Won-Suk Lee
          </td>
          <td>2026-01-09</td>
          <td>Immunotherapy Advances</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Dogs play a major role in sustaining transmission of Leishmania infantum to people, thus prevention and treatment of canine leishmaniosis (CanL) to reduce transmission represents an unmet public health need. Although advances have been made in understanding how immunopathology correlates to infectiousness as CanL progresses, the immune mechanisms underlying transition between disease stages and terminal decline remain ill-defined. To address this knowledge gap, we generated a comprehensive atlas of peripheral immune cells from control dogs and naturally-infected dogs using single-cell RNA sequencing. The LeishDog Atlas captures the cellular and transcriptional complexity underlying CanL, tracing shifts in immune composition and gene expression across progressive, well-defined disease stages. Notably, we identified distinct myeloid, CD4+ and CD8+ T cell phenotypes and transcriptional states associated with disease progression. This resource provides a valuable framework for understanding systemic immune dysregulation in CanL, including determinants of T cell exhaustion and myeloid cell activation, and establishes a foundation for comparative, translational, and mechanistic studies of CanL immunopathology and transmissibility.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8412687f28e64e4d6b2558529c494e2ee4440eca" target='_blank'>
              A single-cell transcriptomic atlas of peripheral blood immune cells spanning progressive canine leishmaniosis
              </a>
            </td>
          <td>
            Danielle P. Uhl, Daniel J. Holbrook, Max C Waugh, S. Dey, Najmeeyah Brown, Karen I. Cyndari, Jacob J. Oleson, Paul M. Kaye, Christine A. Petersen
          </td>
          <td>2025-12-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Glioblastoma (GBM) is a highly lethal brain tumor with limited treatment options and resistance to immune checkpoint inhibitors due to its immunosuppressive tumor microenvironment (TME). Here, we identify OLIG2 as a key regulator of immune evasion in GBM stem-like cells, inhibiting CD8+ T cell-dependent antitumor immunity, while promoting pro-tumor macrophages polarization. Mechanistically, OLIG2 recruits HDAC7 to repress CXCL10 transcription, inducing STAT3 activation in tumor-associated macrophages (TAMs) and decreasing CD8+ T cell infiltration and activation. Genetic deletion of OLIG2 significantly increases CXCL10 secretion, shifting TAMs toward an anti-tumor phenotype and enhancing CD8+ T cell activities. Furthermore, upregulated OLIG2 expression is correlated to resistance to immune checkpoint inhibitors (ICIs) in GBM patients. OLIG2 inhibition by either genetic deficiency or pharmacological targeting with CT-179 sensitizes GBM tumors to anti-PD-L1 therapy, enhancing antitumor immune responses and prolonging survival. Our findings reveal OLIG2+ glioma stem-like cells as critical mediators of immune evasion and identify the OLIG2/HDAC7/CXCL10 axis as a potential therapeutic target to enhance immune checkpoint inhibitors efficacy and to improve immunotherapy outcomes in aggressive GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aff43cea879c5dd8f3d291281826afe6d22909b7" target='_blank'>
              Oligodendrocyte transcription factor 2 orchestrates glioblastoma immune evasion by suppressing CXCL10 and CD8+ T cell activation.
              </a>
            </td>
          <td>
            Xinchun Zhang, Jinjiang Xue, Cunyan Zhao, Chenqiuyue Zeng, Jiacheng Zhong, Gangfeng Yu, Xi Yang, Yao Ling, Dazhen Li, Jiaxiao Yang, Yun Xiu, Hongda Li, Shiyuan Hong, Liangjun Qiao, Song Chen, Q. R. Lu, Yaqi Deng, Zhaohua Tang, Fanghui Lu
          </td>
          <td>2026-01-27</td>
          <td>The Journal of clinical investigation</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/59359ad678fb5970076eddf100c364fea7a28f75" target='_blank'>
              Adrenergic signaling induces a pro-tumorigenic B cell state in colorectal cancer
              </a>
            </td>
          <td>
            Meike S. Thijssen, Simone L. Schonkeren, Linde Coolkens, Yuchi Zou, Lieve Temmerman, Joëlle de Vaan, M. Idris, Jorunn Vrancken, Kim Wouters, Nathalie Vaes, Marion J. Gijbels, Sharon Scardellato, Erwin Wijnands, Willine J. van de Wetering, F. Verhaegen, L. J. Dubois, Erik Biessen, Carmen López Iglesias, Kim M Smits, A. Bardelli, Stefano Casola, W. Boesmans, V. Melotte
          </td>
          <td>2026-01-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Xenotransplantation of gene-edited pig kidneys offers a promising solution to the shortage of kidneys for organ transplantation. We recently performed a gene-edited pig kidney transplantation into a living human recipient with end-stage kidney disease. Here, using transcriptomics, proteomics, metabolomics and multiplexed imaging, we conducted high-dimensional immune profiling in this individual. Despite profound depletion of circulating T cells, early T cell-mediated rejection occurred within 1 week after transplantation, likely driven by subtherapeutic immunosuppression and the presence of residual CD8+ T cells in lymph nodes. This T cell-mediated rejection event was reversed by intensified immunosuppression. After treatment, adaptive immunity remained suppressed, whereas innate immune activation, characterized by sustained monocyte and macrophage activity along with elevated levels of interleukin-1 beta and granulocyte–macrophage colony-stimulating factor, persisted. Comparative transcriptomic analysis showed that xenograft rejection profiles resembled those typically observed in human allograft rejection, while also revealing unique innate immune signatures. We did not detect antibody-mediated rejection. The levels of circulating pig donor-derived cell-free DNA rose during the initial rejection episode and declined with treatment, supporting the potential of cell-free DNA measurements as a noninvasive biomarker of xenograft rejection. These findings define the distinct immune landscape of kidney xenotransplantation and highlight the need for regimens targeting both innate and adaptive immunity to improve outcomes. High-dimensional immune profiling of a living recipient of a pig-to-human xenotransplant provides insight into the immune landscape of xenotransplantation and directions for improved immunosuppression strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4d98f157c93f6286ac76303fb8e8b35d2f6f44e7" target='_blank'>
              Immune profiling in a living human recipient of a gene-edited pig kidney
              </a>
            </td>
          <td>
            Guilherme T. Ribas, André F. Cunha, Jonathan P Avila, A. Giarraputo, Leela Morena, Karina Lima, R. B. Gassen, Jia-Yun Chen, Jia-Ren Lin, Sandro Santagata, Claire T Avillach, B. Ryback, Martin S Lindner, S. Bercovici, Ivy A. Rosales, Tatsuo Kawai, H. Nakaya, Robert B Colvin, Thiago J. Borges, Leonardo V. Riella
          </td>
          <td>2026-01-01</td>
          <td>Nature Medicine</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of B-cell malignancies, but its success in acute myeloid leukemia (AML) remains limited. Durable responses depend on the formation of long-lived memory T cells, whereas T cell exhaustion contributes to non-response and relapse. In patients with AML who achieved remission after cord blood transplantation, we here first observe enrichment of memory T cells with high expression of the chemokine receptor CXCR4. Next, we show that engineering CAR-T cells to co-express CXCR4 enhances their persistence and anti-leukemic activity in patient-derived xenograft models. Using single-cell profiling and metabolic analysis, we find that CXCR4 promotes memory-associated transcriptional programs, reduces exhaustion, and supports oxidative metabolism. These effects are observed with CAR-T cells targeting CD25 or CD96 as AML-associated targets. Our results indicate that CXCR4 strengthens CAR-T cell memory and durability, offering a strategy to improve immunotherapy outcomes in AML and beyond. CAR-T cell efficacy is often limited by the inability to maintain a memory T cell program. Here, the authors show that intrinsic CXCR4 expression enhances CAR-T cell persistence and memory differentiation in acute myeloid leukemia.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d2a1a8fac6df24e06173a348494a1e7d9ae0ffe6" target='_blank'>
              CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting
              </a>
            </td>
          <td>
            Ari Itoh-Nakadai, Minggao Liang, Michiho Shindo, Chen Bibi, Mariko Tomizawa-Murasawa, Saera Fujiki, Akiko Kaneko, Emi Kanamaru, Mari Hashimoto, Hiroshi Kajita, Yoshinari Ando, Miki Kojima, Jonathan Moody, Makoto Iwasaki, S. Takagi, Ryo Nakagawa, Saumya Agrawal, Hanae Amitani-Iijima, Kaori Sato, Yuriko Sorimachi, Nahoko Suzuki, Takehiro Fukami, Kazuharu Hanada, Satoshi Morita, Kazushige Katsura, Takehisa Matsumoto, Maiko Kobayashi, Masahiko Kato, Yasuyuki Negishi, Mikako Shirouzu, Y. Najima, K. Takubo, C. Hon, N. Uchida, Shuichi Taniguchi, Y. Momozawa, P. Carninci, Leonard D. Shultz, Yoriko Saito, Michiel J. L. de Hoon, Jay W. Shin, Fumihiko Ishikawa
          </td>
          <td>2026-01-26</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b9e77e33cbcc04a9a109c08426224fcfb14cc985" target='_blank'>
              Hallmarks of adaptive immunity in a metastatic clear cell renal cell carcinoma (ccRCC) long-term elite survivor
              </a>
            </td>
          <td>
            Felicia Tucci, Edward Drydale, James Bancroft, Sakina Amin, Jane Pernes, Giulia Gardumi, Tinashe Kanyowa, Maria Lima, Nadia Nasreddin, Olivia Lombardi, Simon J. Leedham, A. Rendek, Lisa Browning, Emmanuel Bugarin Estrada, Ruddy Montandon, Santiago Revale, H. Slawinski, David Mole, Andy Protheroe, Shivan Sivakumar, R. Bashford-Rogers
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c9ae85bd79cada9f97140c874baf065a8524c49a" target='_blank'>
              NF1 Loss Remodels Tumor Niches for Immune Evasion
              </a>
            </td>
          <td>
            Milad Ibrahim, Irineu Illa-Bochaca, Tara Muijlwijk, Ines Delclaux, K. S. Ventre, G. Jour, Paola Angulo Salgado, Shi Qiu, Agrima Dutt, Amanda W. Lund, Iman Osman, Markus Schober
          </td>
          <td>2026-01-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Hematopoietic bone marrow progenitors are increasingly implicated as an origin of immunosuppression in cancer. We have previously shown that trained immunity induction using nanomedicine potentiates checkpoint blockade therapy. Here, we studied how this approach’s induction of trained immunity systemically overcomes the immunosuppressive tumor microenvironment. We found changes in the tumor microenvironment to mirror functional changes in the hematopoietic system in a melanoma mouse model. Single cell sequencing methods disclosed a shift in the tumor-associated macrophage population from immunosuppressive to antitumorigenic. Uniquely, a trained immunity and checkpoint blockade combination therapy mobilized natural killer cells which, in conjunction with the functional changes in the myeloid cell compartment, effectively activated T cells. Last, we established the effectiveness of our approach in mouse models of breast, lung, and pancreatic cancer. Collectively, our data show that the systemic induction of trained immunity rebalances the immune system for effective checkpoint blockade therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/779280ac3e11ac6a4d5d5956af8561bae6f79622" target='_blank'>
              Systemically inducing trained immunity overcomes solid tumors’ immunosuppressive microenvironment
              </a>
            </td>
          <td>
            Bram Priem, Lisa Willemsen, Tom Anbergen, Yuri van Elsas, Jeroen Deckers, David P. Schrijver, Stijn R. J. Hofstraat, Iris V. Messing, J. Munitz, Dionne Honing, Geoffrey Prévot, Yohana C. Toner, Judit Morla, William Wang, A. Ranzenigo, Isabella Sirchia, T. Post, Raphaël Duivenvoorden, E. Kluza, G. Cremers, J. Kreijtz, C. Pérez-Medina, M. V. van Leent, Abraham J. P. Teunissen, Roy van der Meel, Yi Zhou, C. Glass, J. Ochando, L. A. Joosten, Z. Fayad, R. Netea-Maier, M. Netea, M. D. de Winther, Thijs J. Beldman, A. Griffioen, Willem J. M. Mulder
          </td>
          <td>2026-01-01</td>
          <td>Science Advances</td>
          <td>0</td>
          <td>126</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3db36268a555fc7a6dc2e97243ae5ab64bd0ba57" target='_blank'>
              A macrophage-derived noncanonical WNT niche drives immune exclusion in pancreatic cancer
              </a>
            </td>
          <td>
            Na Hyun Kim, Youngmin Song, San Sung Kwon, Sang Hyub Lee, Eun Na Kim, Jung Joo Hong, Seung Hyeok Seok, Yi Rang Na
          </td>
          <td>2026-02-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background Elevated levels of SPP1+ tumor-associated macrophages (TAMs) are associated with reduced CD8+ T cell infiltration and poorer prognosis in cancer patients, but direct evidence demonstrating a causal role for SPP1+ TAMs in excluding CD8+ T cells is still missing. The precise mechanisms by which SPP1-activated signaling pathways and macrophage-derived factors regulate CD8+ T cell trafficking remain poorly understood. Methods We established multiple tumor mouse models to study the function of macrophage SPP1 in the tumor environment, especially its role in the relationship between macrophages and CD8 T cells. We combined the single-cell (sc) RNA sequencing data of clinical tumor samples and tumor tissues from Spp1fl/fl-Lyz2-Cre mice to identify the differences in SPP1-related genes and found that SPP1 could regulate the expression of CXCL9 and CXCL10 in macrophages. Through Western blotting, immunofluorescence staining, and flow cytometry analyses, we elucidated the mechanistic basis by which macrophage-specific SPP1 deficiency suppressed tumorigenesis. Results This study demonstrated that macrophage-derived SPP1 played a crucial role in suppressing CD8 T cell infiltration, promoting tumor progression, and diminishing the effectiveness of immune checkpoint inhibitor (ICI) therapy. Sc-RNA sequencing analysis revealed a marked increase in CD8 T cell populations within tumor tissues of Spp1fl/fl-Lyz2-Cre mice. Furthermore, a negative correlation was observed between CD8 T cells and SPP1 macrophages in human colorectal cancer specimens. Genetic deletion of SPP1 in macrophages markedly enhanced tumor growth suppression in a manner dependent on CD8 T cell-mediated immunity. Mechanistically, SPP1 deficiency in macrophages led to elevated mitochondrial reactive oxygen species (ROS) production, resulting in the accumulation of cytosolic double-stranded DNA (dsDNA) fragments. This accumulated dsDNA activated the cGAS-STING pathway, leading to subsequent STAT1 phosphorylation. The enhanced STAT1 activity upregulated the expression of chemokines CXCL9 and CXCL10, thereby facilitating CD8 T cell recruitment into the tumor microenvironment. Conclusions Deletion of SPP1 in TAMs upregulates CXCL9/10 production by activating the ROS-DNA fragment/cGAS-STING/STAT1 pathway, thereby enhancing CD8 T cell infiltration, inhibiting tumor progression, and improving ICI treatment outcomes in tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1e7657751d93b44bbd54e91b8c85fc6c5af08a99" target='_blank'>
              Targeting macrophage-derived SPP1 enhances CD8 T cell infiltration via ROS-DNA fragment/cGAS-STING/STAT1-mediated CXCL9/10 in tumor microenvironment
              </a>
            </td>
          <td>
            Juanjuan Wang, Yi Shi, Yunhuan Gao, Ningning Zhu, Yuqing Liu, Yuan Zhang, Chen Xu, Rongcun Yang
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Rationale: CAR-T cell therapy has demonstrated remarkable promise for managing specific autoimmune disorders. However, it remains unclear, whether long-term immunosuppressive therapy in autoimmune patients adversely affects the phenotype and function of patient-derived CAR-T products. This study aimed to compare the characteristics of T cells and manufactured CAR-T cells from patients with multiple myeloma (MM) and chronic inflammatory demyelinating polyneuropathy (CIDP). Methods: T cells isolated from MM and CIDP patients, as well as healthy volunteers (for baseline comparisons only), were analyzed. CAR-T cells were generated using an identical manufacturing process. A comprehensive analysis was conducted, including flow cytometry for phenotypic and functional assessment, transcriptomic profiling via RNA sequencing, and in vitro functional assays such as cytokine secretion and cytotoxicity tests. Results: T cells from CIDP patients showed phenotypes and functional profiles more comparable to those from healthy volunteers. In contrast, MM-derived T cells showed increased CD8⁺ T cell frequency, elevated exhaustion markers, reduced naïve and less-differentiated subsets, and enhanced effector molecule production upon non-specific stimulation. CAR-T manufacturing reduced these inherent differences, yielding similar differentiation states, transcriptomic profiles, and convergent cytotoxic capacities. However, distinct immunomodulatory features persisted, as CIDP-derived CAR-T cells displayed reduced activation markers and lower IFN-γ secretion upon antigen stimulation compared to MM-derived CAR-T cells. Conclusions: Our study reveals that CAR-T manufacturing process can reduce pre-existing T-cell heterogeneity across different patient populations. These findings support the feasibility of autologous CAR-T therapies in immunosuppressed autoimmune patients, demonstrating that critical cytolytic functions are preserved despite residual alterations in cytokine profiles.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4cf1eaca4d6bfcd23af7d3f5b62d6d6605d50fed" target='_blank'>
              CAR-T manufacturing reduces heterogeneity between CIDP and multiple myeloma patient-derived T cells
              </a>
            </td>
          <td>
            Xu Wang, Pu Wang, Qi Zhou, Xianzheng Wei, Yuhang Jin, Ying Liao, Xuan Zhao, Rui Hou, Sijin Li, Zhangchun Guan, Wen Ma, Dan Liu, Ming Shi
          </td>
          <td>2026-01-22</td>
          <td>Theranostics</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Effective T cell reconstitution in people living with HIV is central to durable immune control and cure strategies. Sustained thymic output underpins T cell recovery and requires continuous seeding by T cell-committed progenitors originating in the bone marrow (BM). Using the SIV/rhesus macaque model, we identified a thymus-seeding progenitor (TSP; CD4⁻CD8⁻CD34⁺CD38⁻CD7⁺) in BM declining rapidly following SIV infection. This loss closely associated with reduction in T cell lineage committed differentiation of BM-derived hematopoietic stem and progenitor cells (HSPCs). Importantly, both the decline in TSPs and the impairment of pre-thymic T cell potential were strongly associated with early loss of viral control, independent of peripheral T cell dynamics. Plasma interleukin-6 (IL-6) levels robustly predicted the magnitude of TSP loss and the restriction of T cell-biased HSPC differentiation. Integrated transcriptomic and proteomic analyses revealed inflammatory imprinting of HSPCs characterized by activation of the IL-6-JAK-STAT axis, inflammasome engagement, and coordinated suppression of key T cell specification factors, including RUNX1, FYN, and ZAP70. In a nonanimal model of thymopoiesis, IL-6 exposure of rhesus macaque and human HSPCs inhibited their transition from DN1 (CD38⁻) to DN2 (CD38⁺) TSP states, indicating an early block in T cell lineage commitment. Conversely, ex vivo IL-6 receptor blockade restored thymocyte differentiation to levels comparable to untreated controls. Collectively, these findings demonstrate that pathogenic inflammation restricts pre-thymic T cell development early after infection, directly contributing to loss of viral control. These findings have important implications for understanding the mediators of anti-viral T cell immunity and HIV cure.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d1635d5db962d98f76f1b83fc5632d8a21ccd0a2" target='_blank'>
              Interleukin-6 restricts pre-thymic T cell lineage commitment of progenitors driving loss of SIV control
              </a>
            </td>
          <td>
            Saleem Anwar, Naseem Sadek, Christian M. Beusch, Ahmet F. Coskun, Mohamed S. Abdel-Hakeem, R. P. Johnson, Frank J. T. Staal, Vijayakumar Velu, Mirko Paiardini, Brandon F. Keele, Guido Silvestri, David E. Gordon, J. Tomalka, Sheikh Abdul Rahman
          </td>
          <td>2026-02-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8779b2bf6cba17b1530e13526c071bfe44406db3" target='_blank'>
              Regulatory T cells clonally expand and contribute to stromal cell function in fibrotic response to synthetic implants
              </a>
            </td>
          <td>
            Joscelyn C. Mejías, Kavita Krishnan, Anna Ruta, A. S. Ramanujam, Elise F. Gray-Gaillard, Locke Davenport Huyer, David R Maestas, Sushma Nagaraj, Frank Haoning Yu, Alexandra N. Rindone, Peter Abraham, Maria Browne, E. Fertig, Drew M. Pardoll, Jennifer H. Elisseeff
          </td>
          <td>2026-01-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="Simple Summary Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide, and many patients do not respond well to immunotherapy. In this study, we identified a unique group of macrophages—called NFKBIZ+ M0 macrophages—that are enriched in patients non-responsive to anti-PD-1 treatment. These macrophages are activated by hypoxia and release factors such as VEGFA and HBEGF that promote new blood vessel formation and tumor growth. They also produce inflammatory molecules that suppress the immune system, helping the tumor evade immune attack. Further analysis revealed that specific signaling pathways (FOSB–VEGFA and FOS–HBEGF) drive this harmful macrophage behavior. Our findings uncover a new mechanism linking hypoxia, angiogenesis, and immune evasion to treatment resistance in HCC and suggest potential therapeutic targets to improve immunotherapy outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ce50b60fe1db2dee500e6f910be7f3a05fceb0c3" target='_blank'>
              Single-Cell Transcriptomic Profiling Reveals That Macrophage-Induced Angiogenesis Contributes to Immunotherapy Resistance in Hepatocellular Carcinoma
              </a>
            </td>
          <td>
            Xinyu Pan, Baolin Liao, Zhijie Hu, Yuanyan Xiong
          </td>
          <td>2026-01-01</td>
          <td>Biology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c9bc787e32b19937cc86d82b167fee2834cae712" target='_blank'>
              T CELLS PROMOTE THE GROWTH OF SMALL-CELL LUNG CARCINOMA VIA AN IL-6/CD74 AXIS
              </a>
            </td>
          <td>
            Maya Baron, Zoé Ginestet, Debadrita Bhattacharya, Myung Chang Lee, Alexandros P. Drainas, Clara L. Poupault, Y. Nishiga, Alec E. Dallas, B. Nabet, Julien Sage
          </td>
          <td>2025-12-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Current therapies for inflammatory bowel disease (IBD) often fail to achieve complete remission and are associated with systemic toxicity owing to their broad immunosuppressive effects. To overcome these limitations, we developed a bioengineered extracellular vesicle (EV) platform that modulates key immune signaling pathways to efficiently restore the T-cell balance in inflamed intestinal tissues. EVs derived from Wharton’s jelly mesenchymal stem cells were engineered to display PD-L1 on their surface and encapsulate miR-27a-3p. Surface PD-L1 engages the PD-1 checkpoint in activated T cells, attenuating T-cell receptor signaling via SHP2-mediated dephosphorylation of ZAP70 and AKT. In parallel, miR-27a-3p suppresses prohibitin 1 (PHB1), a mitochondrial regulator of Th17 cell bioenergetics and inflammatory function, thereby reducing Th17 polarization and increasing the number of FOXP3⁺ regulatory T cells. These dual-targeting EVs preferentially localized to inflamed intestinal tissues via chemokine (CCR2/CXCR4) and PD-1-dependent mechanisms. In humanized mouse models of colitis, these EVs attenuated mucosal inflammation, suppressed effector T-cell responses, and preserved epithelial integrity. In IBD patient-derived colonoid cultures, PD-L1/miR-27a-3p EVs maintained epithelial viability and barrier integrity without inducing cytotoxicity or structural disruption. Transcriptomic and single-cell analyses revealed the downregulation of inflammatory and exhaustion signatures, along with the enrichment of regulatory subsets. Collectively, this study presents a cell-free immunotherapeutic approach that reprograms T cells in inflamed tissues through the PD-1 and mitochondrial signaling pathways while maintaining intestinal epithelial integrity, offering a promising therapeutic strategy for IBD and other T cell-driven inflammatory disorders.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/21a759c51278c1cf53050a54d395a9872336d71e" target='_blank'>
              Engineered extracellular vesicles reprogram T cells by targeting PD-1 and PHB1 signaling in inflammatory bowel disease
              </a>
            </td>
          <td>
            Mi-Kyung Oh, Hyun Sung Park, Dong-Hoon Chae, Aaron Yu, Jae Han Park, Jiyoung Heo, Keonwoo Cho, Jiho Kim, Byeonghwi Lim, Jun-Mo Kim, Jordan Axelrad, Kyung Ku Jang, Jong Pil Im, S. Koh, Byung-Soo Kim, Kyung-Rok Yu
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>1</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9d522a0c1e585eda2d8238200dfededee05868fa" target='_blank'>
              Leveraging TNFR2 for antitumour immunity: T reg depletion and myeloid reprogramming versus T cell costimulation
              </a>
            </td>
          <td>
            L. Mårtensson, P. Holmkvist, Kirstie Cleary, Carolin Svensson, M. Semmrich, Niyaz Yoosuf, Alexandra Gabriela Ferreira, M. Kovacek, Mimoza Boden, Therese Blidberg, Osman Dadas, J. Mattsson, David Ermert, Elin Birgersson, Vincentiu Pitic, Martin C Taylor, Mona Yazdani, Ulla-Carin Tornberg, Ingrid Karlsson, Sean H Lim, S. Beers, Mark Cragg, B. Frendéus, I. Teige
          </td>
          <td>2026-01-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b58655f2ee5e1833c4162ee24f906c63fe582479" target='_blank'>
              Gene expression profiling of dendritic cell tolerance dysfunction in women with Systemic lupus erythematosus
              </a>
            </td>
          <td>
            Ana Laura Hernández-Ledesma, E. L. Coss-Navarrete, S. Salazar-Magaña, Diego Ramírez-Espinosa, L. Tinajero-Nieto, Estefania Torres-Valdez, A. Peña-Ayala, Guillermo Félix-Rodriguez, G. Frontana-Vázquez, Jair Santiago García Sotelo, G. Trynka, F. Rosetti, S. L. Fernandez-Valverde, María Gutiérrez-Arcelus, D. Alpízar-Rodríguez, Alejandra Medina-Rivera
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>51</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e65f5c64085c6fc68c98dbdc3df860af53a5b25d" target='_blank'>
              Type I IFN Dynamics Define an Early Checkpoint for Survival and Orchestrate Systemic Neutrophil Heterogeneity in Lethal Viral Infection
              </a>
            </td>
          <td>
            Riho Saito, Akisawa Satomi, Hiroki Sugishita, Yukiko Gotoh, Tomohiko Okazaki
          </td>
          <td>2026-01-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Human gastrointestinal (GI) tissues are a major site of HIV-1 viral persistence, but the nature of the GI reservoir remains poorly described. To characterize the GI HIV reservoir, we profiled cells from GI tissue and matched PBMCs from 10 people with HIV on antiretroviral therapy using single-cell RNA sequencing. We identified distinct compartment-specific patterns of gene expression, highlighting key differences between blood and colon CD4+ T cell populations. vRNA+ cells from both blood and GI tissue were heterogeneous and found in multiple subtypes of CD4+ T cells, although vRNA+ cells were particularly enriched in cells with Th17 or Treg17 phenotypes. Transcriptomic comparison of HIV vRNA+ and vRNA– T cells revealed 116 differentially expressed genes that were associated with HIV infection, including ZBED2, MAF, and IL17F. These data provide what we believe to be new information regarding the GI-resident HIV reservoir and suggest that compartment-specific patterns of gene expression are associated with HIV infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5304bb5c0336b41afad4253045c39c12a29c6255" target='_blank'>
              Single-cell characterization of the gastrointestinal HIV reservoir reveals heterogeneous cellular phenotypes
              </a>
            </td>
          <td>
            Jackson J Peterson, Shipra Chandel, K. James, Elizabeth S Bennett, V. Wu, Cory H White, Brigitte Allard, Matthew L Clohosey, Taylor Whitaker, Caroline E. Baker, Susan Pedersen, A. Peery, Cynthia L Gay, Michael R. Betts, David M. Margolis, N. Archin, Edward P Browne
          </td>
          <td>2025-12-23</td>
          <td>The Journal of Clinical Investigation</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="Lung adenocarcinoma (LUAD) exhibits substantial heterogeneity in tumor immune microenvironment (TIME) composition, shaping disease progression and therapeutic response. Here, we integrated transcriptomic and clinical data from TCGA‐LUAD to develop a TIME‐associated prognostic model. LASSO Cox regression identified eight key genes—S100P, CPLX2, CD200R1, LINC01857, CLEC7A, CLEC17A, COL6A5, and CX3CR1‐ that yielded a risk score separating patients into two groups with distinct immune states. High‐risk tumors were characterized by diminished CD4+ Th1 and CD8+ T cell infiltration, expansion of M2 macrophages, and cytokine profiles consistent with immune suppression, whereas low‐risk tumors displayed immune‐active features, including elevated IL‐27 signaling. Single‐cell RNA sequencing of a murine LUAD model revealed that early tumors featured a T cell‐enriched microenvironment with elevated IL‐27 signaling, whereas late tumors acquired a macrophage‐driven immunosuppressive landscape. Interstitial macrophages acquired an M2‐like phenotype, upregulated PD‐L1, and suppressed CD4+ and CD8+ T cell activity through the CD86‐CTLA4 and SELPLG‐SELL axes. Functionally, IL‐27 blockade accelerated tumor growth, whereas recombinant IL‐27 restrained tumor progression and enhanced PD‐L1/CTLA‐4 blockade efficacy by augmenting Th1 and cytotoxic T cell responses. These findings define a TME‐based prognostic classifier and position IL‐27 as a stage‐dependent therapeutic target that restores T cell immunity and boosts checkpoint blockade efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2cc2066e706ddd6bc43aa3abe99cd395ec53999b" target='_blank'>
              A tumor Microenvironment‐Derived Prognostic Model Guides IL‐27 as a Therapeutic Strategy to Restore T Cell Immunity in Lung Adenocarcinoma
              </a>
            </td>
          <td>
            Gaopu Xie, Donglin Cai, Gang Zhang, Hongda Zhao, Xu Wang, Li Zhu, Jing Ni, Xia Yi, Jun Liang, Mengmeng Liang
          </td>
          <td>2026-01-01</td>
          <td>Advanced Biology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/34649c6562aa2175c877d0871438b8882a670ac3" target='_blank'>
              Integrated single-cell analysis reveals interferon-driven immune signatures in a DENV1 human infection model
              </a>
            </td>
          <td>
            A. Vermeersch, T. Verdonckt, C. Struyfs, E. De Meester, A. Waickman, S.J. Thomas, K. Ariën, O. Lagatie, F. van Nieuwerburgh
          </td>
          <td>2026-01-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Background Neoadjuvant immunotherapy has reshaped the treatment paradigm for esophageal squamous cell carcinoma (ESCC), yet mechanisms of resistance in non-responders remain poorly understood. Specifically, the spatial orchestration of the tumor microenvironment that limits effective antitumor immunity is not fully elucidated. Methods Integrating spatial transcriptomic analysis with large-scale tissue pathology, we mapped the spatial architecture of the immune landscape in immunotherapy-resistant ESCC to identify cellular and molecular determinants of treatment failure. Results We revealed a distinct immune exclusion phenotype in non-responders, characterized by peritumoral CD8+ T cell enrichment coupled with intratumoral depletion. At the invasive front, we identified COL11A1+ cancer-associated fibroblasts (CAFs) and SPP1+ tumor-associated macrophages as spatially correlated markers of immune exclusion, demarcating regions characterized by limited T cell infiltration. Mechanistically, a distinct subpopulation of LAMC2+ tumor cells localized at the tumor boundary acts as the master orchestrator of this barrier. These LAMC2+ cells exhibit aberrant lactate metabolism and elevated stemness, driving CAF activation via Semaphorin 3C secretion. Strikingly, this ‘LAMC2+ boundary tumor cell-immune-privileged niche’ axis exhibits pan-cancer correlations with immunotherapy resistance, positioning LAMC2 as a robust predictive biomarker. Conclusion In this study, we identify the tumor invasive margin as a critical determinant of immunotherapy resistance in ESCC. By defining the specific spatial markers and molecular architecture of an immune-privileged niche associated with the immune-exclusion barrier, our findings demonstrate the value of spatially resolved microenvironmental analysis. Moreover, we propose that therapeutic targeting of this boundary niche represents a promising strategy to overcome resistance in ESCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/858298d1227537940c73aee34b8d245e5b4c9498" target='_blank'>
              An Immune-privileged niche mediates immunotherapy resistance in esophageal carcinoma
              </a>
            </td>
          <td>
            Li Wan, Boye Li, Tianyun Ma, Min Wang, Fei Xie, Haotian Ge, Zixuan Xiao, Xinyi Chen, Lingda Meng, Li Zhang, Kunxin Xie, Qilong Wang
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background Serum amyloid A (SAA), an acute-phase pro-inflammatory protein, is overexpressed in several cancers and is involved in shaping pro-tumor responses. We have previously reported that lung cancer stem cells secrete SAA, which contributes to tumor progression by inhibition of TH1 immunity. Here, we extended our studies to examine the mechanism of SAA mediated immunosuppression in both antigen-presenting cells (APCs) and the subsequent activation of T cells. Methods & results Using ex vivo co-culture systems and in vivo mice models, we found that SAA impaired dendritic cell and macrophage activation and drove macrophages toward an M2 phenotype with reduced antigen presentation. Lung cancer cells overexpressing SAA also consistently showed impaired CD8+ T cell infiltration and cytotoxicity, while SAA neutralization were efficient at enhancing CD8+ T cell activation and response to anti-tumor immunity. Mechanistically, we found that the immunosuppressive phenotype induced by SAA on APCs is mediated in part by CD36. Critically, inhibiting SAA by neutralization antibody recovered APC activity and enhanced T cell-dependent tumor control. Conclusion our results identify SAA as an important immunosuppressive mediator in the tumor microenvironment, implying that the SAA neutralizing antibody may be a potential target for the improvement of lung cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f10076dc13711bdee9c69a81615daf0299024df" target='_blank'>
              SAA restricts T cell mediated anti-tumor immunity by limiting antigen presentation in lung cancer
              </a>
            </td>
          <td>
            Mei Huang, Run Shi, Cong Xu, Yihan Zhang, Xiaoyue Du, S. Wen, Chunbin Wang, F. Jiang, Guoren Zhou, Xin Wang, Bo Shen
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Radiotherapy is a critical modality in cancer treatment, not only to eradicate cancer cells but also to trigger anti-tumor immunity. Interleukin-21 (IL-21), an immunomodulatory cytokine with potential in cancer therapy, has unexplored synergy with radiotherapy. Our study, leveraging human cancer databases and tissue microarrays, identified a positive correlation between IL-21 and radiotherapy outcomes, particularly in tumor microenvironment (TME) activation. In mouse tumor models, IL-21 combined with radiation significantly enhances TME, boosting CD8+ T cell activation and function, reducing tumor burden, and extending survival. Single-cell transcriptome sequencing revealed that the combination of IL-21 and radiation increased the cytotoxicity of effector and memory CD8+ T cells and prevented their exhaustion. These effects were further validated in humanized mice, where IL-21 combined with radiation reduced A549 tumor growth and enhanced CD8+ T cell function. Post-neoadjuvant radiotherapy samples from patients with esophageal cancer showed a positive correlation between IL-21 levels and CD8+ T cell infiltration. Our findings suggest that IL-21 is a promising adjuvant to radiotherapy, potentially improving the treatment efficacy through TME enhancement. This study provides a foundation for future clinical exploration of IL-21 for enhancing radiotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/42bba82008c61c07a67483aebafda8e002ff3cb9" target='_blank'>
              IL-21 enhances the cytotoxicity of intratumoral CD8+ T cells improving radiation efficacy.
              </a>
            </td>
          <td>
            Xinyang Li, Xueqi Xie, Baochao Wei, Xiaozheng Sun, Minxin Chen, Rufei Liu, Q. Tao, Yiheng Huang, Qian Wang, Shuangshuang Ma, Ling Wei, Rong Xiao, Zhaoyun Liu, Jinming Yu, Meng Wu, Dawei Chen
          </td>
          <td>2026-01-08</td>
          <td>JCI insight</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Background Oncolytic herpes simplex virus (oHSV) therapy is a live virus-based immunotherapy that lyses tumor cells which release antigens and activate antitumor immunity. oHSV therapy has been shown to increase ATP production and release of extracellular ATP (eATP). In the extracellular tumor microenvironment, eATP functions as an immune-activating damage-associated molecular pattern but is hydrolyzed to extracellular adenosine (eADO), which can be immune-suppressive. eADO is generated by the sequential action of ectoenzymes CD39 and CD73 (NT5E). Here, we examined the role of immunosuppressive eADO signaling in regulating antitumor immune efficacy of oHSV. Methods We evaluated changes in eADO signaling in vitro and in patient specimens after virotherapy. A genetic CD73 knock-out mouse model and blocking antibodies were used to assess the impact of CD73 on virotherapy in two different solid tumor models. Single-cell RNA sequencing was employed to assess changes in immune cell infiltration and communication. Flow cytometric immunophenotyping and immunofluorescent imaging were utilized to confirm single-cell sequencing predicted changes in tumor microenvironment. Results Transcriptomic analysis of patient tumors pre-virotherapy and post-virotherapy with CAN-3110 revealed increased expression of the adenosine receptor gene ADORA2B after treatment. High NT5E gene expression, as well as gene signatures suggestive of adenosine signaling, correlated with a significantly worse prognosis for patients with solid tumors. Single-cell sequencing of immune cells recruited to tumor-bearing brain hemispheres in CD73 knockout mice revealed an increase in macrophage-mediated antigen presentation and CD4+ T cell cross-communication. Intracranial tumor-bearing CD73 knock-out mice treated with oHSV showed significant therapeutic improvement as the result of oHSV compared with wild-type mice. Combination of virotherapy with CD73 antibody blockade also resulted in enhanced antitumor efficacy. Conclusions Here, we identify that immunosuppressive eADO signaling in the TME is a major barrier to oHSV therapy and CD73 blockade prevents tumor immune escape. The combination of oHSV with CD73 blockade supports the development of an antitumor immune memory response in solid tumors. This study supports clinical development of this combination strategy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3c25b7632b9e2aab5320e79e74bc5a8b75449a94" target='_blank'>
              CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation
              </a>
            </td>
          <td>
            Sara A Murphy, Jiaqi Li, Upasana Sahu, J. Swanner, Cole T Lewis, Benedict Anchang, Yan Cui, E. Chiocca, Balveen Kaur, Sara A Murphy
          </td>
          <td>2026-01-01</td>
          <td>Journal for ImmunoTherapy of Cancer</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="Background Myeloid-derived suppressor cells (MDSCs) have a dominating presence in the postoperative period, mediating the suppression of natural killer (NK) cells and promoting cancer metastases after surgery. However, their phenotype and effects on postoperative cellular immunity remain incompletely understood. This study aims to functionally characterize surgery-induced (sx) MDSCs and identify potential therapeutic strategies to mitigate their immunosuppressive effects. Methods We used multicolor flow cytometry to characterize sx-MDSCs from n=55 patients with cancer undergoing surgery at various time points. Furthermore, single-cell RNA sequencing was performed on a cohort of patients. Our functional ex vivo sx-MDSC:NK cell suppression assay was used to investigate the activity of sx-MDSCs and to screen a 147 small molecule library to identify sx-MDSC antagonists. Lastly, we used preclinical murine models of postoperative metastases to evaluate the therapeutic potential of the inhibitors identified. Results Sx-MDSCs significantly expanded after surgery and single-cell RNA sequencing identified signatures resembling immunosuppressive monocytes, including an upregulation of PI3K signaling. These sx-MDSCs also suppressed NK cell activity from patient samples and the small molecule screen identified PI3K-γ inhibitors as potent modulators of sx-MDSC activity. In our murine models, inhibiting PI3K-γ with specific inhibitors reduced postoperative metastases, further corroborating the role of this pathway in sx-MDSC-mediated immune suppression. Conclusions Our findings highlight the critical role of PI3K-γ signaling in postoperative sx-MDSC-mediated immune suppression. Targeting this pathway with PI3K-γ inhibitors represents a promising therapeutic strategy to prevent NK cell suppression and reduce postoperative metastases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cb532f80a9f75fcf605458e25b23096cd62d5262" target='_blank'>
              Preventing surgery-induced natural killer cell suppression and metastases by inhibiting PI3K-gamma signaling in myeloid-derived suppressor cells
              </a>
            </td>
          <td>
            L. Angka, G. Tennakoon, David Cook, Andre B. Martel, M. Market, Christiano Tanese de Souza, Emma Cummins, Ismael Samudio, Natasha Kekre, Michele Ardolino, B. Vanderhyden, M. A. Kennedy, Rebecca C Auer
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5e7fef8cebaddbe902d6222cb458263868c9968" target='_blank'>
              Dual-inactivation of Regnase-1 and SOCS1 rewires exhausted CD8+ T cell fate to enhance anti-tumor functionality
              </a>
            </td>
          <td>
            Isabelle Le Mercier, David Monteiro, Katarina Halpin-Veszeleiova, Karrie Wong, Anne Dodson, Gustavo J. Martinez, Dominick A Matos, Bashar Hamza, Ashish Yeri, Seamus McKenney, Sharon Lin, Nicole Protheroe, Alexander Smashnov, Paul Dunbar, Mitali Ghose, C. Calnan, Hugh Gannon, Somya Jain, Frank Thompson, Sophie Capobianco, Glenn J. Hanna, Eric Fagerberg, S. Shenker, Sean Keegan, Gregory Kryukov, Jason Merkin, Ribhu Nayar, Caroline P. Bullock, Christopher Wrocklage, L. Cadzow, F. Stegmeier, M. Forget, C. Bernatchez, John Gagnon, Fiona A McHugh, Dipen Sangurdekar, Michael Schlabach, Micah J. Benson
          </td>
          <td>2026-01-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>52</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/35d699fa79c5948bd439d7d11d4aa1b44f1e64ec" target='_blank'>
              Macrophage Antigen Presentation Is Unleashed by Pan-RAS Inhibition to Promote Antitumor Immunity
              </a>
            </td>
          <td>
            Jie Shen, Weini Li, Xin He, Lianjun Zhang, Huidi ShuCheng, ChunBo Zeng, Mingtian Che, Wei Fan, Suda Jo, Heping Yang, Yuan Yuan, Zakir Khan, Zhi Chen, DuoYao Cao
          </td>
          <td>2026-02-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Liver cancer incidences increase dramatically beyond 55 years of age, suggesting that age-associated changes contribute critically to tumor initiation. However, the mechanisms linking liver aging and cancer initiation are not well defined. This study investigates the role of CD44, a marker of liver tumor-initiating cells (TIC), in age-associated liver pathophysiology. Aged livers showed accumulation of CD44-expressing hepatocytes exhibiting enrichment of immune modulatory genes and activation of the immunosuppressive IL6/JAK/STAT3 pathway. Indeed, in adoptive transfer assays, antigen-exposed CD8+ T cells mounted a lower IFN-γ response in aged livers than in young livers, indicating an immunosuppressive aged milieu. Concordantly, spatial analyses showed that the proximal neighbourhoods of Cd44-expressing hepatocytes are enriched in T cells exhibiting reduced cytokine and chemokine gene expression. Finally, hepatocyte-specific knock out of Cd44 mitigated the IL6/JAK/STAT3 gene signature in aged livers. Overall, these findings suggest that CD44 expression in aged hepatocytes promotes activation of the immunosuppressive IL6/JAK/STAT3 pathway and this is associated with impaired T cell effector function.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b8cfbe41c4f5eea58d4484e39d30b0c559a09da" target='_blank'>
              Aging-induced hepatocyte CD44 drives IL6/STAT3 signaling and associates with impaired neighboring T cell function
              </a>
            </td>
          <td>
            Armin Gandhi, Kathryn Lande, Yichen Li, Filipe A. Hoffman, Michael LaPorte, Shirong Tan, Garrett Evensen, Benji Portillo, M. Teneche, Rouven Arnold, Adarsh Rajesh, Jessica Proulx, Shanshan Yin, Aaron P. Havas, Charlene Miciano, Qian Yang, Elizabeth Smoot, S. Mamde, Andrew Davis, Kevin Y. Yip, Allen Wang, Bing Ren, April E. Williams, S. Kaech, Peter D. Adams
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3541227a821e9e9e6e75e4ddf9b12cd905133ab3" target='_blank'>
              A CD40-Targeted IL-21 Fusokine Enables Rapid Generation of Human IL-10⁺Granzyme B⁺ Regulatory B Cells
              </a>
            </td>
          <td>
            A. Pennati, S. Yuan, Rahul Das, Catigan Hedican, Amar Yeware, Jacques Galipeau
          </td>
          <td>2026-01-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Senescent cells play important roles in various biological processes that promote fitness and health, however, their timely elimination by immune cells is critical to maintain tissue homeostasis and prevent disease. Despite this, senescent cells progressively accumulate systemically with age, suggesting that certain immune cells also become senescent and dysfunctional during aging. Supporting this, we previously demonstrated that CD8 T cells, immune cells capable of targeting senescent cells, increasingly develop characteristics of senescence with advancing age in humans. Here, we further characterized the senescence state of human SA-βGal-expressing CD8 T effector cells, their functional capabilities, and their involvement in aging and disease. Single-cell RNA sequencing revealed that SA-βGal-expressing CD8 T cells with unique transcriptional signatures develop in all stages of T cell differentiation, including in effector memory (EM) T cells. SA-βGal-expressing CD8 TEM cells expressed various classical markers of senescence and were significantly impaired in their ability to proliferate, produce cytokines, and eliminate senescent human stromal cells, compared to CD8 TEM cells with low SA-βGal activity. Gene signatures of senescent SA-βGal-expressing CD8 TEM cells were enriched in CD8 T cells from older human donors, patients with age-related disorders, cancer, and smokers. Furthermore, our results demonstrate that T cell senescence is distinct from and dominant over T cell exhaustion, limiting the response of CD8 TEM cells to immunotherapy. Collectively, our study demonstrates that the senescence state impairs the functions of CD8 TEM cells and reveals the involvement of senescent and dysfunctional CD8 TEM cells in aging, disease, exposure to toxins, and responses to immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d6fb99de056c53f31e0f49731763d6313026abce" target='_blank'>
              Senescent CD8 T Effector Memory Cells are Functionally Impaired, Enriched in Aging and Disease, and a Barrier to Immunotherapy
              </a>
            </td>
          <td>
            Paolo S. Turano, Elizabeth Akbulut, N. Aquino, Luis Garza-Martínez, Sukhwinder Singh, George S. Yap, Patricia Fitzgerald-Bocarsly, R. Martínez-Zamudio, U. Herbig
          </td>
          <td>2025-12-19</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Background Antiangiogenics promote immune activation by reducing myeloid-derived suppressor cells (MDSCs) and enhancing natural killer (NK) and T cell functions in metastatic RCC patients. However, these effects are transient, leading to compensatory immunosuppression. Platelets (PLT) and their extracellular vesicles (PLT-EVs) modulate immune and angiogenic pathways, suggesting a role in immune reprogramming during therapy. Methods Circulating EVs were longitudinally profiled in metastatic RCC patients (n=8) undergoing Pazopanib therapy. EVs, isolated by differential ultracentrifugation from baseline, 3- and 6-month plasma samples, were characterized by bead-based multiplex assay and nanoparticle tracking analysis. Results were correlated with blood counts, RNA-seq and flow cytometry immune profiles. Results Pazopanib induced temporally structured EV compartment alterations. After three months, EVs were enriched in immune markers (CD8, CD56, CD19, CD1c, HLA-DR), consistent with immune activation, whereas PLT-derived markers (CD41b, CD42a, CD29) were diminished. By six months, PLT-EV markers recovered, with CD62P+ and CD29+ EVs co-expressing immunoregulatory and angiogenic molecules (CD209, CD105). PLT-EV abundance correlated with the expansion of regulatory T cells (Tregs), PD-L1+ monocytes and MDSCs, together with suppression of NK cells. PLT activation and PDGF signaling pathways decreased in PBMC from patients with clinical benefit. Conclusions Despite the small sample size and absence of functional experiments, our results suggest that Pazopanib promotes cytotoxic immune programs but, by six months, reprograms PLT-EVs towards different adhesion characteristics contributing to Treg and MDSC expansion while suppressing NK activity. PLT-EVs may influence the balance between immune activation and suppression during anti-angiogenic therapy, suggesting PLT-EVs as biomarkers and therapeutic targets in mRCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3b6ad24127a68aa48867264bc8f9e8e0c3b3b86d" target='_blank'>
              Pazopanib-associated remodeling of platelet-immune cell crosstalk and immune suppressive platelet-derived extracellular vesicles in metastatic RCC
              </a>
            </td>
          <td>
            Gianpiero Lupoli, Stefano Bergamini, J. Salsetta, A. Mereu, A. Cova, Elisa D’Angelo, Eriomina Shahaj, E. Vergani, Martina Stroscia, Emma Di Carlo, L. Rivoltini, E. Verzoni, V. Huber
          </td>
          <td>2026-01-07</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>79</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eaaff9dad9a60083319c3fb56581e38fedd65c55" target='_blank'>
              Senescent host-derived extracellular vesicles potentiate antitumor immunity via bystander T cell activation
              </a>
            </td>
          <td>
            Chenlu Yao, Chenhui Weng, Heng Wang, Bingbing Wu, Rong Sun, Huaxing Dai, Fang Xu, Qingzhen Han, Dong Zheng, Yumin Wu, Chao Wang
          </td>
          <td>2025-12-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Background Tumor-associated macrophages (TAMs) are key drivers of the immunosuppressive tumor microenvironment (TME), thereby limiting the efficacy of immune checkpoint inhibitors (ICIs). However, the underlying mechanisms remain unclear. Methods Both genetic (Akr1b3 knockout) and pharmacologic (epalrestat) approaches were employed to examine the impact of Aldo-keto reductase family 1 member B1 (AKR1B1) inhibition on TAMs and T-cell function in vitro and in vivo. Mechanistic insights were obtained through RNA sequencing, flow cytometry, immunofluorescence staining, and co-culture assays. To assess therapeutic relevance, 4T1 breast cancer and LLC lung carcinoma mouse models were used to evaluate the effects of epalrestat on tumor growth, immune infiltration, and T-cell responses. Clinical relevance was validated in patient cohorts with triple-negative breast cancer (TNBC) and lung adenocarcinoma (LUAD). Results AKR1B1 is highly expressed in TAMs and correlates with CD8+ T-cell dysfunction. Targeting AKR1B1 enhances antitumor immunity by reprogramming TAMs. Mechanistically, AKR1B1 modulates macrophage metabolism via the glutathione/reactive oxygen species axis, suppressing nuclear factor κB activation and downregulating C-C motif chemokine ligand 5 (CCL5) production, thereby inducing CD8+ T-cell dysfunction and establishing an immunosuppressive TME. Inhibition of AKR1B1, either by gene knockout or selective pharmacologic blockade, reprograms TAMs toward an immunostimulatory phenotype, increases CCL5–CCR5 (C-C motif chemokine receptor 5) signaling, restores CD8+T cell effector function, and strengthens antitumor immunity. Clinically, high AKR1B1 expression is associated with poor prognosis and immune suppression in TNBC and LUAD. Notably, targeting AKR1B1 improves responses to ICIs in both breast and lung cancer models. Conclusions AKR1B1 as a critical regulator of TAM-mediated immunosuppression and highlight its therapeutic potential to enhance the efficacy of ICIs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/160f049c2f738290afe33bc6f397a041f83f45c0" target='_blank'>
              Targeting AKR1B1 reprograms tumor-associated macrophages to enhance antitumor immunity
              </a>
            </td>
          <td>
            Yuqing Liu, Chao Zhou, Yabin Tang, Huimin Lei, Ayinazhaer Aihemaiti, Hongyu Liu, Peichen Zou, Jun-ting Xie, Xu Guo, Ruixue Xia, Bao-Hui Han, Hongzhuan Chen, Liang Zhu
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cd5525dc695c7cab7bc678df063ceac946d09faa" target='_blank'>
              Myeloid cells contribute to bystander CD8 T cell accumulation in metabolic-associated steatohepatitis and are sufficient for fibrosis
              </a>
            </td>
          <td>
            Cynthia Lebeaupin, Katelyn L. Donahue, S. Lal, Stephen M. Christensen, Shoh Asano, Marc H. Wadsworth, Kathryn Bound, Saurav De, James McMahon, Franklin Schlerman, Chang Wang, Xiao Chen, A. M. Barron, Thomas A. Wynn, Kevin M. Hart, Thomas Fabre
          </td>
          <td>2026-01-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Reprogramming the immunosuppressive milieu in pancreatic cancer (PaCa) remains an important yet unmet therapeutic goal. Although tumor-associated macrophages (TAMs) are known to promote tumor growth and metastasis, little is known about the underlying mechanisms driving macrophage plasticity in PaCa. Herein, we show that extracellular vesicles (EVs) released by PaCa cells as well as circulating EVs in patient plasma, facilitate cellular crosstalk thereby promoting preferential skewing of recipient macrophages towards an M2-like TAM phenotype. PaCa-EV educated macrophages predominantly secrete anti-inflammatory cytokines, adapt an M2-like metabolic phenotype, have a higher expression of PD-L1, and suppress the proliferation of CD8+ T cells. An increased payload of miR-182-5p in PaCa-EV cargo causes a decrease in TLR4 expression in recipient macrophages and a concomitant upregulation of JAK/STAT3 pathway and elevated secretion of IL-10 and TGF-β, leading to increased PD-L1 expression. Most notably, targeted therapeutic delivery of antagomiR-182-5p in pancreatic tumor-bearing mice with varying immunogenic potential results in a significant decrease in tumor volume, increased survival, restoration of M1/M2 ratio, and an overall increase in CD8+ T cell activation in the TME. Taken together, we demonstrate a direct role of EVs in subverting the immune microenvironment and altering macrophage plasticity in a manner conducive to both tumor growth and proliferation. As such, a targeted delivery of microRNA inhibitors as drugs for altering macrophage plasticity may likely achieve better therapeutic response in pancreatic tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/934885801642cb8c2056560a4186551b7da4ccea" target='_blank'>
              Extracellular vesicle-derived miRNA-182-5p educates macrophages towards an immunosuppressive phenotype in pancreatic cancer
              </a>
            </td>
          <td>
            Baldev Singh, Pankaj Gaur, Pritha Bose, Yanjun R. Zhang, Yaoxiang Li, Zihao Zhang, Jeyalakshmi Kandhavelu, William Klotzbier, Meth B. Jayatilake, Shivani Bansal, Mohd Farhan, Sunain Deol, P. Banerjee, Keith Unger, Seema Gupta, Vivek Verma, Amrita K. Cheema
          </td>
          <td>2026-01-16</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7fda0edb364952e5067fda86230619632242ae72" target='_blank'>
              Cancer-Associated Mesothelial Cells Drive Immune Escape and Therapy Resistance in Ovarian Cancer
              </a>
            </td>
          <td>
            M. Chauvin, Julien Roche-Prellezo, Virginie Lafont, Henri-Alexandre Michaud, Estelle Tromelin, Robin Michel, Clara Freixinos, Marie-Charlotte Meinsohn, Pierre-Emmanuel Colombo, Nathalie Bonnefoy, Laurent Gros, David Pépin
          </td>
          <td>2026-01-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ce380aea2613d07a2569ea17ef622bcc9b49b6c" target='_blank'>
              Myeloid CD209 impairs T-cell activation by inducing ICAM-2–ERM–dependent cortical stiffening
              </a>
            </td>
          <td>
            Ting Pan, Tingting Wang, Jiaqi Wu, Heping Wang, Bo Zeng, Yangyang Li, Ming Yi, Ruirui He, Lingyun Feng, Zhihui Cui, Guoling Huang, Panyin Shu, Yuan Wang, Xi Li, Yanyun Du, Zhen Li, Xue Xiao, Chenhui Wang
          </td>
          <td>2026-01-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Despite recent advances in immunotherapy for advanced malignancies, Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to current immunotherapy due to dense fibrosis, limited antigen presentation, and myeloid-driven immune suppression. Here we report the tumor-targeting, immune remodeling, and safety profiles of the attenuated Salmonella enterica serovar Typhimurium strain CRC2631, and of iSTORM, a next-generation derivative engineered for tumor-localized CMTM6 silencing. CRC2631 preferentially colonizes orthotopic and genetically engineered PDAC tumors, with enrichment in primary lesions and metastases. Tumor-localized CRC2631 induces chemokine and adhesion programs consistent with leukocyte recruitment, increases intratumoral activated T-cell fractions, and triggers transcriptional signatures aligned with innate sensing, interferon signaling, antigen-processing and presentation, and apoptosis programs. iSTORM extends this platform by delivering CMTM6-targeting shRNA to modulate a PD-L1-stabilizing, myeloid-associated immune-evasion programs within tumor-colonized tissue. Compared with CRC2631, iSTORM increases intratumoral CD8+ T cells, shifts T-cell state toward activation with reduced exhaustion-prone features, strengthens antigen-presentation programs, and achieves deeper tumor control. A lyophilized formulation preserves immune remodeling while improving deployability. Mechanistically, glycan arrays and functional studies support mannose-rich glycan-guided tumor engagement. iSTORM toxicity studies, including systemic cytokine, hematologic, blood chemistry, and lethality demonstrate a favorable safety profile. Collectively, these findings establish iSTORM as a safe, programmable, CMTM6-silencing microbial immunotherapy platform that selectively targets and penetrate PDAC tumors to unleash anti-tumor immune activities. What is already known on this topic PDAC is highly resistant to immune checkpoint blockade because dense stroma and myeloid-dominated suppression prevent effective T-cell infiltration; attenuated Salmonella strains can selectively colonize tumors but first-generation agents showed limited efficacy and safety concerns. What this study adds This study defines CRC2631/iSTORM as a tumor-selective microbial immunotherapy that exploits surface-exposed, mannose-rich N-glycans to colonize PDAC, delivers CMTM6 silencing, and restores CD8+ T-cell activation and tumor control in models resistant to PD-1 blockade immunotherapy. How this study might affect research, practice or policy These findings provide a mechanistic blueprint for glycan-guided, CMTM6-targeted bacterial “living drugs,” support rational combination strategies for deepening therapeutic effect, and establish a lyophilized, biocontained platform that could be developed into scalable microbial immunotherapies for PDAC and other immunologically cold solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/de69e456272d47e1287958aec83b80a0b830f6b6" target='_blank'>
              CMTM6-Silencing Microbial Immunotherapy Reprograms PDAC Tumors and Restores T-cell Function
              </a>
            </td>
          <td>
            CY Chabu, R. Kazmierczak, M. Hasani, N. Patterson, Q. Wang, L. Canti, M. Tesfay, A. Cios, B. Dhagat, M.Q Pastor, C. De la Nuez, T. Verburg, J. Moyer, K. Gunter, M. Mwanza, O. Moaven, G. Li, P. de Figueiredo, B.M Nagalo
          </td>
          <td>2026-01-28</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Glioblastoma remains a therapeutic challenge due to its immunosuppressive tumor microenvironment and resistance to immunotherapy. This study investigates the role of CXCL8 signaling in recruiting immunosuppressive neutrophils and driving poor prognosis in glioblastoma. Analysis of TCGA data revealed significant upregulation of CXCL8 in glioblastoma tissues, correlating with reduced survival and neutrophil chemotaxis pathway activation. We identified a distinct low-density neutrophil subpopulation (L-NEUs) in GBM patient blood, characterized by immature markers (CD16low, CD13low, CD10low) and CXCL8-dependent migration. Integrative bioinformatics identified RNASE2 and THBD as L-NEU-specific markers, both upregulated in GBM and associated with poor prognosis. Functional studies demonstrated that CXCL8 overexpression in macrophages enhanced L-NEU recruitment. RNASE2 (secretory) and THBD (transmembrane) emerged as dual biomarkers and therapeutic targets, with pan-cancer survival analysis linking their overexpression to adverse outcomes in glioblastoma, renal carcinoma, and others. These findings define CXCL8-driven neutrophil recruitment as a key immunosuppressive mechanism in glioblastoma and propose RNASE2/THBD-targeted strategies to improve immunotherapy efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a9772d493fa3bf49beedb5af4b793057af3d659" target='_blank'>
              CXCL8-dependent recruitment of neutrophils by the tumor microenvironment drives poor prognosis in glioblastoma patients
              </a>
            </td>
          <td>
            Jiajun Wang, Chao Wang, Zhiming Sun, Antian Zhang, Zihui Niu, Kang Zhang, Shuai Wang, Chao Zhang, Xingjie Shi, Dong Yu, Shiqiang Hou, Ning Lin
          </td>
          <td>2025-12-26</td>
          <td>BMC Cancer</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e3bbdd9bcc92736e4b8070a3a41a9e7c618c1a80" target='_blank'>
              ILC2s govern imprinting of alveolar macrophage-mediated immunity upon secondary helminth infection in the lung
              </a>
            </td>
          <td>
            Jonathan Pollock, Jhanvi H. Patel, Lisa-Marie Graf, Andreas Ruhl, Daniel Radtke, David Voehringer
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Background While cancer vaccines have demonstrated promising clinical potential, their therapeutic efficacy against advanced tumors remains suboptimal, highlighting the critical need to elucidate resistance mechanisms and develop targeted solutions. We previously developed a stimulator of interferon genes (STING)-activating PC7A nanovaccine that elicits strong antitumor efficacy in multiple tumor models. In this study, we systematically investigated the mechanisms mediating nanovaccine resistance and provided targeting approaches to overcome this therapeutic barrier. Methods Vaccine efficacy at early stage and advanced-stage tumors was investigated in the B16-OVA melanoma model and TC-1 human papillomavirus-induced cancer model, with tumor microenvironment being comprehensively analyzed by flow cytometry. In a vaccine-resistant tumor, elevated immunosuppressive activity of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) was assessed through multi-analysis including surface marker staining, reverse transcription-quantitative PCR, and functional T cell-suppression assay. To investigate the CD300ld blockade strategy, we employed CD300ld-knockout (KO) mice for genetic ablation, or recombinant protein capable of competitive inhibition for pharmacological intervention. For clinical relevance assessment, we tested different cancer vaccine formulations at late-stage tumors in humanized-CD3000ld mice. Results In contrast to early stage vaccination, PC7A nanovaccine administration at the late tumor stage exhibited minimal therapeutic effects on tumor progression, while concurrently increasing PMN-MDSC infiltration and enhancing their immunosuppressive activity. KO of CD300ld, a critical immune suppressor on PMN-MDSCs, abolished both PMN-MDSC recruitment and their T-cell suppressive function, restoring the antitumor efficacy of PC7A vaccine in multiple advanced tumor models. Furthermore, in wild-type and CD300ld humanized mouse models, competitive blockade of CD300ld using recombinant extracellular domain proteins overcame resistance of advanced tumors to different cancer vaccine formulations. Conclusion Our results reveal that vaccination at the late tumor stage significantly augments the recruitment and immunosuppressive capacity of PMN-MDSCs, driving resistance of advanced tumors to cancer vaccines. The findings demonstrate PMN-MDSCs as critical mediators of vaccine resistance in advanced tumors and highlight modulation of PMN-MDSCs by CD300ld blockade as a promising strategy to enhance the therapeutic efficacy of cancer vaccines, particularly for patients with late-stage malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e8f582413d465b6868ffeb464c255ca4250b3ab9" target='_blank'>
              CD300ld blockade overcomes PMN-MDSC-mediated vaccine resistance in advanced tumors
              </a>
            </td>
          <td>
            Xianglei Wang, Shiyao Xue, Yuwei Li, Miaomiao Yang, Haotian Yu, Mengyan Wang, Suxin Li, Zhigang Lu, Min Luo
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ded847f9a961858c4472f12805dacdcbb17a082a" target='_blank'>
              Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of EBV+ diffuse large B-cell lymphoma
              </a>
            </td>
          <td>
            É. Fennell, S. Law, Alexander C. Dowell, Matthew Pugh, Christina M. Enright, Aisling M. Ross, Aoife Hennessy, Ciara I Leahy, Nadezhda Nikulina, Alex G. Richter, L. Mundo, Lorenzo Leoncini, S. Lazzi, M. Siciliano, Stefan Dojcinov, Leticia Quintanilla-Martínez, Ken H. Young, Maher K Gandhi, Graham S. Taylor, Paul Murray
          </td>
          <td>2026-01-28</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) of classic Hodgkin Lymphoma (cHL) contribute to the development of immunosuppressive tumor microenvironment (TME) and are associated with worse treatment outcomes. However, detailed features, functions and therapeutic vulnerabilities of cHL TAMs remain largely unknown. To address this, we analyzed cHL diagnostic biopsies by Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) and assessed transcriptional, proteomic and metabolic profiles of in vitro TAM models. We show that Reed–Sternberg (RS) cells induce a disease-specific TAM phenotype, characterized by elevated expression of factors involved in chemotaxis, angiogenesis, extracellular matrix remodeling and tumor immune escape. RS cell-conditioned TAMs expressed TGFβ, CCL17 and tryptophan catabolizing enzymes, IDO1 and IL4I1, promoting regulatory T cell recruitment and activation. In addition, we identified the expression of PIM1/2/3 kinases in cHL TAMs and characterized PIMs as critical hubs orchestrating RS-macrophage interactions. Pharmacological PIM blockade attenuated the RS-induced TAM transcriptional program. In established TAMs, PIM inhibition or PROTAC-mediated degradation decreased the expression of multiple factors associated with pro-tumoral TAM functions, including IL8, MMP9, CHI3L1/2, CD206, CD209, PD-L1, CCL17, TGFβ, IL4I1 and IDO1. PIM blockade attenuated TAM-dependent eosinophil chemoattraction, extracellular matrix remodeling, angiogenesis and regulatory T-cell development. Taken together, our study highlights the role of PIMs in the regulation of pathogenic TAM functions in cHL, further supporting the rationale of PIM targeting in this disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1982195fb047b4fe2306569c314b17e32eb5f1b8" target='_blank'>
              PIM kinase inhibition attenuates pro-tumoral and immunosuppressive functions of macrophages in classic Hodgkin lymphoma
              </a>
            </td>
          <td>
            Maciej Szydłowski, E. Kurtz, F. Garbicz, Julia Maroszek, Michal Pawlak, Natalia Ochocka, Marcin Tabaka, Monika Prochorec-Sobieszek, A. Szumera-Ciećkiewicz, P. Górniak, O. Szymańska-Giemza, Grzegorz Rymkiewicz, A. Kołkowska-Leśniak, Wojciech Kukwa, E. Paszkiewicz-Kozik, Justyna Totoń-Żurańska, Sylwia Radomska, Z. Pilch, D. Nowis, Jakub Gołąb, M. Kurlapski, J. Zaucha, Alicja Braczko, Marcin Kaszkowiak, Paweł Wołkow, K. Wiktorska, J. Brognard, Sabina Lichołai, E. Lech-Maranda, P. Juszczyński
          </td>
          <td>2025-12-26</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Background/Objectives: Bone marrow mesenchymal stromal cells (MSCs) are therapeutic cells that adopt an immunomodulatory phenotype when exposed to pro-inflammatory cytokines. Recent research efforts uncovered that many therapeutic benefits of MSCs can be attributed to the secretion of extracellular vesicles (EVs) such as exosomes, small membrane vesicles of endocytic origin present in the cellular secretome. EVs’ formation and release are impacted by the autophagy pathway, which recycles proteins and organelles via lysosomal degradation. Methods: To evaluate how modulation of autophagy affects properties of MSC EVs enriched in exosomes under pro-inflammatory conditions, we treated the cells with either tamoxifen (TX) or chloroquine (CQ), two drugs known to stimulate or inhibit autophagy, respectively, together with IFNγ. MSC EVs enriched in exosomes were then purified from serum-free media, and their immunoregulatory properties were evaluated ex vivo using activated CD4 T cells; small RNA sequencing was also conducted to determine EVs’ microRNA content. Results: Our data indicate that MSCs treated with CQ + IFNγ yield EVs that possess somewhat higher capacity to decrease T cell proliferation compared to other EVs. Small RNA sequencing revealed that, although similar microRNAs were found in EVs isolated from all treated cells, the treatments exerted more effect on the levels of multiple microRNAs that are known to regulate either cancer or inflammation-related biological pathways in target cells. Conclusions: Overall, we conclude that the co-treatment of MSCs with TX or CQ in the presence of pro-inflammatory cytokine IFNγ has the potential to modulate microRNA content of EVs, potentially affecting biological properties of such EVs and their effect on target cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ce2bb11a7de2fec2c7f0ea8f816d32970804b872" target='_blank'>
              Functional and Molecular Characterization of Extracellular Vesicles Enriched in Exosomes Released by Bone Marrow Mesenchymal Stromal Cells Exposed to IFNγ in Combination with Autophagy Modulators Tamoxifen or Chloroquine
              </a>
            </td>
          <td>
            Vladimir Beljanski, Maria J Moreno Hollweg, Renee Potens, Tanner Blaylock, Andres B. Irausquin, Nikhila Paleati, L. Nathanson
          </td>
          <td>2025-12-24</td>
          <td>Non-Coding RNA</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="ABSTRACT Bispecific antibodies are used for the treatment of hematological malignancies as well as solid tumors. One of their main effector mechanisms is the recruitment of effector cells such as CD8+ T cells and CD16A+ NK cells to tumor cells. Bispecific innate cell engagers (ICE®) harnessing CD16A+ NK cells have been shown to induce significant tumor cell lysis in preclinical models, translating to promising signs of clinical activity together with a well-managed safety profile. However, how killing of tumor cells by NK cells influences other innate immune cells in the tumor microenvironment, such as dendritic cells (DCs), instrumental in bridging innate and adaptive tumor immunity, is largely unknown. Thus, we here analyzed whether antibody-dependent cell-mediated cytotoxicity by NK cells affected human DC subpopulations. We could show that killing of tumor cells leads to a strong activation of human conventional DCs type 1 (cDC1), DC2, and DC3 with enhanced expression of co-stimulatory molecules as well as the secretion of proinflammatory cytokines. Further, DC subpopulations as well as surviving tumor cells showed increased expression of the immunoregulatory molecule PD-L1 that is known to dampen T-cell immunity. Nevertheless, ADCC boosted the capacity of cDC1 and DC2 to prime naïve T cell responses but not of DC3. Thus, our data suggests that the therapy with bispecific antibodies targeting NK cells may have the potential to facilitate adaptive antitumor immune responses via activation of cDC1 and DC2.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b68faec76c8019914aaaeb0bb112e3f2ed84b4a" target='_blank'>
              NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells
              </a>
            </td>
          <td>
            L. Heger, Tomasz Kaszubowski, L. Amon, C. H. Lehmann, Susanne Wingert, J. Medina-Echeverz, Joachim Koch, Holger Hackstein, A. Purbojo, Arndt Hartmann, Christoph Alexiou, R. Cesnjevar, J. Pahl, Diana Dudziak
          </td>
          <td>2026-01-18</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="Macrophage (M-), granulocyte (G-), and granulocyte–macrophage (GM-) colony-stimulating factors (CSFs) regulate myeloid cell function, yet their relative roles during inflammation remain poorly defined. To uncover how CSFs shape spatial immune niches in Crohn’s disease, we performed Xenium single-cell spatial transcriptomics on ileal tissues, revealing cell-type–specific expression and source–target interactions for each CSF. GM-CSF, unlike M-CSF or G-CSF, was locally enriched in ulcerated regions where lymphocytes adjacent to macrophage aggregates signaled through STAT5 phosphorylation. To study functional consequences, we developed a csf2rb−/− zebrafish model of intestinal injury. Using this model, we found that loss of GM-CSF signaling exacerbated epithelial damage and inflammation, whereas recombinant human GM-CSF limited injury by restraining ILC1 expansion, sustaining ILC3 maintenance, and promoting IL-22 production. Cross-species single-cell analysis revealed conserved ILC gene modules and GM-CSF–dependent transcriptional networks linking lymphoid and myeloid populations. These findings establish GM-CSF as a critical spatial regulator of myeloid– lymphoid crosstalk and intestinal immune homeostasis in Crohn’s disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f00007d07a69aab09e62b90dd50c0a25c3fde56" target='_blank'>
              GM-CSF regulates ILC states and myeloid cell signaling during ulceration in Crohn’s disease
              </a>
            </td>
          <td>
            Joshua K. Morrison, Ksenija Sabic, Neha Maskey, Sayali Talware, Nai-yun Hsu, Colleen Chasteau, Elizabeth Aslinger, Jake Herb, Shikha Nayar, Rachel M. Levantovsky, Christopher Tastad, Rachel Moss, A. Soto, M. Garcia-Barros, Jessy Ntunzwenimana, Mariel Glass, Michelle Bao, Jiayu Zhang, Huajun Han, Jane Stevens, Lorena Tavares, T. H. Thin, S. Khaitov, Alexander Greenstein, R. Brody, Jaime Chu, A. Mortha, Judy H Cho, Ling-shiang Chuang
          </td>
          <td>2026-02-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. Despite advances in surgery and chemotherapy, outcomes remain poor in metastatic cases, with five-year survival rates below 30%. This stagnation highlights the urgent need for novel therapeutic strategies. Growing evidence indicates that the tumor immune microenvironment (TIME) plays a central role in OS progression, metastasis, and resistance to treatment. Immunosuppressive cells, including tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs), dominate the TIME, while cytotoxic T cells often exhibit exhaustion. Stromal barriers, hypoxia, and metabolic constraints further impair immune activity. Recent single-cell and spatial transcriptomic studies reveal that immune and stromal architectures strongly correlate with prognosis and therapeutic response. These features contribute to the limited efficacy of current immunotherapies, including immune checkpoint inhibitors (ICIs) and CAR-T cells. In this review, we summarize the cellular, molecular, and spatial components of the OS TIME, critically evaluate current immunotherapeutic strategies, and highlight emerging translational approaches aimed at overcoming immune resistance and improving clinical outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3f2b045dec1043e90d16aee9ed935ba08b0a4239" target='_blank'>
              Targeting the osteosarcoma immune microenvironment for improved immunotherapy and translational applications
              </a>
            </td>
          <td>
            Jinlin Cai, Shijie Qiu, Biao Sun, Jianbin Ge, Zhe Yu, Chao Wang
          </td>
          <td>2025-12-21</td>
          <td>Discover Oncology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c872e20ed96ce9671cd91e8697d416593c662410" target='_blank'>
              Cellular stress, cell death, and extracellular vesicles: redefining the therapeutic landscape of rheumatoid arthritis
              </a>
            </td>
          <td>
            Barathan Muttiah, A. Wahab
          </td>
          <td>2025-12-24</td>
          <td>Clinical Rheumatology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="CD8⁺ T lymphocytes are pivotal effectors of adaptive immunity, executing cytotoxic mechanisms essential for pathogen clearance, tumor surveillance and tissue protection. Their activity is shaped by antigenic stimulation, cytokine networks and the metabolic and structural architecture of the tissue microenvironment. Physical exercise has emerged as a potent, non-pharmacological modulator of CD8⁺ T cell biology, capable of influencing recruitment, activation, differentiation and functional persistence. Acute exercise mobilizes effector and memory subsets, enhances trafficking to peripheral tissues and transiently alters activation thresholds, while sustained training remodels subset composition, preserves mitochondrial competence and attenuates immunosenescence. These adaptations are orchestrated through integrated neuroendocrine, vascular and metabolic pathways that recalibrate chemokine gradients, nutrient availability and energetic support. However, the magnitude and direction of these effects are highly context-dependent, varying with host physiology, disease state and microenvironmental constraints. This Review integrates mechanistic and translational evidence across physiological and pathological settings—including cancer, infectious, neurological and metabolic diseases—to clarify when and how exercise can be leveraged to reinforce cytotoxic immunity. We highlight key methodological and biological challenges, and propose biomarker-guided, microenvironment-informed and adaptively titrated exercise interventions as a framework for advancing exercise from an adjunctive measure to a modulatory, precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/697b8e18eede93afa0da0c621d293296cae7424c" target='_blank'>
              Modulating CD8⁺ T cell immunity through exercise: mechanistic insights and implications for precision immunotherapy
              </a>
            </td>
          <td>
            Xinyuan Zhao, Xu Chen, Pei Lin, Yunfan Lin, Weiyao Feng, Meiyan Zou, Nina Li, Li Cui
          </td>
          <td>2026-01-01</td>
          <td>Theranostics</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/beabceacb63b3dbb4387a84c771d3db87e43801f" target='_blank'>
              IL-21 mediates crosstalk between T cells and NK cells during the remission of type 1 diabetes
              </a>
            </td>
          <td>
            K. Lei, Xinyu Li, T. Zhong, Rong Tang, Qiaolin Deng, Paul E. Love, Zhiguang Zhou, Bin Zhao, Xia Li
          </td>
          <td>2026-01-01</td>
          <td>Nature Metabolism</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Chronic HIV infection drives B cell dysfunction associated with the accumulation of tissue-like memory (TLMs) and activated memory B cells (MBCs) but decline in resting memory B cells. TLMs express multiple inhibitory receptors and lack response to soluble antigens. However, their origin and the mechanisms driving their expansion in HIV infection remain unclear. From bulk heavy chain BCR sequencing of MBC subsets from 5 PLWH with no detectable viremia, we hypothesized that TLMs (CD21- CD27- B cells) were significantly less mutated but also less diverse than other MBCs, suggesting an enrichment for innate-like B cells or that they belong to a less mature subset. Subsequent detailed multi-omics study of an immune response to a transient HIV viremia in an elite controller demonstrated a functional increase in Env-reactive IgG and MBCs with non-TLM phenotype. Single-cell RNA/BCR sequencing of PBMCs enriched for B cells revealed an orchestrated TNF-α response followed by interferon-α and -γ responses across all B cell subsets. This study provides new insights into multifaceted functional B cell response to transient HIV viremia and highlights TLM heterogeneity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/46013734e573b53cbb67c0c4d1938bb50c8f4ad7" target='_blank'>
              Multifaceted B cell response to transient HIV viremia in elite controllers
              </a>
            </td>
          <td>
            L. Muir, Ondrej Suchanek, Peter Thomas, Sarah A. Griffith, E. Touizer, C. Rees-Spear, Robert Krause, M. Yoshida, C. Pinder, Rutuja Patil, Marko Z. Nikolić, K. Doores, M. V. van Gils, A. Leslie, A. Sigal, Ravindra K. Gupta, M. Clatworthy, Laura E McCoy
          </td>
          <td>2026-01-01</td>
          <td>PLOS Pathogens</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="Immune checkpoint blockade (ICB) therapy is one of the cornerstones of cancer treatment regimens, but the overall response rates remain low because of suppressive immune cells, such as myeloid-derived suppressor cells (MDSC). Therefore, it is unmet need to target MDSC to achieve better outcomes of ICB therapy. Inositol-requiring enzyme 1α (IRE1α) is identified as a key regulator for the generation of MDSC. Here, we evaluated the potential of KIRA6, an inhibitor for IREα kinase activity and RNase activity, to abrogate MDSC-mediated immune suppression. KIRA6 significantly suppressed 4T1 tumor growth, decreased MDSC population and enhanced T cell infiltration. Two dosages of KIRA6 treatment directly inhibited extramedullary myelopoiesis and MDSC generation in vivo. KIRA6 abrogated the induction of MDSC from bone marrow cells and abolished the immunosuppressive capability of MDSC in vitro. Meanwhile, KIRA6 not only attenuated G-CSF production from tumor cells thereby blocking the induction of MDSC, but also caused apoptosis of tumor cells. Moreover, KIRA6 treatment diminished MDSC generation, restored T cell proportion in both local and systemic immune landscapes and eventually overcame resistance to anti-PD-1 therapy. Our work establishes the evidence for KIRA6 as an impressive agent for abrogating MDSC-mediated immune suppression, killing tumor, and overcoming ICB resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5734c0f30eda05dc79c00e03122bb8b481259562" target='_blank'>
              KIRA6 restrains the generation of myeloid-derived suppressor cells and overcomes resistance to anti-PD-1 therapy
              </a>
            </td>
          <td>
            Chun Chen, Jing Chen, Xiaowen Lin, Jiali Hu, Yuncong Zhang, Dingjie Liu, Xumei Ouyang, Jing Li, Wenting Li, Shiying Xie, Ya Meng, Meixiao Zhan, Yongjun Peng, Hong-Wei Sun
          </td>
          <td>2025-12-27</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Background Although immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with certain cancers, their efficacy is largely confined to “hot” tumors characterized by robust infiltration of tumor-specific CD8+ T cells. Conversely, tumors expressing B7-H4 often exhibit an immunologically “cold” tumor microenvironment with poor T cell infiltration, contributing to primary resistance to programmed cell death protein 1 (PD-1) blockade. Methods We evaluated the association between B7-H4 expression and clinical outcomes in ICI-treated patients using public immunotherapy datasets. The role of B7-H4 in mediating resistance to PD-1 therapy was examined in mouse tumor models. A fully human anti-B7-H4 monoclonal antibody (clone A8) was generated via phage display screening from a non-immunized human single-chain variable fragment library. In vitro assays assessed antibody-induced tumor cell death and immune activation, while in vivo efficacy was tested in MC38-mH4 and SKOV3-hH4 tumor models, as well as human colorectal cancer organoids. Statistical analyses included Student’s t-test, one-way analysis of variance, and Kaplan-Meier survival analysis, with p<0.05 considered significant. Results High B7-H4 expression was associated with inferior prognosis in patients receiving ICI therapy. In MC38-mH4 tumors, B7-H4 expression conferred resistance to anti-PD-1 treatment. We identified A8, a novel antibody targeting the IgV-like domain of B7-H4, with cross-reactivity to both human and mouse B7-H4. A8-hIgG1 and its Fab fragment induced dynamin-dependent endocytosis of B7-H4, resulting in lysosomal accumulation, altered lysosomal membrane permeabilization and intracellular acidification, ultimately triggering ferroptosis, a form of immunogenic cell death. A8 binding was enhanced under acidic conditions (pH 5.5), promoting lysosome-dependent degradation of B7-H4. A8-induced ferroptosis enhanced dendritic cell maturation, macrophage phagocytosis, and T cell activation. In vivo, A8 promoted CD8+ T cell and HER2 chimeric antigen receptor-T cell infiltration, inhibited tumor growth, and synergized with PD-1 blockade to overcome primary resistance in multiple preclinical models. This immunogenic and lysosome-dependent cell death mechanism was unique to A8 among the anti-B7-H4 antibodies tested. Conclusions Our study identifies a novel mechanism by which a fully human anti-B7-H4 antibody induces lysosome-dependent immunogenic tumor cell death. These findings support the therapeutic potential of A8 as a single agent or in combination with PD-1 blockade to overcome immune resistance in B7-H4-expressing “cold” tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e4a65850dabefc9f3db32818917c7d119a6fd83c" target='_blank'>
              Fully human anti-B7-H4 antibody induces lysosome-dependent ferroptosis to reverse primary resistance to PD-1 blockade
              </a>
            </td>
          <td>
            Renlu Zhang, Yang Wang, Yue Wu, Bingyu Zheng, Qiumei Cao, Yunhan Chen, Zhengyun Cao, Yanyang Zhu, Linlin Zhou, Qiuyu Zhang
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>1</td>
          <td>4</td>
        </tr>

        <tr id="Background Mismatch repair deficiency (dMMR) colorectal cancer (CRC) is characterized by abundant tumor-infiltrating lymphocytes and tertiary lymphoid structures (TLSs). However, while B cells are pivotal for TLS formation, their function and the signaling pathways driving their activation in dMMR CRCs remain undefined. Methods Data from The Cancer Genome Atlas (TCGA) database analyzed by XCELL method and multiplex immunofluorescence (MIF) staining tissue slides were used to compare the abundance and distribution of TLSs and B cell populations between dMMR and proficient MMR cohorts. Then MLH1 knockdown models both in vitro and in vivo were used to mimic dMMR/high microsatellite instability (MSI-H) tumors and explore the influence of tumor cells on B cell behavior. Results TCGA analysis and MIF staining revealed a significant association between memory B cell abundance, TLS formation, and improved prognosis in dMMR CRCs. In vivo MLH1 knockdown models showed that B cell depletion enhanced tumor growth and reduced the efficacy of anti-PD-1 treatment in dMMR CRCs. Furthermore, in vitro experiments demonstrated a dsDNA/STING/type I interferon (IFN)/STAT1/ccl19 signaling pathway mediating the dMMR-induced increase in memory B cells. Conclusions In conclusion, these findings show that CCL19 generated by STING/type I IFN/STAT1 pathway in dMMR/MSI-H CRC cells can promote the expansion of memory B cells, which suppresses tumor growth and enhances the efficacy of PD-1 blockade.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bb65cbe9f6749b0489caab027f55d644dd2e9a2c" target='_blank'>
              Memory B cell subset shapes antitumor immunity and response to PD-1 blockade in mismatch repair-deficient colorectal cancers
              </a>
            </td>
          <td>
            Huilin Huang, Zhian Chen, Xinyuan Mao, Jiaqiang Jiang, Yijie Xi, Yihong Wan, Lingzhi Wang, Xinhua Chen, Yanfeng Hu
          </td>
          <td>2026-01-01</td>
          <td>Journal for ImmunoTherapy of Cancer</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Silicosis is a progressive lung fibrosis lacking effective treatment. Mesenchymal stem cells (MSCs) show antifibrotic potential, but their survival is impaired by the early inflammatory microenvironment. The therapeutic value of repeated MSC administration remains unclear. A murine silicosis model was analyzed by single-cell RNA sequencing, bronchoalveolar lavage fluid (BALF) cytokine assays, and human Bone Marrow-Derived Mesenchymal Stem Cells (hBMSCs) transcriptomics after BALF exposure. Mice received either single or repeated intratracheal hBMSCs doses. Cell retention, lung function, imaging, histology, and fibrosis markers were assessed. The role of ZC3H4 in macrophage activation was examined by in vivo expression profiling, in vitro knockdown, and functional assays. Early silica exposure triggered strong M1 inflammation, high BALF cytokines, and hBMSCs senescence signatures. Repeated hBMSCs dosing improved cell persistence, reduced fibrosis on imaging and histology, enhanced lung function, and decreased collagen deposition compared with a single dose. Mechanistically, MSC therapy suppressed macrophage ZC3H4 expression, while ZC3H4 knockdown reduced macrophage activation and fibroblast migration. Repeated hBMSCs administration enhances therapeutic efficacy in silicosis by improving cell persistence and attenuating fibrosis, partly through ZC3H4-mediated regulation of macrophages.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ac0b00294ed8c4f98e0c63883faa1d16f5193df" target='_blank'>
              Enhanced therapeutic efficacy of repeated bone marrow–derived MSC administration in a murine model of pulmonary fibrosis
              </a>
            </td>
          <td>
            Zihan Zhou, Jiawei Ding, Shuhua Han, Yuanfang Duan, Jie Chao, Jie Huang
          </td>
          <td>2025-12-23</td>
          <td>Stem Cell Research & Therapy</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Pattern recognition receptors (PRRs) are crucial modulators of the tumor immune microenvironment (TIME); yet, their comparative efficacy remains poorly characterized. Platelet factor 4 (PF4/CXCL4) exerts paradoxical effects in cancer, and its regulation by PRR signaling is unclear. Here, we systematically screened PRR agonists in murine tumor models and identified TLR8 agonists as the most potent inducers of a pro-immunogenic TIME, superior to agonists targeting TLR3/7/9 or NOD1/2. TLR8 activation drove CD45+ leukocyte infiltration, potentiated conventional dendritic cell (cDC) and macrophage phagocytosis and migration, amplified recruitment of CD8+ and conventional CD4+ (cCD4+) T cells, lowered Treg proportions, elicited pro-inflammatory and tumoricidal phenotypes in innate immune cells and CD8+ T cells. Notably, TLR8 agonism suppressed tumor growth in both immunocompetent and T cell-deficient mice, indicating the involvement of both innate and adaptive immunity. Mechanistically, TLR8 agonists upregulated PF4 expression in macrophages, cDC2, and CD8+ T cells via the NF-κB pathway. PF4 in turn recruited cCD4+ T cells via CXCR3, and its local overexpression mimicked the antitumor effect of TLR8 activation. Beyond PF4, TLR8 signaling mediated PF4-independent effects, including Treg suppression via IFN-γ and enhanced macrophage phagocytosis. Combination of a TLR8 agonist with anti-PD-1 therapy markedly and synergistically improved survival of tumor-bearing mice. Thus, TLR8 agonists optimally remodel the TIME through PF4-dependent T cell recruitment and PF4-independent ancillary mechanisms. Our finding that the antitumor activity of locally induced PF4 contrasts with its reported protumor effects when expressed systemically clarifies the context-dependent duality of PF4 in cancer. These results position TLR8 agonists as promising candidates for combination immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/85ebcb231bddc85df8191e4fd391daf600c79ad8" target='_blank'>
              TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms
              </a>
            </td>
          <td>
            Qikai Zhou, Zhixue Wang, Yixian Cao, Zhengheng Zheng, Wen Li, Zifeng Fu, Wenqin Luo, , Bin Ma
          </td>
          <td>2026-02-12</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Mesenchymal stem cells (MSCs) are recognized for their capacity to modulate immune responses, including those directed against tumors. In this study, we investigated the temporal effects of MSCs administration on anti-tumor immunity in a murine 4T1 breast cancer model. BALB/c mice were intraperitoneally injected with MSCs either 24 h (MSC1d) or 14 days (MSC14d) after orthotopic implantation of 4T1 mammary carcinoma cells. Early MSC administration (MSC1d) exhibited changes in immune cell phenotypes consistent with enhanced antitumor potential, including increased activity of natural killer (NK) cells, dendritic cells (DCs), macrophages, and T lymphocytes. These immunological changes correlated with reduced tumor growth and prolonged survival. Mice in the MSC1d group exhibited elevated serum levels of pro-inflammatory and anti-tumor cytokines (TNF-α, IFN-γ, IL-6, and IL-17), alongside decreased concentrations of immunosuppressive cytokines (TGF-β and IL-10). Tumor tissue analysis revealed increased infiltration of NK cells expressing markers associated with antitumor activity (IFN-γ-producing CD178⁺), CD80⁺/CD86⁺/I-A⁺ TNF-α-producing DCs, Th1-type CD4⁺ T cells, and Granzyme B-expressing CD8⁺ cytotoxic T lymphocytes (CTLs). Additionally, spleens of MSC1d-treated mice displayed significantly elevated populations of CD11c⁺ DCs, TNF-α/IFN-γ-secreting NK cells, CD4⁺ Th1 and Th17 cells, and CD8⁺ CTLs expressing markers associated with cytotoxic function (TNF-α, IFN-γ, and IL-17). Conversely, late MSCs administration (MSC14d) was associated with immunosuppression. Tumors from MSC14d-treated mice showed a decreased presence of IFN-γ⁺ and IL-17⁺ NK1.1⁺ cells, F4/80⁺ macrophages, IL-12⁺ DCs, and cytotoxic T cells. Spleens from these mice revealed a significant expansion of regulatory T cell (Treg)-like populations, including CD25⁻, FoxP3⁻, CD25⁺FoxP3⁻ cells, and TGF-β/IL-10-producing CD3⁺ and CD4⁺ T cells. Furthermore, serum levels of immunosuppressive mediators TGF-β and vascular endothelial growth factor (VEGF) were significantly elevated in the MSC14d group. Collectively, these findings demonstrate that the immunomodulatory effects of MSCs on breast cancer are highly dependent on the timing of their administration. Mesenchymal stem cells delivered during early tumor development enhance phenotypes consistent with antitumor potential and suppress tumor progression, whereas administration during later stages promotes immune evasion and tumor growth.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c808072251961d94efaa18f265914925e1e7ece9" target='_blank'>
              Temporal dynamics of mesenchymal stem cell administration influence immune modulation in a 4T1 breast cancer model
              </a>
            </td>
          <td>
            Dragana Papic, Dragica Pavlovic, Danijela Nićiforović, V. Jurišić, V. Volarevic
          </td>
          <td>2026-01-01</td>
          <td>Cell Transplantation</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Non-small cell lung cancer (NSCLC) patients present greatly different responses to immunotherapy. The main clinical challenge lies in the poor response to immune checkpoint inhibitors (ICIs), and the underlying mechanisms remain unclear. Here, single-cell RNA sequencing and bulk RNA sequencing data were comprehensively analyzed. Tumour samples from NSCLC patients treated with ICIs were subjected to multiplexed immunofluorescence staining, and PBMCs were extracted from peripheral blood for flow cytometry. Primary cells were isolated from the PBMCs of NSCLC patients for in vitro coculture experiments, and a murine subcutaneous Lewis lung carcinoma (LLC) model was used for in vivo experiments. This study proposed the hypothesis that CD8 + CD101 + TIM3 + T cells (CCT T cells) are differentiated from CD8 + CD101-TIM3 + T cells (Pre-CCT T cells). This differentiation process is mediated by M2 macrophages via the SPP1‒CD44 pathway and influences the immunotherapeutic response of NSCLC. Analysis of NSCLC clinical samples revealed that lower proportions of tumour-infiltrating CCT T cells and M2-TAMs were associated with a better immunotherapeutic response. According to in vitro experiments, coculture with M2 macrophages significantly increased the CD101 expression in Pre-CCT T cells, whereas in vivo experiments revealed that the removal of bone marrow-derived M2-TAMs significantly lowered the proportion of CCT T cells, inhibited tumour growth, and improved the response to anti-PD-1 therapy. Besides, blockade of the SPP1‒CD44 pathway remarkably weakened the CD101 expression in Pre-CCT T cells in coculture experiments. Moreover, blockade of the SPP1‒CD44 pathway in vivo significantly inhibited tumour growth and enhanced the response to anti-PD-1 therapy in C57BL/6 mice. Our study provides insights into the promotion of Pre-CCT T-cell differentiation by M2 macrophages through the SPP1‒CD44 pathway and elucidates its important role in anti-PD-1 therapy, thus providing potential strategies for increasing immunotherapy efficacy in NSCLC patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67b0ca799ab4499d0ce5b771108a27e20fae270e" target='_blank'>
              M2 macrophages modulate the differentiation of CD8 + CD101-TIM3 + T cells via the SPP1‒CD44 pathway, influencing the immunotherapeutic response in NSCLC
              </a>
            </td>
          <td>
            Guoyue Zhang, Yue Wu, Di Qi, Jia Zhou, Xiaojuan Wu, Junyi Du, Rui Xu, Xianzhi Du
          </td>
          <td>2026-01-06</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background Although most studies of anticancer T-cell immunity focus on αβ T cells, γδ T cells are attracting increasing attention due to their involvement in antitumor immune responses in various cancer entities, including melanoma. While immune checkpoint blockade (ICB) using the antagonistic programmed cell death protein 1 (PD-1) antibodies nivolumab and pembrolizumab significantly improved the survival of patients with melanoma with distant metastasis, prognosis remains poor. PD-1 is not only expressed by αβ T cells but also by γδ T cells, making this numerically minor population of unconventional T cells, whose role in melanoma is still elusive, a target of ICB. Methods Here, we present a detailed γδ T-cell profiling study in late-stage melanoma at single-cell level using mass and polychromatic flow cytometry, T-cell receptor repertoire analyses and immunohistochemistry. Results Our analyses link high frequencies of peripheral Vδ1 T cells before the start of anti-PD-1 therapy to a significantly reduced overall survival. In these patients, the Vδ1 compartment is dominated by a late-differentiated senescent-like phenotype that is presumably unresponsive to therapy. This phenotype is less prevalent at the tumor site and analysis of RNA sequencing data revealed that the abundance of Vδ1 T cells within the tumor was positively associated with survival. Conclusions Our study suggests that Vδ1 T cells are associated with clinical outcomes, with a responsive subset expanding under ICB in patients where such a response remains possible. The observed clinical effects may be supported by the infiltration of these cells into the tumor, where they contribute to cancer immunosurveillance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ad77c14a3cfc3aa02688cb2c4360370f794926a0" target='_blank'>
              Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma
              </a>
            </td>
          <td>
            Nicola Herold, Jonas Bochem, Johanna Leyens, Svenja Wingerter, Stephan Forchhammer, Janine Spreuer, M. Deseke, Can Yurttas, Paola Nocerino, Rita Antunes Dos Reis, T. Amaral, N. Wagner, K. Thiel, Daniel Soffel, Kristin Bieber, P. Terheyden, D. Wesch, H. Oberg, Susanne Sebens, Manfred Claassen, Alfred Königsrainer, Claus Garbe, Graham Pawelec, F. Meier, Markus W. Löffler, B. Weide, I. Prinz, S. Ravens, Shahram Kordasti, T. Eigentler, K. Wistuba-Hamprecht
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>61</td>
        </tr>

        <tr id="Abstract Autoreactive B cells that remain in lymphatic tissue after anti-CD20 antibody therapy are considered a major contributing factor to relapse in patients with autoimmune diseases. Natural killer (NK) cells contribute to the depletion of autoreactive B cells by anti-CD20 antibodies via antibody-dependent cellular cytotoxicity (ADCC). However, the impact of germinal centre–associated signals CD40 ligand (CD40L) and interleukin-4 (IL-4) on ADCC was unknown. This study used a combination of flow cytometry, immunohistochemistry, and ex vivo functional assays using peripheral blood mononuclear cells to investigate how CD40L and IL-4 affect NK cell–B cell interactions. CD40L and IL-4 significantly upregulate human leukocyte antigen (HLA)-E and total HLA Class I expression on the surface of B cells from healthy donors, as well as patients with rheumatoid arthritis and systemic lupus erythematosus. The upregulation of HLA-E and total HLA functions to inhibit B-cell depletion by NK cell–mediated ADCC induced by rituximab via NKG2A and killer cell immunoglobulin-like receptors (KIR). Moreover, B cells that have differentiated through the germinal centre have higher expression of HLA-E and total HLA compared with naive B cells and are more resistant to depletion by rituximab. In accordance with this, blockade of NKG2A and inhibitory KIRs by monalizumab and lirilumab, respectively, increased antibody-dependent cellular cytotoxicity against autologous B cells in vitro. Overall, this study identifies a novel mechanism of resistance of B cells to NK cell cytotoxicity and indicates that blockade of the HLA-E:NKG2A and HLA:KIR checkpoint axes could be beneficial for improving B-cell depletion in patients with autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/561c6ec6e23006f00b4f4e6e274ad061de6f4f0c" target='_blank'>
              CD40L and IL-4 lymph node-associated signals protect B cells from rituximab-induced ADCC via KIR and NKG2A
              </a>
            </td>
          <td>
            Lara V Graham, Russell B Foxall, Margaret Ashton-Key, Salim I Khakoo, Souraya Sayegh, Maria Leandro, Venkat R Reddy, M. Cragg, Matthew D. Blunt
          </td>
          <td>2026-01-13</td>
          <td>Clinical and Experimental Immunology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Immunotherapy has transformed cancer treatments, but the majority of cancer patients would inevitably develop resistance to immunotherapy. Th17 cells play complex but crucial roles in anti-cancer immune response, although their therapeutic potential remains underutilized. Segmented filamentous bacteria (SFB) function as prototypical commensal bacteria that can induce intestinal Th17 cells and impact host immune response. In this study, we investigated how SFB antigen-mediated immune responses modify the tumor microenvironment and enhance anti-tumor efficacy through a coordinated gut–lung immunological axis. We engineered B16F1 melanoma cells to express either the SFB3340 epitope (B16-3340, an I-Ab-restricted epitope derived from SFBNYU_003340 and recognized by 7B8 TCR) or a control vector (B16-MEM) to evaluate SFB antigen effects on tumor immunogenicity. We found that expression of the SFB epitope in cancer cells decreased the number of lung tumor nodules, and SFB colonization further reduced tumor growth in a lung metastasis model. In addition, Th1, Th17, and CD8+ Tc1 cells were all increased in the lungs of the B16-3340 tumor-bearing mice compared with B16-MEM control tumor-bearing mice without triggering a compensatory expansion of immunosuppressive Tregs. Interestingly, SFB triggers systemic metabolic changes and an increase metabolites from aromatic amino acid degradation pathways, providing biochemical evidence for a functional gut–lung conduit, which integrates innate microbial detection with adaptive tumor-specific immunity. Our research provides evidence to further investigate and develop novel cancer immunotherapies that utilize microbial antigens and microbiome modifications to improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c5429a38be4e5ce2d81f913e703a35d6e85fa2f2" target='_blank'>
              Commensal bacteria antigen-mediated immune response enhances anti-tumor immunity
              </a>
            </td>
          <td>
            Jessica Tzu-Chieh Lee, Soo Ngoi, Brian Deng, Megan Hill, Kai He, Yi Yang, Bei Liu
          </td>
          <td>2025-12-24</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Immune checkpoint blockade (ICB) therapy can restore T cell function in tumors, but not all patients benefit, and the mechanisms behind this remain unclear. In this study, we used patient-derived organotypic (PDO) cultures from metastatic melanoma to examine transcriptomic and cellular changes following ex vivo T cell stimulation. Genomic and transcriptomic features were preserved during PDO formation, capturing melanoma heterogeneity. PDOs from ICB-responsive patients showed rapid T cell expansion upon T cell stimulation, unlike those from ICB-resistant tissue. Resistant tissue harbored T cells lacking activation and checkpoint markers, suggesting non-tumor-reactive T cells. A T cell-specific transcriptomic score, activated in responsive PDOs, correlated with improved overall and relapse-free survival in metastatic melanoma patients treated with ICB. These findings demonstrate that ex vivo analysis is a viable tool to investigate mechanisms of ICB response and may help identify predictive biomarkers for patient outcome.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ed50cf99fb67ea8136c8c566f1253db09fe9441" target='_blank'>
              Modeling anti-tumor immune responses using patient-derived melanoma organoids
              </a>
            </td>
          <td>
            Kamila Kaminska, B. Phung, Jacob Karlström, M. Lauss, K. Harbst, Teresa Svensson, Kristian Pietras, Kari Nielsen, Ana Carneiro, Henrik Ekedahl, K. Isaksson, G. Jönsson
          </td>
          <td>2025-12-23</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="Background Giant cell tumor of bone (GCTB) presents considerable complexity in tumor microenvironment (TME) because of its intricate intercellular heterogeneity and the presence of an immunosuppressive milieu. In order to understand the complex gene expression patterns and cell interactions in GCTB, we carried out a thorough investigation using single‐cell RNA sequencing (scRNA‐seq). Methods We examined scRNA‐seq data from 7091 cells that were collected after surgical removal of GCTB. Following the initial quality control process, 10 separate groups of cells were distinguished, which consisted of dendritic cells, endothelial cells, macrophage cells, mast cells, monocyte cells, neutrophil cells, tumor cells, osteoclast cells, pericyte cells, and T cells. Additional analysis uncovered distinct categories within tumor‐associated macrophages (TAMs), CD8+ T cells, and CD4+ T cells. The differentiation mechanisms of TAMs, CD8+ T cells, and CD4+ T cells were explored using pseudo‐time trajectory analysis. The CellPhoneDB study revealed the interactions between various cell types within the TME of GCTB. Results TAMs have been identified as the main infiltrating cells in GCTB. These TAMs exhibit several subtypes that are characterized by specific marker genes and functional states. The identification of several subgroups within CD8+ T cells that are involved in regulating immunological checkpoints underscores the difficulties encountered when attempting to employ immune checkpoint blockade therapy for GCTB. T cell exhaustion poses a major barrier to the efficacy of antitumor immune responses. Research suggests a strong correlation between TAMs and exhausted T cells (Texs) in the TME. The high number of regulatory T cells (Tregs) highlights the immunosuppressive nature of the immunological environment in GCTB. Significant interactions have been observed between TAMs and tumor cells, highlighting their crucial involvement in immune evasion strategies. Conclusion This scRNA‐seq study provides a general overview of the different cellular compositions and immune interactions within GCTB. The identified subtypes and communication networks provide valuable information about the immunosuppressive environment of GCTB, laying the foundation for prospective therapeutic approaches targeting specific cell types or interactions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e77dc33f2650929ccb5e19eeed4e2c7dc7b4c11a" target='_blank'>
              Single‐Cell Sequencing Reveals the Immunosuppressive Trajectory in the Tumor Microenvironment of Human Giant Cell Tumor of Bone
              </a>
            </td>
          <td>
            Yiming Liu, Wei Luo, Yude Xu, Xiguan Yao, Libing Dai, Qiao Feng, Peigeng Wang, Weichao Yang, Yi Feng, Haixiong Miao, Suixiang Huang, Dongping Ye
          </td>
          <td>2026-01-01</td>
          <td>BioMed Research International</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Arising from extracranial cancers, brain metastases (BrM) are the most prevalent brain malignancy in adults. Even though there are recent advances in systemic cancer therapies and immunotherapies, the prognosis for BrM remains poor, with median survival rather dismal. The central nervous system (CNS) presents a distinct immunological and structural landscape that restricts immune surveillance and effective therapeutic delivery. This immune privilege is enforced by the blood brain barrier (BBB), specialized myeloid populations, in conjunction with reduced lymphatic drainage, which collectively constrains the effector immune cell trafficking and antigen presentation. Thus, immunotherapeutic strategies that have revolutionized systemic oncology, such as immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR)-T cell therapies, have presented only rather modest benefit in BrM. While immunotherapy-focused research has largely focused on T-cell-mediated mechanisms, an accumulation of recent findings suggest that B cells play multifaceted and underexplored roles within the unique CNS tumor microenvironment (TME). Aside from antibody production, B cells contribute to antigen presentation, cytokine secretion, and the formation of tertiary lymphoid structures which are functions that can either promote or suppress antitumor immunity depending on their differentiation state and local cues. In primary brain tumors, like glioblastoma (GBM), B cell infiltration has been linked to both enhance immune activation and immune regulation, yet their significance in BrM remains comparatively undefined. Understanding how B cells adapt and function within the niche constraints of the CNS, such as how they influence immune suppression, antigen presentation, and TME remodeling, may reveal new therapeutic vulnerabilities and allow for harnessing complementary B cell-based immunotherapies instead of T cell-focused approaches. This review synthesizes current knowledge on the structural and immunological features that differentiate BrM from primary brain tumors and extracranial metastases. We highlight the emerging evidence on B cell biology in the CNS, and discuss their immunostimulatory and immunoregulatory capacities, while exploring ongoing efforts to leverage B cell-based immunotherapies in brain malignancies, specifically proposed BrM. By defining the immunological landscape of BrM and the therapeutic promise of B cells, this work suggests a new possibility in CNS oncology, where humoral immunity may be harnessed to target brain metastatic malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c5a210795e3e1b6334405a1361204bc8f48954b0" target='_blank'>
              B cell immunity and therapeutic opportunities in brain metastases
              </a>
            </td>
          <td>
            Grace Jones, Alina R Murphy, Catalina Lee-Chang
          </td>
          <td>2026-01-14</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/92d7ccb154548987305467a7c4fe8a00f89e75f8" target='_blank'>
              SUMO2 Deletion Changes Chromatin Accessibility and Enhances Cytotoxic T Cell Activation and Tumor Infiltration
              </a>
            </td>
          <td>
            Mohottige D Neranjan Tharuka, Dai-Hua Chen, Maria Luisa Jurgensen Amaral, Tianchen Ren, Yixuan Kuang, Shih-Ting Huang, Nikhil Chilakapati, Bing Ren, Stephen P. Schoenberger, Ye Zheng, Yuan Chen
          </td>
          <td>2026-01-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="In preclinical models, optimum tumor control by radiation therapy incorporates CD8 T cell control of residual cancer cells. Tumor control by these CD8 T cells is negatively regulated by myeloid and T regulatory cell expansions in the tumor following radiation treatment. We demonstrate using ex vivo 3D tumor models and novel in vivo cell tracking models that radiation results in upregulation of the costimulatory molecules CD80 and CD86 on tumor macrophages and on monocytes that enter the tumor following radiation. This regulation of CD80 is not dependent on adjuvant signaling via MyD88 or STING in the myeloid cells. While we would anticipate that CD80 and CD86 would have a positive impact on anti-tumor immunity, we demonstrate that blockade of CD80 and CD86 signaling limits CD4 infiltrates in tumors and prevents the Treg expansion caused by radiation treatment. Importantly, this treatment results in improved tumor control following radiation therapy. These data link the inflammatory activation of myeloid cells in irradiated tumors to the Treg expansion following radiation and ensuing suppression of anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b1ce60db011c72d77a0495e2fb83689f7db3d3d" target='_blank'>
              Radiation therapy causes a STING and MyD88-independent upregulation of CD80 and CD86 in macrophages and monocytes that limits tumor control
              </a>
            </td>
          <td>
            Aanchal Preet Kaur, J. Baird, Alejandro F. Alice, Gwen F. Kramer, David J. Friedman, Eva Moran, M. Crittenden, Michael J. Gough
          </td>
          <td>2025-12-19</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Despite durable viral suppression, cellular sources of human immunodeficiency virus type 1 (HIV-1) persistence in human lymphoid tissues remain uncharacterized, with germinal center (GC) macrophages representing an understudied, potentially noteworthy reservoir population. Using integrated spatial, phenotypic, and molecular profiling of 42 excisional lymph nodes (LNs) from 39 individuals living with HIV-1 Clade C, including 25 under suppressive antiretroviral therapy (ART), we reveal that GC macrophages harbor HIV-1 DNA, RNA, and proteins, defining them as a functional HIV reservoir. Super-plex imaging confirms HIV co-localization with GC macrophages, which were predominantly IBA-1+CD68+and CD206−CD163−. Among individuals with sustained viral suppression, the presence of proviral DNA (3/6) and inducible multiply spliced HIV-1 RNA (3/3) confirms that LN-resident myeloid cells serve as inducible HIV-1 reservoirs. These reservoirs were markedly enriched in the LNs, with both CD4+ and myeloid compartments showing higher inducible activity than their peripheral blood counterparts. While CD4+ T cells remain the predominant source of inducible, replication-competent HIV, our detection of a LN myeloid reservoir underscores the imperative to redesign cure approaches to eliminate reservoirs across both CD4+ T cell and myeloid lineages.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b25f4bc7e5b9342be9b9516fab322d9e829ccf36" target='_blank'>
              IBA-1+CD68+ Germinal Center Macrophages Harbor Proviral and Inducible Clade C HIV Reservoirs in ART-Suppressed Human Lymph Nodes
              </a>
            </td>
          <td>
            Z. Ndhlovu, Merantha Moodley, Tanvir Hossain, Caroline Chasara, T. Khaba, B. Mahlobo, Nicole Reddy, K. Reddy, T. Ngubane, Johan Pansegrouw, Crystal A Mendoza, P. Madlala, T. Ndung’u, T. Mahmoudi
          </td>
          <td>2026-01-07</td>
          <td>Research Square</td>
          <td>0</td>
          <td>69</td>
        </tr>

        <tr id="

 Anti-interferon-γ autoantibodies (AIGAs) immunodeficiency syndrome is an emerging adult-onset immunodeficiency causing opportunistic infections. However, its comprehensive immune landscape remains elusive. This study presents the first single-cell RNA sequencing (scRNA-seq) analysis of AIGAs immunodeficiency syndrome, aiming to delineate its pathogenic mechanisms.



 We performed scRNA-seq on peripheral blood mononuclear cells (PBMCs) from 8 AIGAs immunodeficiency syndrome patients (4 infective, 4 stable phase) and 3 healthy controls. Findings were validated by flow cytometry in an expanded cohort (15 patients vs. 10 controls).




 Single-cell RNA sequencing of PBMCs from patients with AIGAs immunodeficiency syndrome identified a comprehensive immune subset profile, including effector memory CD4
 +
 T cells, naive CD4
 +
 T cells, regulatory T cells, GNLY
 +
 CD8
 +
 Tem, GZMK
 +
 CD8
 +
 Tem, naive CD8
 +
 T cells, naive B cells, memory B cells, plasma cells, ISG
 +
 atypical B cells, monocytes, and NKT cells. ScRNA-seq analysis revealed a significantly higher proportion of Th1 cells (16.62% vs. 6.94% in controls) and ISG
 +
 B cells (2.95% vs. 0.53%), alongside a lower proportion of plasma cells (9.30% vs. 17.79%) and memory B cells (9.54% vs. 27.35%). Flow cytometry consistently confirmed the increase in Th1 cells (21.84% [14.87–27.57] vs. 11.96% [7.19–15.74]) and decreases in marginal zone B cells (2.87% [1.71–4.45] vs. 8.60% [6.77–15.65]), memory B cells (13.85% [5.72–20.23] vs. 22.96% [16.39–33.83]), and class-switched B cells (6.11% [2.39–9.10] vs. 10.18% [5.35–15.77]). Transcriptome analysis demonstrated upregulated expression of interferon-response and HLA genes (e.g., HLA-DQB1, HLA-DQA1, HLA-DRB1), whereas IRF1 was downregulated across all subsets; functional enrichment analyses further highlighted significant activation in IFN signaling and B cell activation pathways. CellChat and pseudotime analyses indicated that CD4
 +
 Tem and CD14
 +
 monocytes drive sustained Th1 inflammation and monocyte hyperactivation through enhanced pro-inflammatory and antigen-presenting interactions, with T-cell differentiation skewed toward terminal effectors and B-cell development disrupted by ISG
 +
 B cell emergence, premature plasma cell formation, and IGLC3-biased class switching, collectively delineating the interferon-mediated immunopathology of AIGAs immunodeficiency syndrome.





 In summary, this first single-cell atlas maps AIGAs immunodeficiency syndrome as a Th1-skewed, IFN-γ-driven disorder sustained by CD4
 +
 Tem–CD14
 +
 monocyte crosstalk. It combines T-cell activation, expanded Th1 and ISG
 +
 B cells, and loss of memory/plasma B cells to drive autoantibody generation. Skewed T- and B-cell trajectories and polygenic up-regulation of interferon/HLA genes provide a clear mechanistic rationale for targeted therapy.

">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fb5ad0a7e725df5bed64985b2e694d342b5d7474" target='_blank'>
              Upregulation of interferon-γ activation in patients with anti-interferon-γ autoantibodies immunodeficiency syndrome: insights from single-cell analysis
              </a>
            </td>
          <td>
            S. Liang, Xue-mei Huang, , Siyao Wu, Limei Hong, N. Chen, Zengtao Luo, Y. Ning, Meng-chan Wang, 
          </td>
          <td>2026-02-03</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f517628343fca7d577007526b6194b2f13cd9d26" target='_blank'>
              Immune checkpoint inhibitors amplify type 2 immune mediated repair by pro-regenerative scaffolds
              </a>
            </td>
          <td>
            Jordan Garcia, Anna Ruta, Frank Haoning Yu, Joscelyn C. Mejías, Alexis N Peña, Natalie Rutkowski, Elise F. Gray-Gaillard, Constance Dubois, Chris C. Cherry, Maria Browne, Katlin B. Stivers, David R Maestas, Kavita Krishnan, Alexander T. F. Bell, E. Fertig, C. Cooney, Damon Cooney, Patrick Byrne, A. Hillel, Kellie N. Smith, Hongkai Ji, Robert Anders, Drew M. Pardoll, Jennifer H. Elisseeff
          </td>
          <td>2026-02-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="Cytomegalovirus (CMV) is a prevalent β-herpesvirus that persists asymptomatically in immunocompetent hosts. In people with HIV-1 (PWH), CMV is associated with HIV-1 persistence and particular inflammatory-related comorbidities. The true causative role of CMV in HIV-associated pathologies, however, remains unclear given that nearly all PWH are coinfected with CMV. In this study, we examined acute phase immune and virological dynamics in cohorts of SIV-infected rhesus macaques (RMs) that were naturally seropositive or -negative for rhesus CMV (RhCMV). We observed prior to SIV, RhCMV expanded a polyclonal population of target CCR5+CD4+ T cells in gut and lymph nodes that expressed the chemotactic receptor CXCR3 and were largely not specific for RhCMV. Upon SIV infection, RhCMV+ RMs exhibited higher peak viremia and elevated levels of SIV DNA in the upper and lower intestine. Greater seeding of SIV DNA was associated with a maintenance of CCR5-expressing CD4+ T cells that were enriched within the RhCMV+ gut along a CXCR3/CXCL9 chemotactic axis. Overall, the data suggest that RhCMV can promote SIV susceptibility within a diverse, polyclonal pool of CD4+ T cells that are not entirely RhCMV specific.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c5d4abf9b37dd67fbc5de74537b3c674d6a16eb1" target='_blank'>
              RhCMV expands CCR5+ memory T cells and promotes SIV reservoir seeding in the gut mucosa
              </a>
            </td>
          <td>
            Chrysostomos Perdios, Naveen Suresh Babu, Celeste D. Coleman, Anna T. Brown, Shevon N. Alexander, Matilda J. Moström, C. Allers, Lara Doyle-Meyers, C. Fennessey, Lori A. Rowe, Brandon F. Keele, Amitinder Kaur, Michael L. Freeman, Joseph C. Mudd
          </td>
          <td>2025-11-25</td>
          <td>JCI Insight</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Vaccination is the preferred strategy for preventing infections such as influenza in elderly individuals; however, its efficacy is often suboptimal due in part to age-related declines in immune function. In this study, we discovered that the infusion of mesenchymal stromal cells (MSCs) restored defects in the splenic stromal cell network and lymphocyte architecture in aged mice while also increasing specific antibody levels following vaccine immunization. This significantly protected aging mice from influenza infection. Mechanistically, the delivered MSCs localized in the splenic marginal zones, where they positioned themselves near marginal reticular cells (MRCs) and stimulated MRC proliferation, partially through the action of vascular endothelial growth factor A (VEGFA). This MSC‒MRC interaction orchestrated the reconstruction of the stromal network, thereby restoring lymphocyte homeostasis and germinal center reactions. Importantly, the MSC-mediated enhancement of the vaccine response was further validated in aged cynomolgus monkeys. Collectively, our findings provide new insights into the application of MSCs in addressing age-related immune decline and highlight splenic MRCs as critical therapeutic targets.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a624280664a2bdb72020df258084df4d8fd37533" target='_blank'>
              Mesenchymal stromal cells counteract with age-related immune decline and enhance vaccine efficacy by modulating endogenous splenic marginal reticular cells in elderly models
              </a>
            </td>
          <td>
            Jialing Liu, Zhishan Li, Qiong Ke, Qiuli Liu, Yueming Sun, Rong Yan, Huolin Ye, Yuxi Zhang, Jie Ren, Hong Chen, Gang Li, Tao Wang, Xubo Li, Yuzhe Wang, Yuan Qiu, Xiaoran Zhang, Zhenxiao Yao, Rui Fang, Jianqi Feng, Lili Chen, Weiqiang Li, Xiaoyong Chen, Andy Peng Xiang
          </td>
          <td>2026-01-09</td>
          <td>Cellular and Molecular Immunology</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cf69b4287a6d159662b47625d7394a44821aab08" target='_blank'>
              JAK-STAT Pathway Heterogeneity Governs Immunotherapy Response in Breast Cancer
              </a>
            </td>
          <td>
            Jianbo Zhou, Heng Zhang, Hailin Tang, Lei Yu, Fu Peng
          </td>
          <td>2026-02-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Lymph nodes, brain, bone, and liver are recognized as the four most common metastatic sites for lung adenocarcinoma (LUAD). Metastasis to these locations exhibits some common features, such as immune suppression, and distinct tumor microenvironment (TME) heterogeneity involving differentiation of immune cells, impacting treatment efficacy and prognosis. Lymph node metastases are characterized by immune suppression with exhausted CD8+ T cells, expanded regulated T cell (Tregs), M2-polarized macrophages, and high programmed death ligand-1 (PD-L1) expression. Brain metastases display an “immune desert” phenotype due to blood–brain barrier constraints, reduced T-cell infiltration, and microglia-mediated immunosuppression. Bone metastases involve osteoclast activation, RANKL/OPG pathway dysregulation, and metabolic reprogramming, while liver metastases show Kupffer cell-driven PD-L1/ programmed death 1(PD-1) axis suppression and elevated Treg infiltration. Key biomarkers across all types of metastases include PD-L1, cytokine profiles, immune cell ratios, and metabolic markers. Therapeutic strategies focus on combination therapies such as immune checkpoint inhibitors (ICIs) with metabolic modulators, localized drug delivery, and biomarker-guided approaches. Challenges in this field encompass spatial heterogeneity, dynamic TME evolution, and clinical translation barriers. Future research directions highlight spatial transcriptomics, microbiome interactions, and organoid models to optimize personalized immunotherapy. This article aims to provide a comprehensive review of regarding TME alterations across these four main metastatic locations of LUAD. It will also discuss relevant TME biomarkers and their clinical significance on therapeutic response and prognosis. We expect this article to serve as a source of evidence and inspiration for the future development of treatment strategies based on LUAD TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8eac0fc7ba7c67303e9257f2a2d91aba7b28ddab" target='_blank'>
              Unraveling the alterations and biomarkers in the tumor microenvironment in lung adenocarcinoma metastases and their indications for therapeutic response and prognosis
              </a>
            </td>
          <td>
            Chao Guan, Xiangmin Li, Xiaoshan Zeng, Zhenguang Du, Zhicheng Zhou, Jungang Zhao, Lele Song, Li Yu
          </td>
          <td>2025-12-01</td>
          <td>Therapeutic Advances in Medical Oncology</td>
          <td>1</td>
          <td>3</td>
        </tr>

        <tr id="Acne, the most prevalent inflammatory skin condition globally, lacks comprehensive understanding of its cellular and molecular mechanisms. This research integrates single-cell transcriptomics with spatial immunofluorescence to detail cellular composition and functional states in healthy skin, mild acne, and severe acne. Findings indicate that keratinocytes in mild acne secrete antimicrobial peptides and maintain barrier defense, but transition to abnormal differentiation and pathological keratinization in severe acne. Natural killer (NK) cells initially amplify inflammation and activate the immune response, but later become exhausted and apoptotic. This interaction creates a “dual immune-barrier imbalance,” driving acne progression. Functional enrichment and pseudo-time analyses demonstrated a strong association between disease severity and TNF, and chemokine signaling pathways, as well as NK cell-mediated cytotoxicity and Wnt/p53-apoptosis pathways. These findings were corroborated by immunofluorescence validation. This study introduces an innovative pathological model that establishes theoretical foundations for early diagnosis and precision interventions, while also outlining future therapeutic strategies centered on “immune-barrier co-regulation.” The findings provide essential insights into the pathogenesis of acne and open avenues for investigating novel intervention targets.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/46e83afe735e0121344e0a07c8a405ac15ec431c" target='_blank'>
              Single-cell transcriptomics and spatial validation reveal dysfunction of keratinocytes and NK cells driving acne development
              </a>
            </td>
          <td>
            Xinheng Wang, Changzhao Gao, Dandan Yang, Jiahui Pan, Rihua Jiang
          </td>
          <td>2025-12-31</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fa3ea2bba5477695ec904d1360c6f71b6b797a04" target='_blank'>
              Single-Cell RNA Sequencing Reveals Impaired Regulatory T Cell Function and a Pro-inflammatory Th17 Profile in Systemic Sclerosis
              </a>
            </td>
          <td>
            G. Villanueva-Martin, G. Borrego-Yaniz, M. Acosta-Herrera, J. Callejas-Rubio, Norberto Ortego, N. Mages, S. Börno, María Gutiérrez-Arcelus, Javier Martin, L. Bossini-Castillo
          </td>
          <td>2026-01-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Mice with normalized microbial exposure (NME) harbor an immune system that more accurately reflects that of humans compared to mice maintained as specific pathogen-free (SPF). An explanation for the observed alterations in the composition of the T cell compartment in NME mice has not been reported. We compared the T cell landscape in NME versus SPF mice at baseline and after acute LCMV infection. Using the immgenT dataset, we found no unique T cell populations in NME, but the landscape shifted towards activated T cells with increased propensity for effector functions and improved pathogen clearance. CD8+ KLRG1+ cells (immgenT CD8_cl12) are significantly expanded in NME mice. Their predominance was a result of both increased formation and the conversion of other memory populations to a KLRG1+ phenotype. Thus, NME mice provide insight into a diverse T cell compartment rich with cells previously found to be limited in SPF mice.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e35067f860e89ed6db89320689ff0d4f134a8ce8" target='_blank'>
              Diverse Microbial Exposure Enhances CD8 + T Cell Effector Memory Output and Function
              </a>
            </td>
          <td>
            Claire E. Thefaine, Erin D Lucas, Katharine E Block, Mark Pierson, Emma M. Dehm, M. Huggins, O. Casey, D. Zemmour, Stephen C. Jameson, Sara E. Hamilton
          </td>
          <td>2026-02-04</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Intratumoral microbiota, once considered passive bystanders, are now recognized as active modulators of the tumor immune microenvironment (TIME)—the complex network of immune cells, stromal components, and signaling molecules within tumors—and ultimately shape immunotherapy outcomes in lung cancer. This review aims to elucidate the exact roles of intratumoral microbiota in lung cancer immuno-therapy responses and the potential mechanism, offering novel perspectives for overcoming resistance. We conducted a narrative review of the literature using a PubMed and Web of Science search of articles written in English from inception to November 2025. We summarize current evidence on the characteristics of intratumoral microbiota in lung cancer and their associations with patient outcomes following immune checkpoint inhibitor (ICI) treatment. We discuss how intratumoral microbes, their metabolites, and extracellular vesicles influence and remodel TIME, thereby either promoting or counteracting ICI efficacy. Furthermore, we explore the potential of microbial signatures as predictive biomarkers and highlight microbiota-targeted strategies—including probiotics, engineered bacteria, and rational antibiotic use—to overcome resistance and enhance clinical benefits. Collectively, available data support intratumoral microbiota as crucial modulators and promising therapeutic targets in lung cancer, and decoding their multifaceted interactions may inform precision microbiota-targeting strategies to improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c2006fdd2f61405d8e1cfadd1dbfd7f850047381" target='_blank'>
              Intratumoral Microbiota in Lung Cancer: Emerging Roles in TME Modulation and Immunotherapy Response
              </a>
            </td>
          <td>
            Xue Yang, Liyuan Yin, Zhuoying Tian, Qing-xia Zhou
          </td>
          <td>2025-12-25</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background Acquired resistance to KRAS G12C inhibitor sotorasib remains a critical challenge in non-small cell lung cancer treatment. A deeper, rational understanding of resistance mechanisms can enable the development of therapeutic strategies to overcome resistance. Methods We established a syngeneic resistant model after prolonged AMG-510 treatment in C57BL/6 mice. In addition, the in vitro co-culture model and multiple methods including flow cytometry and western blot were used to assess the changes of immune microenvironment during resistance. Finally, a serial combinatorial therapy strategy was applied in the resistant mouse model to evaluate its ability to reverse resistance. Results Upregulation of PD-L1 in KRAS G12C tumors drives an immunosuppressive tumor microenvironment and promotes acquired resistance characterized by reduced infiltration of cytotoxic CD8+ T cells and a marked expansion of myeloid-derived suppressor cells through JAK2/STAT3/IL-6 Pathway. These mechanisms promote tumor immune evasion and protection from cell apoptosis, thereby establishing a microenvironment that sustains acquired resistance to sotorasib. Critically, sequential administration of a PD-L1 inhibitor (PD-L1i) effectively reprogrammed the immunosuppressive microenvironment, restoring antitumor immunity and re-sensitizing resistant tumors to sotorasib treatment. Conclusions These results identify the PD-L1-driven immunosuppressive microenvironment as a key mediator of sotorasib resistance and propose PD-L1i as a synergistic strategy to overcome resistance, which warrants clinical exploration of sequential or combinatorial regimens.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/588efb3d398ea4a33daa464e7dd7bba4c6035b3b" target='_blank'>
              Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.
              </a>
            </td>
          <td>
            Shougeng Liu, Yiting Jiang, Yudong Fu, Simeng Wang, Rao Fu, Minmin Gao, Yingxi Zhao, Sihong Chen, Yuan Yang, Weiming Yang, Lina Jia, Mingze Qin, Xiaohui Zhang, Wei Cui, Lihui Wang
          </td>
          <td>2026-02-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="This review explores the alterations in natural killer (NK) cell function in acute myeloid leukemia (AML) and their implications for disease progression and therapeutic outcomes. As key effectors of innate immunity, NK cells are critical in recognizing and eliminating malignant cells. In AML, however, NK cells frequently exhibit numerical and functional deficiencies, resulting in compromised immunosurveillance that facilitates tumor immune escape and disease advancement. We systematically examine the application of single-cell omics technologies in AML research to elucidate the omics profiles and phenotypic distribution of NK cells within the leukemic microenvironment, characterizing their dysfunctional state by upregulated inhibitory receptors, downregulated activating signals, an altered cytokine milieu, and complex cellular crosstalk within the bone marrow (BM) niche. Furthermore, this article correlates functional dynamics of NK cells with conventional and emerging treatments, including CAR-NK immunotherapy, underscoring their potential role in disease monitoring and prognostic stratification. We also discuss promising NK cell-based immunotherapeutic strategies for AML, emphasizing the potential of modulating or engineering NK cells to enhance antitumor immunity. A deeper understanding of NK cell biology and regulatory mechanisms in AML is essential for developing novel immunotherapies and improving patient prognosis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1339d92d7c12a10a1838887d8e65053310a42400" target='_blank'>
              Defining the role of natural killer cells in acute myeloid leukemia through the lens of single-cell omics
              </a>
            </td>
          <td>
            Chen Liang, Meichi Yue, Kehui Zhang, Sining Zhou, Xiaojing Xu, Shiwei Wang, Shiping Liu
          </td>
          <td>2026-01-30</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Despite the promise of immune checkpoint blockade (ICB) in head and neck squamous cell carcinoma (HNSCC), mediators of response are poorly understood. To address this, here we analyzed oropharyngeal HNSCCs treated with neoadjuvant durvalumab (anti-PDL1) alone or in combination with tremelimumab (anti-CTLA4) from the CIAO clinical trial (NCT03144778). We found that only the total abundance of intratumoral bacteria predicted ICB response, which was validated in multiple independent cohorts. High intratumoral bacteria abundance was associated with an immunosuppressive tumor microenvironment, characterized by an accumulation of neutrophils coupled with depletion of T cells and other adaptive immune cells. Experimental elevation or reduction in intratumoral bacteria abundance in orthotopic models of HNSCC in female mice recapitulated immunological associations observed in participant tumors. Increasing intratumoral bacteria abundance was sufficient to induce resistance to anti-PDL1 ICB, irrespective of bacterial species tested. Together, these findings demonstrate that high intratumoral bacteria abundance is a key suppressor of antitumor immunity and promotes immunotherapy resistance. McGrail and colleagues report that high intratumoral bacteria abundance is associated with an immunosuppressive microenvironment and resistance to immune checkpoint blockade in head and neck squamous cell carcinoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ff6bc6b862a40ed54d2a498d13ad74d8fec00fa9" target='_blank'>
              Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance in head and neck squamous cell carcinoma
              </a>
            </td>
          <td>
            Natalie L. Silver, Jin Dai, Travis D. Kerr, Jessica Altemus, Rekha Garg, Hannah Simmons, Tyler J. Alban, Laura Noȅl-Romas, Vladimir Makarov, David J. H. Shih, Shweth V. Kumar, Akeem Santos, Rehan Akbani, Adam Burgener, Mohammed Dwidar, Neil D. Gross, Andrew G Sikora, Elias J Sayour, Apollo R Stacy, Christian Jobin, Timothy A. Chan, R. Ferrarotto, Daniel J. McGrail
          </td>
          <td>2026-01-01</td>
          <td>Nature Cancer</td>
          <td>4</td>
          <td>75</td>
        </tr>

        <tr id="During neuroinflammation, CD11c+CD11b+ myeloid cells accumulate at the cribriform plate, a key cerebrospinal fluid (CSF) and antigen outflow site in mice. At this site, podoplanin (PDPN)-expressing cells, including lymphatic vessels and meningeal layers, expand to create a distinct drainage microenvironment. In this study we sought to characterize myeloid cells which populate this region using a mouse model of neuroinflammation, experimental autoimmune encephalomyelitis (EAE). Utilizing a combination of immunohistochemistry, flow cytometry, and scRNAseq, we report that macrophages and dendritic cells (DCs) from this region display unique expressional signatures related to tolerance, cell death, and reduced inflammatory profile. Together this data supports that myeloid retention at the cribriform plate and olfactory bulb meninges promotes a local immunosuppressive environment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e549a88421337952511a13714c86e5c4e653df94" target='_blank'>
              Cribriform Plate Microenvironment Assembles a Suppressive Myeloid Network during EAE-induced Neuroinflammation
              </a>
            </td>
          <td>
            C. Laaker, Martin Hsu, Andy Madrid, Jenna M Port, Sophia M. Vrba, Melinda Herbath, Cameron M Baenen, Mohan Kumar, Thanthrige Thiunuwan Priyathilaka, Matyas Sandor, Z. Fabry
          </td>
          <td>2026-01-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>44</td>
        </tr>

        <tr id="Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs and involving both innate and adaptive immunity. Dendritic cells (DCs) play a crucial role in linking innate and adaptive immune responses, and therefore they deeply participate in the initiation and development of SLE. Deleted in breast cancer‐1 (DBC1) is a negative regulator of deacetylase SIRT1 (the mammalian homolog of silent information regulator 1) and involves in tissue inflammation. Roles of DBC1 in immune cells remain largely unknown, especially in DCs. We here identified that DBC1 is upregulated in activated DCs, and DBC1 deficiency weakened DC maturation while promoting B7‐H1 expression. DC conditional knockout of DBC1 ameliorated murine lupus pathology by decreasing autoantibodies, complement C3, plasma cells, and follicular T helper (Tfh) cells, whereas promoting regulatory T‐cell development. We further demonstrated that Dbc1−/− DC lowered proinflammatory cytokine secretion such as IL‐4, IL‐6, and IL‐12, and reduced signal transducer and activator of transcription 5 (STAT5) signal. With STAT5 overexpression, the protective effect by Dbc1−/− DC was abolished in the lupus model. Therefore, targeting the DBC1‐STAT5 axis in DCs diversifies the therapeutic strategies for SLE.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d1facac1c1eb12f3330a72458012f015712e82b1" target='_blank'>
              Regulation and Mechanism of Deleted in Breast Cancer‐1 on Dendritic Cell Function in Systemic Lupus Erythematosus
              </a>
            </td>
          <td>
            Z X Xiao, Rongzhen Liang, Yan Liu, Changyuan Huang, Qiannan Fang, Xiaojiang Hu, Julie Wang, Nancy Olsen, Dehua Wu, S. Zheng
          </td>
          <td>2026-01-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Although chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable therapeutic effects in treating hematologic cancers, its effectiveness in solid tumors remains significantly restricted. the primary reason is the immunosuppression mediated by the tumor microenvironment (TME), which leads to rapid exhaustion of infiltrating CAR-T cells. To enhance CAR-T cell efficacy against solid tumors, we pursued improvements in two aspects. First, we constructed fibroblast activation protein (FAP)-directed CAR-T cells to enhance their anti-CAF capability within the TME, thereby alleviating the immunosuppressive barrier. Second, we utilized IL-15, an efficient activator of CAR-T cells that inhibits activation-induced cell death, restores effector functions, and increases the proportion of the T stem cell memory (TSCM) subpopulation. In this study, we report the generation of FAP/IL-15 CAR-T cells, which target FAP and autonomously synthesize and secrete IL-15. Our data demonstrate that treatment with FAP/IL-15 CAR-T cells exhibited stronger activation characteristics in a FAP antigen-dependent manner, selectively targeting CAFs within the solid TME. Moreover, endogenous IL-15 secretion enabled CAR-T cells to adopt a TSCM-like phenotype with enhanced memory characteristics, thus improving cell survival, proliferation, activation, and therapeutic efficacy against solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/00800864326cc50fb8931bc76773d901179d7f53" target='_blank'>
              A new strategy for CAR-T therapy in solid tumors: IL-15-autocrine signaling augments tumor stroma depletion and promotes a TSCM subset in the TME
              </a>
            </td>
          <td>
            Yanyang Pang, Leiyuan Chen, Qinghui Sun, Na He, Zhiheng Lai, Xi Wang, Zhihao Xie, Wenli Yang, Wu Wang
          </td>
          <td>2025-12-27</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="IBD pathogenesis is underpinned by an imbalance between excess inflammation caused by effector T-cells and inadequate suppression by regulatory T-cells (Tregs). Interleukin-37 (IL-37) is a potent, anti-inflammatory cytokine that signals via its receptors IL-1R5 and IL-1R8. Hence, augmenting anti-inflammatory mechanisms that drive IL-37 expression is a strategy to control IBD-associated inflammation. However, the role of IL-37 and its receptors in T-cells remains incompletely understood. Here, we investigated T-cell expression profiles of IL-37 and its receptors to understand the drivers of dysregulated T-cell responses in IBD and develop novel, more effective therapies. T-cell subsets from healthy control (HC), Crohn’s disease (CD) and ulcerative colitis (UC) peripheral blood mononuclear cells (PBMC) and lamina propria mononuclear cells (LPMC) were assessed for expression of IL-37 and its receptors by flow cytometry. CD3+IL-1R8+ T-cell transcriptomes underwent RNA sequencing. The phenotype and suppressive capacity of Tregs supplemented with IL-37 was assessed in vitro. Our results indicate that IL-37 and its receptors were differentially expressed among PBMC and LPMC T-cell subsets in IBD patients compared to HC. Transcription signatures unique to IBD were revealed, particularly histone and mitochondrial pathways. Remarkably, culturing Tregs with IL-37 preserved FOXP3 expression and suppressiveness at a level comparable to treatment with the well-established Treg stabilizing agent rapamycin. Altogether, our study identified differences in T-cells expressing IL-37 and its receptors that are indicative of T-cell dysfunction in IBD. These findings highlight a novel and promising avenue for restoring immune homeostasis in IBD by targeting and boosting the IL-37 signalling pathway.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f7971d3fabc270531c7b130ac64f2f5758d25e1e" target='_blank'>
              Characteristics of T-Cells Expressing IL-37 and Its Receptors in Inflammatory Bowel Disease
              </a>
            </td>
          <td>
            Indiana Zorkau, P. Eggenhuizen, Marie Lee, Steven X. Cho, Kylie R. James, A. Ellisdon, J. Whisstock, J. Ooi, Marcel F. Nold, C. Nold-Petry, Rimma Goldberg
          </td>
          <td>2026-02-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>74</td>
        </tr>

        <tr id="Immune dysregulation is a hallmark of human immunodeficiency virus (HIV) infection, characterized by persistent immune activation and systemic inflammation that drive T cell exhaustion and senescence, contributing to disease progression and non-AIDS comorbidities, most notably tuberculosis (TB). With rising HIV prevalence, the incidence of HIV-TB co-infection continues to rise, highlighting the need to understand their immunopathological interplay. This narrative review aims to examine the association between immune dysregulation in HIV-TB co-infection, with a focus on cytokine profiles and immunological biomarkers. Relevant literature was retrieved from multiple databases, with evidence demonstrating differential expression of cytokines—IL-17A, IFN-γ, TNF, IL-10, IL-6, IL-4, and IL-2—and T cell activation markers, such as CD38 and HLA-DR on CD4+ T cells in latent and active TB among HIV-infected individuals. These immune mediators are consistently co-expressed at higher levels in active TB compared to latent TB, suggesting heightened immune activation of both innate and adaptive immune responses in HIV-TB co-infection. However, these findings are largely based on observational data, and the precise mechanism by which cytokine and T cell biomarker dysregulation contributes to HIV-TB pathogenesis remains incompletely understood, underscoring the need for larger, mechanistic studies to address these gaps in the pathogenic pathway.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f8710218f39c3691e0e971a9da488e3a8f2ec29a" target='_blank'>
              Immune Dysregulation in HIV-TB Co-Infection: Role of Cytokines and T Cell Biomarkers—A Narrative Review
              </a>
            </td>
          <td>
            C. Gunawan, Anton Sumarpo, A. Indrati
          </td>
          <td>2026-01-01</td>
          <td>Pathogens</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Cancer cells employ diverse strategies to evade immune surveillance and resist therapy, including immune exclusion—a phenomenon where cytotoxic T cells fail to infiltrate the tumor microenvironment (TME), severely limiting immune checkpoint inhibitor (ICI) efficacy. Emerging evidence suggests that platelets, traditionally known for their role in hemostasis, may act as key players within the TME. This review introduces a novel perspective on tumor-infiltrating platelets (TIPs) as potential orchestrators of immune exclusion, linking them to the six Delphi-defined criteria, which were established through international cancer experts based on modified consensus Delphi process: lack of chemotactic factors, immunosuppressive cytokines, specific cancer-associated fibroblast (CAF) subtypes, mechanical barriers, disordered vasculature, and increased T-cell apoptosis. We further explore TIP-mediated contributions to related features, such as epithelial-mesenchymal transition (EMT), M2 macrophage polarization, and CXCL12 signaling, which exacerbate exclusion and promote metastasis. Through integration of mechanistic studies and pan-cancer TCGA analyses, we reveal that TIPs exhibit significant, yet heterogeneous, correlations with immune exclusion features across diverse solid tumors. By elucidating these mechanisms, this review underscores the potential role of TIPs as promising therapeutic targets to dismantle immune barriers, enhance ICI responses, and curb metastasis, advocating for platelet-targeted combinations in future immunotherapy trials.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c9c997ce4b80550d0a9dd461920b0a62532e9689" target='_blank'>
              Platelets in the tumor microenvironment: potential mediators of immune exclusion and resistance to immune checkpoint inhibitor therapy
              </a>
            </td>
          <td>
            Atefeh Nasir Kansestani, M. Zare, Jun Zhang
          </td>
          <td>2026-01-29</td>
          <td>Cellular Oncology (Dordrecht, Netherlands)</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Tolerogenic dendritic cells (tolDC) are currently in clinical trials for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The methods for producing therapeutic tolDC vary widely, with little being known about the commonalities and differences of distinct cell products in terms of their regulatory actions on CD4+ T cells. We compared human monocyte-derived tolDC generated with vitamin D3 alone or in combination with dexamethasone. We found marked differences in the surface expression of HLA-DR and immune regulatory molecules, but also found commonalities, e.g. a strongly reduced capacity to produce interleukin-12 and a concomitant decreased ability to induce interferon-γ secretion by allogeneic CD4+ T cells. To gain a deeper understanding of how these tolDC types exert their regulatory effects, we co-cultured them with CD4+ T cells from rheumatoid arthritis patients or healthy controls and analysed the gene expression profile and function of the responding T cells. We found that tolDC generated with vitamin D3 alone, but not in combination with dexamethasone, induced potent cytotoxic activity in the responding CD4+ T cells as demonstrated by an enhanced cytotoxic gene signature, increased levels of intracellular granzyme B, and superior cytotoxic activity towards myeloid and B cells. These data identify cytotoxicity as an atypical CD4+ T helper cell effector function induced by some but not all tolDC types, with implications for their individual clinical applications.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e6376b65c8f61913f7a1c8c2873d5f5d98c5c617" target='_blank'>
              Human tolerogenic dendritic cell subtypes exert divergent effects on induction of cytotoxic CD4+ T cells
              </a>
            </td>
          <td>
            Gabrielle Barran, N. Naamane, Abdul Mannan Baru, Amy E Anderson, Jane Falconer, C. Hilkens
          </td>
          <td>2025-12-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="Mesenchymal stem/stromal cells (MSCs) exhibit broad differentiation capability and strong immunoregulatory potential mediated through intercellular communication and the release of diverse paracrine mediators. They represent a promising but still investigational therapeutic approach for managing complications associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). This review provides an updated synthesis of MSC biology, their bidirectional interaction with immune cells, and their functional contribution to the hematopoietic niche. It also evaluates current clinical evidence regarding the therapeutic roles of MSCs and MSC-derived extracellular vesicles (EVs) in acute and chronic graft-versus-host disease (aGVHD/cGVHD), as well as in poor graft function. Mechanistic insights encompass macrophage polarization toward an anti-inflammatory phenotype, inhibition of dendritic cell maturation, enhancement of regulatory T-cell expansion, and modulation of cytokine signaling pathways. Within the bone marrow milieu, MSCs contribute to stromal restoration and angiogenic repair. Recent phase II/III trials in steroid-refractory (SR)-aGVHD have demonstrated overall response rates ranging from 48 to 71%. Efficacy appears particularly enhanced in pediatric patients and with early MSC administration. Across studies, MSC therapy shows a favorable safety profile; however, heterogeneity in response and inconsistent survival outcomes remain notable limitations. For poor graft function, limited prospective studies indicate hematopoietic recovery following third-party MSC infusions, and combination approaches such as co-administration with thrombopoietin receptor agonists are under investigation. MSC-derived EVs emulate many immunomodulatory effects of their parental cells with a potentially safer profile, though clinical validation remains in its infancy. MSC-oriented interventions hold substantial biological and therapeutic promise, offering a favorable safety margin; however, clinical translation is hindered by product variability, suboptimal engraftment and persistence, and inconsistent efficacy across studies. Future directions should emphasize standardized manufacturing and potency assays, biomarker-driven patient and timing selection, optimized conditioning and dosing strategies, and the systematic appraisal of EV-based or genetically modified MSC products through controlled trials.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/73302ce93894dc67dc4c78b9abd8a8e4bdc0a83f" target='_blank'>
              Mesenchymal Stem/Stromal Cells: A Review for Its Use After Allogeneic Hematopoietic Stem Cell Transplantation
              </a>
            </td>
          <td>
            A. Durdu, U. Hatipoglu, Hakan Eminoglu, Turgay Ulaş, M. S. Dal, F. Altuntaş
          </td>
          <td>2026-01-01</td>
          <td>Biomolecules</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7d1643371c79bb28750e28593c02812612c4ec75" target='_blank'>
              PARP inhibition generates enhanced CD8+ central memory T cells by transcriptional and metabolic reprogramming
              </a>
            </td>
          <td>
            Wael Traboulsi, Pankaj Gaur, Subhadip Kundu, Zainab Ramlaoui, Christopher Priestley-Milianta, Aishwariya Iyengar, Nour Shobaki, Dareen Sarhan, Min-Jung Lee, Jung-Min Lee, G. Pavlakis, M. Mkrtichyan, Viia Valge-Archer, S. Barry, Vivek Verma, Seema Gupta, Samir N Khleif
          </td>
          <td>2026-01-12</td>
          <td>Nature Immunology</td>
          <td>0</td>
          <td>80</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are key drivers of immunosuppressive inflammation in the breast cancer microenvironment, promoting tumor progression and resistance to immune checkpoint blockade. Our previous work identified extracellular IFI16/IFI202 as tumor-derived damage-associated molecular patterns which activate pro-inflammatory signaling in TAMs via Toll-like receptor 2, thereby facilitating immune evasion. In this study, we investigated the therapeutic potential of a monoclonal antibody (mAb) targeting extracellular IFI202 to suppress tumor-promoting inflammation and to restore antitumor immunity. We developed a mAb against IFI202 and evaluated its functions in bone marrow-derived macrophages (BMDMs) using ELISA and western blotting. In vivo efficacy was assessed in the mouse mammary tumor virus-polyoma virus middle T-antigen breast cancer model by treating with IFI202 mAb, or anti–programmed death-1 (PD-1) antibody, as monotherapies or in combination. Tumor volume, metastasis, cytokine levels, and immune cell infiltration were analyzed. Statistical significance was assessed using Mann–Whitney U test or ANOVA, with P < 0.05 considered significant. Conditioned medium obtained from 4T1 breast cancer cells pre-incubated with IFI202 mAb suppressed secretion of IL-6 and TNF-α, and inhibited activation of ERK and NF-κB in BMDMs. Intraperitoneal injection of IFI202 mAb in mouse mammary tumor virus-polyoma middle T-antigen mice significantly reduced tumor growth and lung metastasis. In addition, IL-1β expression, CD8+ T cell infiltration, and levels of granzyme B and interferon-γ, were enhanced in the tumors of IFI202 mAb-treated mice, indicating that IFI202 mAb restored cytotoxic function of CD8+ T-cells. Combination of IFI202 mAb with PD-1 mAb significantly improved antitumor efficacy compared to monotherapy. Neutralization of extracellular IFI202 suppresses TAM-mediated inflammation and supports a tumor microenvironment favorable for T-cell–mediated immunity. In combination with anti–PD-1 therapy, IFI202 mAb further enhances antitumor responses, suggesting a promising and tumor-selective strategy that may help overcome resistance to immune checkpoint blockade in breast cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc369356ec770be8eb843d59aff9a9f3d18ca8d9" target='_blank'>
              IFI16/IFI202 blockade suppresses tumor growth through CD8+ T-cell–mediated immunity
              </a>
            </td>
          <td>
            G. Lim, Na-Lee Ka, Seung-Su Kim, Mi-Ock Lee
          </td>
          <td>2026-01-03</td>
          <td>Breast Cancer Research : BCR</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Abstract Immune checkpoint blockade (ICB) has revolutionized tumour therapy by relieving immunosuppression and restoring effector T cell cytotoxicity. However, its clinical utility is constrained by low response rates and acquired resistance. Tumour‐associated neutrophils (TANs), key players in tumour immunoregulation, have emerged as critical mediators of ICB responsiveness and resistance, highlighting the therapeutic potential of combining TAN‐targeted strategies with immune checkpoint inhibitors (ICIs). This review systematically synthesizes current knowledge of neutrophils in ICB resistance from several dimensions: (1) clinical indicators of neutrophils, such as the neutrophil‐to‐lymphocyte ratio (NLR) and tissue TANs abundance, as predictors of ICI response and patients prognosis; (2) multifaceted TAN‐involved resistance mechanisms, including direct T cell inhibition, antigen presentation impairment, function modulation of other immune cells, promotion of tumour angiogenesis, and elevation of tumour mutation burden (TMB); (3) combination therapeutic strategies targeting TAN generation/ exhaustion, recruitment, phenotypic polarization, activation, proangiogenic functions, and neutrophil extracellular traps (NETs), along with progress in related clinical trials. Combinatorial approaches integrating TAN‐targeted therapies with ICIs hold substantial promise for overcoming resistance by reshaping the immune microenvironment. Elucidating neutrophil‐mediated resistance mechanisms and optimizing combination strategies will pave the way for precision tumour immunotherapy. Key points TANs drive ICI resistance via antitumour immune remodelling, angiogenesis promotion, and elevation of tumour mutation burden Neutrophil biomarkers (e.g., NLR, TAN abundance) show strong predictive value for ICI response and prognosis. Targeting TAN recruitment, polarization, function and NETosis represents a promising strategy to overcome ICI resistance. Numerous clinical trials are evaluating combination therapies targeting neutrophils to enhance immunotherapy efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8cb8c196a123899665e6475d21ebf9639c6d4e4b" target='_blank'>
              Targeting neutrophil‐driven immunosuppression: A strategy to overcome immune checkpoint inhibitor resistance
              </a>
            </td>
          <td>
            Ying Ning, Ke Lei, Xinyan Gao, Yan Kong, Yuping Shan, Tian Tian, Zhumei Cui, He Ren
          </td>
          <td>2026-01-01</td>
          <td>Clinical and Translational Medicine</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Most colorectal cancers are resistant to immune checkpoint inhibitors due to an immunosuppressive tumor microenvironment. LINC00673, previously classified as a long non-coding RNA, has been implicated in tumor progression, but its role in antitumor immunity remains poorly understood. We used single-cell RNA sequencing, flow cytometry, and functional assays in Linc00673 knockout and wild-type mouse models treated with programmed death 1 (PD-1) blockade to dissect changes in immune landscape and tumor cell behavior. Linc00673 deletion enhanced the efficacy of PD-1 therapy, reducing tumor burden and prolonging survival. KO tumors showed increased infiltration of cytotoxic CD8⁺ T cells, reduced exhaustion, and improved antigen presentation. The tumor microenvironment shifted toward a pro-inflammatory state, with elevated dendritic cell function, reduced immunosuppressive macrophages, and improved T cell–tumor interactions. Linc00673 also promoted tumor cell migration and immune evasion independently of immune cells, suggesting dual tumor-intrinsic and -extrinsic roles. LINC00673 suppresses antitumor immunity and promotes tumor aggressiveness. Its deletion synergizes with PD-1 blockade, revealing a promising therapeutic target to overcome immune resistance in colorectal cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb9ef0a9a3f2685b8b34be389ae9c671f82a1666" target='_blank'>
              Single-cell RNA sequencing unveils enhanced antitumor immunity in colorectal cancer with PD-1 blockade and LINC00673 deletion
              </a>
            </td>
          <td>
            Yifei Zhu, Yanxi Yao, Yaxian Wang, Zhibing Qiu, Dingpei Zhou, Huixia Huang, Keji Chen, Qingyang Sun, Jiayu Chen, Yuxue Li, Jianqiang Tang, Dawei Li, Ping Wei
          </td>
          <td>2026-01-03</td>
          <td>Biomarker Research</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cf87d56103e47056c8390c382a196ac0a7304b81" target='_blank'>
              Rasal1 impairment unleashes anticancer immunity - a focus on T cells
              </a>
            </td>
          <td>
            Mark E. Issa, Alejandro Schcolnik-Cabrera
          </td>
          <td>2026-01-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Acute myeloid leukemia (AML) remains one of the most aggressive and treatment-resistant hematologic malignancies, driven by clonal expansion of immature myeloid blasts in the bone marrow and peripheral blood. Current therapies—chemotherapy and targeted agents—are limited by poor marrow penetration, systemic toxicity, and rapid development of resistant clones, leaving long-term survival rates low. Clinicians face the persistent challenge of delivering effective therapy while minimizing harm. Platelets and neutrophils—beyond their classical roles in hemostasis and innate immunity—actively support leukemic niches, suppress anti-tumor immunity, and protect malignant cells from cytotoxic attack. These interactions highlight an untapped opportunity: harnessing endogenous cellular networks to deliver therapeutics with precision and potency. Conventional carriers, including liposomes and nanoparticles, fail to exploit these natural trafficking and immune-modulatory mechanisms, limiting marrow-specific targeting and therapeutic durability. We propose cellular hitchhiking using patient-derived platelets and neutrophils as a transformative, patient-tailored strategy. These carriers leverage intrinsic homing mechanisms, immune interface modulation, and prolonged circulation to deliver cytotoxic, immunomodulatory, or gene-based therapeutics directly to marrow and sanctuary sites. Ex vivo priming, biomaterial functionalization, and patient-specific engineering can enhance marrow-targeted drug concentration by several-fold, reduce systemic exposure, and minimize thrombo-inflammatory complications. By converting circulating blood cells into programmable delivery vectors, this approach offers a biologically rational platform with translational potential; however, immediate clinical relevance requires validation in controlled early-phase human studies. Preclinical evidence indicates that cellular hitchhiking can substantially increase bone-marrow drug delivery and reduce systemic exposure; whether these improvements will translate into higher remission rates or lower relapse in patients remains to be established in prospective clinical studies. Integrated into AML management, this strategy provides a biologically rational platform with translational potential; careful preclinical de-risking and early-phase clinical trials are required to determine clinical relevance. Cellular hitchhiking leverages endogenous platelets and neutrophils to deliver therapeutics directly to marrow and leukemic niches, overcoming limitations of conventional drug delivery. Patient-derived carriers enable personalized therapy, minimizing immune rejection, off-target toxicity, and thrombo-inflammatory risk. Targeted delivery integrates immune modulation and cytotoxicity, potentially enhancing anti-leukemic efficacy while sparing normal hematopoietic cells. Ex vivo priming and biomaterial functionalization allow precise control of cargo release, circulation time, and niche-specific engagement. Preclinical data indicate improved marrow delivery and biological effects; whether these translate into improved remission or relapse-free survival in patients remains to be tested. Bridges a critical translational gap by converting circulating blood cells from passive bystanders into programmable therapeutic vehicles. Cellular hitchhiking leverages endogenous platelets and neutrophils to deliver therapeutics directly to marrow and leukemic niches, overcoming limitations of conventional drug delivery. Patient-derived carriers enable personalized therapy, minimizing immune rejection, off-target toxicity, and thrombo-inflammatory risk. Targeted delivery integrates immune modulation and cytotoxicity, potentially enhancing anti-leukemic efficacy while sparing normal hematopoietic cells. Ex vivo priming and biomaterial functionalization allow precise control of cargo release, circulation time, and niche-specific engagement. Preclinical data indicate improved marrow delivery and biological effects; whether these translate into improved remission or relapse-free survival in patients remains to be tested. Bridges a critical translational gap by converting circulating blood cells from passive bystanders into programmable therapeutic vehicles.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c9aef25c19ab7041c8f0c6f9cac97ec6823906be" target='_blank'>
              Hijacking the helpers: platelet and neutrophil trafficking in AML and therapeutic exploitation
              </a>
            </td>
          <td>
            Farshad Heydari, Michael R. Hamblin, Jalal Naghinezhad
          </td>
          <td>2026-01-27</td>
          <td>Experimental Hematology & Oncology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Renal cell carcinoma (RCC) frequently exhibits resistance to immune checkpoint blockade, highlighting the need for strategies that enhance tumor-specific T cell priming and improve immune access to the tumor microenvironment. Here we show that vaccination targeting tumor-associated mitochondrial antigens (TAMAs), derived from tumor-specific mitochondrial DNA (mtDNA) missense mutations, synergizes with PD-1/PD-L1 blockade to overcome checkpoint refractoriness in the RENCA RCC model. TAMAs vaccination elicits antigen-specific T cell responses, increases intratumoral CD8+ T cell infiltration, and reduces immunosuppressive myeloid populations, resulting in delayed tumor progression and improved survival when combined with checkpoint inhibition. In parallel, TAMAs + checkpoint blockade induces vascular remodeling characterized by increased pericyte coverage, reduced vascular leakage, improved perfusion and reduced hypoxia. Mechanistically, vascular remodeling is driven by CD8+ T cell–dependent, IFNγ-associated immune activity and is associated with endothelial apoptosis and diminished intratumoral CD31 signal. We further identify tumor-to-endothelium mitochondrial transfer as a mechanism linking mitochondrial neoantigens to the tumor vascular compartment: tumor-derived mitochondria enter human and mouse endothelial cells in vitro and in vivo, and tumor-associated mtDNA mutations are detectable in endothelial fractions from murine tumors and human RCC specimens. Human endothelial cells can present mitochondrial neoantigens via MHC class I and become targets of TAMAs-specific CD8+ T cell cytotoxicity, including following mitochondrial acquisition from tumor cells. Together, these findings establish mitochondrial neoantigen immunity as a tractable approach to enhance checkpoint responses and reveal mitochondrial transfer as an antigenic bridge that expands immune targeting to the tumor vasculature.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c51a090a5d78abb279f15d71c3d174a0e1f6dc1c" target='_blank'>
              “Tumor-to-endothelium mitochondrial transfer licenses endothelial cells for CD8 + T cell recognition via mitochondrial neoantigen presentation”
              </a>
            </td>
          <td>
            F. Costabile, Pierini Stefano, Renzo Perales-Linares, N. Leli, Adham Bear, Cameron Koch, Beatriz M. Carreno, Michael T. Lotze, Lerry Singh, Marny Falck, Andrea Facciabene
          </td>
          <td>2026-02-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+ DLBCL) is an aggressive malignancy characterized by an immunosuppressive tumor microenvironment (TME), where tumor-associated macrophages (TAMs) often exhibit an M2-like phenotype that facilitates immune evasion. Here, we show that the LSD1 inhibitor ORY1001 reprograms the TME of EBV+ DLBCL through CXCL10-mediated modulation of macrophage polarization. Using a reductionist model in which EBV-negative DLBCL cell lines were transfected with LMP1, we demonstrate that ORY1001 induces robust expression of CXCL10, TNF-α and IL-6 in LMP1+ Riva cells, promoting M1 macrophage differentiation and reprogramming M2 macrophages toward a pro-inflammatory phenotype. This CXCL10-driven macrophage reprogramming was also observed in an additional LMP1+ DLBCL line (U2932) and in primary EBV+ DLBCL cells, in which ORY1001 selectively increased CXCL10 levels in tumor-cell supernatants, and conditioned media from these cultures—but not direct ORY1001 exposure—drove M1 polarization of THP-1 and primary CD14+ monocytes. These effects were dependent on CXCL10-CXCR3 signaling, as pharmacological inhibition of CXCR3 abrogated M1 polarization. In vivo, ORY1001 suppressed tumor growth in LMP1-expressing A20 lymphoma models, increased CXCL10 levels, and enhanced M1 macrophage infiltration. Furthermore, ORY1001 synergized with anti–PD-1 therapy to enhance T-cell activation, granzyme B expression, and tumor regression. These findings highlight LSD1 inhibition as a promising immunoepigenetic strategy to remodel the TME and improve the efficacy of immune checkpoint blockade in EBV-associated lymphomas.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/25afd8013cd9d8c4576a214b23e11d9abd525f45" target='_blank'>
              ORY1001 enhances anti-tumor immunity via CXCL10-mediated macrophage modulation in EBV-positive DLBCL
              </a>
            </td>
          <td>
            Joo Hyun Kim, Hyeon Ji Cho, S. Yoon, Won Seog Kim
          </td>
          <td>2026-01-15</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5a1efb733b8a04b42b870357265aac2d67dd05fa" target='_blank'>
              Crosstalk between Stromal cells and Macrophages Shapes Host Immunity to Mycobacteria
              </a>
            </td>
          <td>
            A. Lösslein, Sebastian Baasch, Leonhard Wagner, K. Ritter, Florens Lohrmann, Katja Gräwe, Nisreen Ghanem, Jana Neuber, Alexandra Hölscher, Markus Sperandio, J. Kolter, Christoph Schell, Roman Sankowski, Sagar, Georg Häcker, Christoph Hölscher, Philipp Henneke
          </td>
          <td>2026-02-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="The PIM kinase family is critically involved in tumorigenesis, yet its role in primary T cells is understudied. We reported that PIM2, distinct from the other two isoforms, inhibits T-cell responses to alloantigen. Here, we further established PIM2 as a key negative regulator in anti-tumor immunity. Pim2 deficiency in tumor antigen-specific or polyclonal T cells enhanced their ability to control tumor growth in murine breast cancer, melanoma and leukemia models. Pim2 deficiency enhanced cytokine production and metabolic activities in tumor-infiltrating CD8 T cells. Pim2 deficiency increased TCF1 expression and memory-like phenotype in CD8 T cells from lymphoid organs. Mechanistically, PIM2 facilitated LC3 lipidation, P62 degradation and autophagic flux in T cells, leading to impaired glycolysis and effector cytokine production. Furthermore, through modulating VPRBP kinase phosphorylation, PIM2 inhibited histone methyltransferase activity of EZH2 in CD8 T cells, causing disrupted memory-like phenotype. Notably, the PIM2 inhibitor JP11646 markedly enhanced antitumor T-cell response. The immunosuppressive role of PIM2 was validated in human T cells, where inhibition of PIM2 enhanced antitumor responses in engineered human T cells including melanoma-specific TCR-T cells and CD19CAR-T cells. Collectively, PIM2 represents a promising target for improving cancer immunotherapy through enhancing effector differentiation and persistence of CD8 T cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b5cbff6560d4101491df0176143e10a965a0ac36" target='_blank'>
              Targeting Pim2 Improves Antitumor Immunity through Promoting Effector Function and Persistence of CD8 T cells.
              </a>
            </td>
          <td>
            Yongxia Wu, Linlu Tian, Allison Pugel, Reza Alimohammadi, Qiao Cheng, Weiguo Cui, Michael I. Nishimura, Lauren E Ball, Chien-Wei Lin, Shikhar Mehrotra, Andrew S. Kraft, Xue-Zhong Yu
          </td>
          <td>2026-01-27</td>
          <td>The Journal of clinical investigation</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Leukemia treatment faces persistent challenges, including chemotherapy resistance and relapse, highlighting macrophage polarization in the tumor microenvironment (TME) as a therapeutic target. Macrophages dynamically shift between antitumor M1 and protumor M2 phenotypes, with M2-polarized tumor-associated macrophages (TAMs) dominating leukemia TMEs. These cells secrete IL-10 and TGF-β, fostering immune evasion, angiogenesis, and leukemia stem cell (LSC) survival. In AML, M2 TAMs correlate with poor prognosis and chemoresistance via CSF-1/IL-10 signaling. Polarization is regulated by transcription factors (STAT6, PPARγ, KLF4), hypoxia, and metabolic reprogramming. Therapeutic strategies focus on: (1) M2 depletion (anti-CD163/CD206 antibodies); (2) Pathway inhibition (CCL2/CCR2 or IL-4/STAT6 blockade); (3) Metabolic modulation (glycolysis/OXPHOS targeting); and (4) Phagocytosis enhancement (CD47-SIRPα blockade, HDAC6 inhibition). Preclinical studies demonstrate CSF-1R inhibitors (e.g., pexidartinib) disrupt LSC-TAM crosstalk, while CAR-M therapy synergizes with phagocytosis-promoting agents. Despite challenges, macrophage-targeted therapies offer transformative potential by remodeling the TME, overcoming resistance, and augmenting immunotherapy. This review outlines mechanistic insights and translational strategies to harness macrophage plasticity for leukemia treatment. We delineate the multifaceted regulatory networks—including NF-κB, STAT1/6, PPARγ, hypoxia, metabolic reprogramming, and exosomal signals—that drive macrophage polarization in hematologic malignancies. We show that M2‐like tumor‐associated macrophage infiltration predominates in AML, promoting angiogenesis, immune evasion, chemoresistance, and correlating with adverse prognosis. We review therapeutic strategies to deplete or reprogram M2 macrophages—such as CSF‐1R inhibitors, anti‐CD163/CD206 antibodies, and CAR‐Macrophage constructs—to restore anti‐leukemic immunity. We highlight emerging combinatorial approaches (e.g., metabolic interventions, TLR agonists, CD47‐SIRPα and immune checkpoint blockade) that synergize to shift TAMs toward a pro‐inflammatory M1 phenotype and enhance chemotherapy efficacy. We propose leveraging single‐cell sequencing and spatial transcriptomics to map TAM heterogeneity and guide precision macrophage‐targeted therapies in hematologic cancers. We delineate the multifaceted regulatory networks—including NF-κB, STAT1/6, PPARγ, hypoxia, metabolic reprogramming, and exosomal signals—that drive macrophage polarization in hematologic malignancies. We show that M2‐like tumor‐associated macrophage infiltration predominates in AML, promoting angiogenesis, immune evasion, chemoresistance, and correlating with adverse prognosis. We review therapeutic strategies to deplete or reprogram M2 macrophages—such as CSF‐1R inhibitors, anti‐CD163/CD206 antibodies, and CAR‐Macrophage constructs—to restore anti‐leukemic immunity. We highlight emerging combinatorial approaches (e.g., metabolic interventions, TLR agonists, CD47‐SIRPα and immune checkpoint blockade) that synergize to shift TAMs toward a pro‐inflammatory M1 phenotype and enhance chemotherapy efficacy. We propose leveraging single‐cell sequencing and spatial transcriptomics to map TAM heterogeneity and guide precision macrophage‐targeted therapies in hematologic cancers.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/023cfef53e175d84bca0acfff247616d2a3dbb65" target='_blank'>
              Macrophage polarization in hematologic cancers: mechanisms and therapeutic strategies
              </a>
            </td>
          <td>
            Zhi-Gang Chen, Huan Yang, Chao Yang, Yu-Tong Xie, Chen-Mo Li, Tong Xiao, Jun-Hong Wu, Ming-Yang Gao, Cong-cong Wang, Yu-le Zhao, Jia Liu, Lei Gao
          </td>
          <td>2026-02-07</td>
          <td>Blood Research</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Ovarian cancer (OC) remains the most lethal gynecologic malignancy, with the regulatory role of innate immunity in its progression and treatment poorly understood. This study provides a thorough characterization of OC immune microenvironment by combining multi-omics data. Our findings show innate immune signals in myeloid cells are central to communication within tumor microenvironment. Analysis of innate immune scores revealed IFIT3+macrophages exhibit the highest innate immune scores. By triggering inflammatory reactions, IFN-α interferon pathways, IFIT3+macrophages are essential for the onset of OC. Using high-dimensional weighted gene co-expression network analysis algorithm, we identified 25 genes associated with IFIT3+macrophages and developed a prognosis model related to innate immunity, which includes ISG20, DYNLT1, and IL1RN. Validation across three cohorts confirmed the model’s strong predictive performance. Low-risk group demonstrated an active immune status, higher immune and microenvironment scores, and higher tumor mutation burden, suggesting they are more likely to benefit from immunotherapy. Furthermore, low-risk group showed increased expression of classical immune checkpoints and trained immunity markers, reinforcing the potential for immunotherapy. Among the genes in the prognostic model, high ISG20 expression was associated with improved overall survival and positively correlated with earlier clinical stages. Enrichment analysis revealed high ISG20 expression activates multiple antitumor pathways. Pan-cancer analysis also suggested ISG20 may be a tumor suppressor, correlating negatively with angiogenesis and epithelial-mesenchymal transition scores. In vitro assays confirmed that knockdown of ISG20 promoted OC cells proliferation, migration and invasion. Molecular docking and molecular dynamics simulations suggest that the Chinese herbal monomer Mulberrofuran K may be a potential therapeutic agent targeting ISG20 for treating OC. In conclusion, we emphasize the significance of innate immunity in OC development and immunotherapy, and find ISG20 to be a prospective biomarker and therapeutic target.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b6a5ee79890cc8af8faf62b6e41e867016886e03" target='_blank'>
              Integrative multi-omics analysis reveals IFIT3⁺ macrophage-associated ISG20 as a prognostic biomarker and elucidates underlying tumor-suppressive mechanisms in ovarian cancer
              </a>
            </td>
          <td>
            Xiushen Li, Wenhao Wu, Sailing Lin, Xiangyu Yang, Huimin Wang, Xiaoyong Chen, Liqin Bao, Qiongfang Fang, Qi Zhang, Jingxin Ma, Lijun Fan, Guli Zhu, Ruiqi Wang, Xiran Wang, Zhaorui Cheng, Weizheng Liang, Xueqing Wu
          </td>
          <td>2026-01-09</td>
          <td>Journal of Ovarian Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Macrophages are pivotal regulators of immunity, with intercellular communication being a central mechanism of their function. Among these communications, chemokines act as critical messengers in macrophage-T cell crosstalk. This review systematically elucidates the notable roles of macrophage-derived chemokines in modulating T cell homeostasis, particularly concentrating on their influence on both CD4+ and CD8+ T cell differentiation, proliferation, exhaustion, secretory activity, metabolic reprogramming (involving glycolysis and OXPHOS), chemotaxis, and memory formation. In the tumor microenvironment (TME), the dualistic nature of chemokines was highlighted: tumor-associated macrophages (TAMs) could secrete immunosuppressive factors, such as CCL22 and CCL5, recruiting inhibitory cells and inducing CD8+ T cell exhaustion. In contrast, M1-like macrophages could produce CXCL9 and CXCL10, activating effector CD8+ T cells, thereby enhancing anti-tumor immunity. Finally, the promising therapeutic potential of targeting specific chemokine signaling axes, such as CCL2/CCR2 and CXCL10/CXCR3, was discussed as a strategy to improve the efficacy of cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4a06e8edc357cf9d46cc116733166db76bc166c3" target='_blank'>
              Macrophage-derived chemokines in T cell regulation: implications for cancer immunotherapy
              </a>
            </td>
          <td>
            Kunpeng Zhang, Jingjing Liu, Qi Liu, Ningning Zhu, Baodong Ye
          </td>
          <td>2026-01-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Non-tuberculous mycobacteria (NTM) infections are difficult to cure completely with current treatments, and no specific drugs are available. However, recent reports have indicated that immune checkpoint inhibitors may effectively treat pulmonary NTM infections. In this study, we investigated the expression of immune checkpoint molecules in macrophages, the host cells of NTM, and assessed their impact on the microenvironment of infected lesions. Bulk-RNA sequencing and western blot analyses revealed that macrophages infected with Mycobacterium avium, an NTM species, exhibited a pro-inflammatory phenotype and increased PD-L1 expression. Additionally, immunostaining of an NTM-infected mouse model and human tissues showed that increased PD-L1 expression in macrophages was associated with decreased T cell infiltration and increased T cell exhaustion (upregulated PD-1 expression) within infected lesions. These findings suggest that NTM infections evade cellular immunity by enhancing PD-L1 expression in macrophages. Therefore, PD-L1 inhibition may be a promising therapeutic strategy against NTM infections.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8ac4e6d1c3dbb18bdbd00c3822726e374ee76d3e" target='_blank'>
              Mycobacterium avium infection induced PD-L1 overexpression in macrophages: a potential involvement with immune escape
              </a>
            </td>
          <td>
            H. Yano, Yukio Fujiwara, R. Mito, C. Pan, Katsuhiko Ono, K. Imamura, T. Niidome, Tomohiro Sawa, Masahiro Yamamoto, T. Sakagami, Yoshihiro Komohara
          </td>
          <td>2026-01-09</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>52</td>
        </tr>

        <tr id="Gliomas with mutant isocitrate dehydrogenase 1 (mIDH1) represent a distinct subgroup of brain tumors characterized by unique metabolic and immunological profiles compared to wildtype IDH1 (wtIDH1) gliomas. Despite recent progress, the cellular mechanisms underlying tumor progression and immune modulation in these subtypes remain poorly understood. In this study, we employed single-cell RNA sequencing (scRNA-seq) to characterize the cellular heterogeneity of wtIDH1 and mIDH1 gliomas, with a particular focus on myeloid cell populations. Our analyses revealed a marked reduction of monocyte-derived tumor-associated macrophages (Mo-TAMs) and lower expression of macrophage migration inhibitory factor (MIF) in mIDH1 gliomas, which was attributable to epigenetic reprogramming. Mechanistic studies using MIF and CD74 knockout mice demonstrated that the MIF-CD74 axis plays a crucial role in regulating the glioma immune microenvironment, thereby driving tumor growth and progression. Importantly, the combination of immune-stimulatory gene therapy (HSV1-thymidine kinase/Fms-like tyrosine kinase 3 ligand; TK/Flt3L) with MIF inhibition significantly extended survival in models of wtIDH1 glioma. These findings highlight the therapeutic potential of targeting the MIF-CD74 pathway and underscore the importance of integrating immunomodulatory strategies for the treatment of glioma. Highlights Mutant IDH1 gliomas exhibit fewer Mo-TAMs and increased Mg-TAMs Mutant IDH1 gliomas have less MIF expression via epigenetic reprogramming. Mesenchymal wtIDH1 glioma cells are main source of MIF. MIF inhibition plus immune stimulatory gene therapy extends survival wtIDH1 glioma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3d9d9e99d312aee7d3e8959371325610d5ce9af0" target='_blank'>
              MIF-mediated reprogramming of myeloid lineage within the glioma tumor microenvironment impacts the efficacy of immune stimulatory gene therapy
              </a>
            </td>
          <td>
            Ziwen Zhu, Noah C. Kanis, Anthony E. George, Michael Albdewi, Yingxiang Li, Anzar A. Mujeeb, Brandon L. McClellan, Gurveer Singh, Jialin Liu, W. Al-Holou, J. Heth, Joshua D. Welch, Justin D. Lathia, Pedro Lowenstein, Richard Bucala, Maria G. Castro
          </td>
          <td>2026-01-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options and a dismal prognosis. While immunotherapy has shown promise in treating some solid tumors, the treatment of GBM has been mostly unsuccessful because of a lack of targetable tumor antigens and high tumor heterogeneity. Here, we report RCAN1-4 as a novel tumor antigen derived from alternative splicing induced by the transcription factor C/EBPβ. Both C/EBPβ and RCAN1-4 are highly expressed in GBM and glioma stem cells as mesenchymal subtype hallmarks. We report an immunogenic HLA-A24-specific splicing junction epitope within exon 4 and exon 5 that is unique to RCAN1-4. This epitope was validated for its ability to stimulate T cell responses in HLA-A24+ donors and GBM patients, leading us to identify RCAN1-4-reactive T cell receptors (TCRs) for the construction of TCR-engineered T cells (TCR-T cells). Functional studies of TCR-Ts demonstrated the in vitro and in vivo killing of RCAN1-4pos GBM tumor cells, highlighting its potential as an immunotherapeutic target in mesenchymal GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc9431f57db16fa14c7bf510b22de1e580e92e77" target='_blank'>
              C/EBPβ-induced alternative splicing of RCAN1 generates a potent TCR-T target in mesenchymal glioblastoma
              </a>
            </td>
          <td>
            Zujian Xiong, Qinglin Kong, Bhuvi Chagantipati, Amelia L Stepniak, Ambika P Jaswal, Chaim T Sneiderman, Yuanyuan Han, Sydney A Jackson, Rebecca A Raphael, Wei Zhang, Muzi Li, Yapeng Chao, Bin Qin, Zeynep Dulkadir, Lance Schwegman, Yihao Zhang, Chloe R Kuminkoski, Megan A Mahlke, Poulomi Nath, Baoli Hu, Pascal O. Zinn, M. Mantica, S. Agnihotri, Yael Nechemia-Arbely, Ian F. Pollack, L.H. Rigatti, Thomas G. Forsthuber, Xuejun Li, Itay Raphael, G. Kohanbash
          </td>
          <td>2025-12-23</td>
          <td>Cellular and Molecular Immunology</td>
          <td>2</td>
          <td>18</td>
        </tr>

        <tr id="Terminally exhausted CD8+ T cells (Ttex) are emerging as clinically relevant immune subsets across solid tumors, marked by sustained inhibitory receptor expression, loss of TCF1, and limited proliferative capacity. Once considered functionally inert, Ttex are now recognized for their residual cytotoxic potential and strong associations with tumor immunogenicity, including microsatellite instability (MSI), high tumor mutational burden (TMB), and neoantigen load. Importantly, the prognostic significance of Ttex is highly tumor-context-dependent, shaped by stromal architecture, mutational burden, and progenitor Tpex availability. This review examines the biology, spatial localization, and prognostic value of Ttex, highlighting the Ttex/CD8+ ratio as a promising biomarker in cancers such as colorectal, lung, and esophageal carcinoma. We summarize recent advances in multiplex imaging, digital pathology, and AI-driven quantification that support the clinical integration of Ttex assessment. In addition, we discuss emerging therapeutic strategies targeting Ttex through immune checkpoint combinations, thymocyte selection-associated high mobility group box protein (TOX) and circRNA-mediated reprogramming, and exhaustion-resistant T cell engineering. Finally, we outline translational priorities including assay harmonization, functional validation, and longitudinal profiling to advance Ttex-based precision oncology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/af1a0b32b60b15c52819ffc31235e60745d2593b" target='_blank'>
              Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology
              </a>
            </td>
          <td>
            Xuejun Guo, Shuhan Ma, Jingwen Wang, Yilin Fu, Wenxue Ma
          </td>
          <td>2026-01-12</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition resulting from dysregulation of the intestinal immune system. CD4+FoxP3+ regulatory T cells (Tregs) play a crucial role in regulating this immune response. The heat shock response (HSR) regulates the inflammatory cascade, preventing misfolding of proteins and regulating immune responses. We have previously shown that Heat Shock Factor 1 (HSF1), the master regulator of the HSR, regulates Tregs in inflammation. Based on this finding, we hypothesized that targeting HSF1 with celastrol, a pentacyclic triterpenoid that activates HSF1, would activate Treg cells and ameliorate intestinal inflammation. To test this, we investigated the impact of celastrol on Tregs both in vitro and in vivo, evaluating its efficacy in HSF1fl/fl-CD4cre mice, and in two murine models of IBD: the adoptive transfer colitis, and TNFΔARE+/− ileitis. Our results demonstrate that celastrol activates HSF1 in Tregs, enhances Treg suppressive function, increases Treg populations in vivo, and ameliorates intestinal inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/204e8c3bffdaa0f6e62b6113f69d15672aaebfe4" target='_blank'>
              Celastrol Activates HSF1 to Enhance Regulatory T Cells Function and Ameliorate Intestinal Inflammation
              </a>
            </td>
          <td>
            Kibrom M. Alula, Colm B. Collins, Tom T. Nguyen, C. M. Aherne, Paul Jedlicka, E. D. de Zoeten
          </td>
          <td>2025-12-31</td>
          <td>Biomolecules</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e3bd3a5ca45d24cd8b7d6b837756f7e1569a107b" target='_blank'>
              A Glycosylation-Dependent Checkpoint Restrains Intestinal Intra-Epithelial Lymphocyte Activation
              </a>
            </td>
          <td>
            Liqing Cheng, Niccolò Bianchi, Hadrien Soldati, Ludivine Bersier, Maximilien Evrard, Aurelie Caillon, A. Chawla, B. Nakken, Peter Szodoray, Elien De Bousser, N. Festjens, T.V. Petrova, Sylvain Lemeille, Laura K. Mackay, Nico Callewaert, Mahima Swamy, Simon M. G. Braun, Simone Becattini
          </td>
          <td>2026-01-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="The hallmark of HIV-1 (HIV) infection is the progressive development of multicellular and systemic immune dysfunction, culminating in AIDS. Dendritic cells (DCs) play a pivotal role in HIV dissemination to CD4 + T cells, which are subsequently depleted by the virus leading to HIV disease progression. Type I interferons (IFNs) are critical for host defense during acute infection but contribute to chronic immune activation during the later stages of HIV disease. This persistent activation leads to immune cell exhaustion. HIV can activate type I IFN responses via several pathways, including the STING pathway, which is activated by, e.g., virus-derived oligonucleotides. Here, we investigated the underlying mechanisms creating HIV-mediated immune dysfunction and role of type I IFNs using a DC and T cell co-culture model. HIV exposure in the DC-T cell co-culture promoted the expansion of suppressive T cells with diminished proliferation and effector functions. The impairment required type I IFNs and subsequent IFNα/β receptor signaling, and our data indicate that this was initiated by HIV-derived ssDNA activation of IFI16/cGAS followed by STING signaling in the DCs. Targeting IFNAR1 with anifrolumab restored the immune functions of both DCs and T cells, as well as T cell proliferation and T cell effector functions, including their secretion of IL-2, IFNγ, and granzyme B. Our findings support that the immune impairments existing in untreated or antiretroviral therapy (ART) treated HIV-infected individuals are mediated, if not fully in part by type I IFN’s negative effect on DC and T cells. Therapeutics targeting IFNα/β receptors, such as anifrolumab, hold potential as combination treatment alongside ART, to achieve a more complete immune restoration and contribute to improved quality of life among people living with HIV.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4e95cbbbde7b7d99cd214bc34fcf814ada296c30" target='_blank'>
              HIV-1 derived oligonucleotides induce a type I IFN/STING dependent immune suppression reversible by targeting IFNARI
              </a>
            </td>
          <td>
            Cecilia Svanberg, Ravi Prasad Mukku, Sabri O. Besler, Francis R. Hopkins, Christopher Sjöwall, Sofi A Nyström, E. M. Shankar, Marie Larsson
          </td>
          <td>2026-01-01</td>
          <td>PLOS Pathogens</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="There has been marked improvement in the clinical outcome of triple-negative breast cancer (TNBC) with the use of immune checkpoint blockade (ICB) although serious immune-related adverse effects are not uncommon. However, other subtypes including luminal ER+ and HER2+ breast cancers are largely unresponsive to ICB. Approximately 35% of TNBCs also do not fully respond to ICB. Here we hypothesize that improving priming by cross-presenting conventional dendritic cells (cDCs) with an agonistic CD40 antibody (aCD40) may be complementary to ICB. Systemic administration of aCD40 induced T cell proliferation and activation in tumor-draining lymph nodes and attracted effector T cells to the tumor bed from the periphery. This effect was largely due to activation and maturation of type 1 conventional dendritic cells (cDC1s). aCD40 alone slowed tumor growth and its combination with ICB cured tumor-bearing mice, accomplishing a “vaccine effect” and the immune-mediated rejection of tumor rechallenge. The anti-tumor effect of aCD40 was cDC1 and CD8 + T cell-dependent, whereas the rejection of secondary tumor rechallenge in cured mice required CD4 + T cells. Importantly, intra-tumoral administration of aCD40 combined with systemic or intra-tumoral ICB—to mimic neoadjuvant therapeutic approaches—induced complete regressions of both treated and distant tumors. These findings demonstrate aCD40 efficacy in preclinical models of breast cancer and further supports intra-tumoral administration of both aCD40 and ICB as an effective treatment that might limit systemic exposure and lower risk of immune-related toxicity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e30c1b6f33680b1d55dd8a89763ae987b7c2a254" target='_blank'>
              Agonistic CD40 elicits CD8+ T-cell-dependent primary responses and CD4+ T-cell-dependent long-term immunity in breast cancer
              </a>
            </td>
          <td>
            Casey Lam, Olivia Lanchoney, Vishnu Maddipatla, N. Markosyan, Nikhil Joshi, Xiaowen Hu, Courtney Ray Fofana, Shan Zeng, Ronald P DeMatteo, Robert H Vonderheide, Jennifer Q. Zhang
          </td>
          <td>2026-01-13</td>
          <td>NPJ Breast Cancer</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Cancer remains one of the most severe global health burdens, and its high mortality is closely linked to the ability of tumor cells to evade immune surveillance. While immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell (CAR-T) therapies have significantly advanced the field of oncology, their efficacy is often limited by complex immune escape mechanisms. This study reviews the main molecular and cellular pathways of tumor immune evasion, including the PD-1/PD-L1 signaling axis, tumor-associated macrophages (TAMs), and other immunosuppressive cells such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). Clinical progress and limitations of single agent immunotherapies are summarized, encompassing primary and acquired resistance as well as unpredictable immune related adverse events. Emerging evidence supports combination immunotherapy approaches such as pairing ICIs with antiangiogenic agents or TAM targeted strategies, which have demonstrated synergistic efficacy across preclinical models and clinical trials. This review aims to elucidate the mechanisms of tumor immune evasion and assess current and emerging therapeutic approaches to guide more precise and effective clinical applications.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e65f7d8b41ca82473df3e2561ea0efa0fce7ec82" target='_blank'>
              Tumor Immune Evasion Pathways and Intervention Strategies
              </a>
            </td>
          <td>
            Che Su
          </td>
          <td>2025-12-28</td>
          <td>Academic Journal of Science and Technology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Immune checkpoint inhibitors (ICIs) have redefined the therapeutic paradigm of non-small cell lung cancer (NSCLC), offering durable remission in select patients by reactivating anti-tumor T cell responses. Yet, this clinical triumph is tempered by the reality that most patients experience either primary resistance or relapse due to acquired resistance, underscoring an urgent need for mechanistically grounded solutions. Resistance arises through a complex interplay of tumor-intrinsic mechanisms, including defects in antigen presentation, interferon signaling disruption, and oncogenic pathway activation (EGFR, KRAS, MET), and tumor-extrinsic factors such as immunosuppressive cell populations, inhibitory cytokines, and metabolic rewiring of the tumor microenvironment (TME). This review provides a comprehensive synthesis of emerging pharmacological strategies aimed at reversing ICI resistance in NSCLC. Promising avenues include dual or multi-checkpoint inhibition (targeting LAG-3, TIGIT, TIM-3), integration of epigenetic reprogrammers to resensitize immune-silent tumors, and metabolic interventions that normalize the TME. Additionally, combination regimens with oncogene-directed therapies, engineered cytokine analogs, neoantigen-based vaccines, and adoptive T cell therapies are reshaping the frontier of immunoresistant NSCLC management. We also highlight pivotal clinical trials—both completed and ongoing that illuminate translational breakthroughs and therapeutic pitfalls. Looking ahead, the field must grapple with key challenges: the refinement of predictive biomarkers, stratification of patients through genomic, immunologic, and microbiome-based profiling, and the management of toxicity in complex combination protocols. Ultimately, a shift toward highly personalized, biomarker-guided therapeutic strategies holds the greatest promise for overcoming resistance and extending the reach of immunotherapy in NSCLC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a4fa2fc3480e331167df24fb59d6d5857202d4b" target='_blank'>
              Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer
              </a>
            </td>
          <td>
            Yuyu Xu, Huiling Shen, Dong Shang, Cailin Zhu
          </td>
          <td>2026-01-08</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Intracellular pathogens must evade cytotoxic immunity to establish persistent infection. Although immune escape is typically viewed through a biochemical lens, the ability of certain pathogens to alter the mechanical properties of infected cells suggests that biophysical mechanisms may also contribute to the process. Here, we show that a subset of CD4+ T cells infected with the human immunodeficiency virus (HIV) resist elimination through a soft phenotype that inhibits killing by mechanosensitive cytotoxic T lymphocytes (CTLs). This phenotype arises from the combined effects of the HIV virulence factor Nef, which remodels the actin cytoskeleton, and intrinsic heterogeneity in the basal cytoskeletal properties of infected T cells. Pharmacological or genetic perturbations that reverse Nef signaling to the cytoskeleton or that stiffen the filamentous-actin cortex sensitize infected cells to CTL-mediated lysis. Taken together, these findings define a novel, biophysical paradigm of immune evasion with implications for HIV cure strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1a4f51743a919ef271e4cd1d83a51db2f6165482" target='_blank'>
              HIV Nef amplifies mechanical heterogeneity to promote immune evasion
              </a>
            </td>
          <td>
            Louise Leyre, Farah Mustapha, Alberto Herrera, Esther Lee, Emily Huntsman, P. Zumbo, J. Weiler, Parul Sinha, Ethan Naing, Connor Smith, Colin C. Kovacs, Micheal Galiano, Nada Wahman, D. Betel, Kiera L. Clayton, Morgan Huse, R. B. Jones
          </td>
          <td>2025-12-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="Inflammatory bowel disease (IBD) is a chronic, immune-mediated intestinal disorder driven by dysregulated immune responses in genetically susceptible individuals. Despite recent advances in treatment, more than 30% of patients either fail to respond initially or lose response over time, underscoring the need for a deeper mechanistic understanding of immunogenetic pathways and the development of individualized therapeutic strategies. We first discuss how newly identified susceptibility genes (e.g., IL23R, NOD2, BDNF, SLC) and their polymorphisms influence immune cell function and epithelial barrier integrity. Single-cell technologies have further revealed novel cell subsets and interactions underlying disease heterogeneity. We then explore the clinical efficacy of classical and emerging targeted therapies, including cytokine-specific biologics, JAK inhibitors, and novel strategies aimed at restoring regulatory T-cell function or blocking integrin-mediated lymphocyte trafficking. Additionally, we highlight promising therapeutic approaches such as fecal microbiota transplantation, microbial metabolite-based interventions, and nanotherapeutics. We further discuss how genetic insights and immune biomarkers can facilitate treatment personalization and improve prognostic stratification. Ultimately, this review emphasizes the transition from broad immunosuppression to precision medicine and proposes integrated approaches—combining multiomics profiling, immune monitoring, and novel therapeutics—to achieve sustained remission and improve long-term outcomes in IBD patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e9934abd1cae4b51fafcf82e95c660b61b5ae0d4" target='_blank'>
              Deciphering the immunocellular regulatory network in inflammatory bowel disease: from susceptibility genes to cellular effectors and toward precision therapies
              </a>
            </td>
          <td>
            Zhuzhu Wu, Xiaolin Wang, Zitong Guan, Mengxue Han, Wenke Ma, Jie Li, Shuai Man, Zhenguo Wang, Qibiao Wu
          </td>
          <td>2026-01-27</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor survival. The immunosuppressive tumor microenvironment (TME) drives resistance to therapy, including immunotherapy. This may be, in part, mediated by the formation of neutrophil extracellular traps (NETs), formed when neutrophils release their intracellular contents. NETs are elevated in PDAC and are associated with nearly every stage of tumor progression. We investigated the influence of NETs on the PDAC TME and immunotherapy response. An orthotopic PDAC model was utilized in C57BJ6 or PAD4-/- mice receiving one of the following: control, DNase, anti-PD-1 therapy, or DNase and anti-PD-1. NET markers, fibrosis, and the TME immune profile were evaluated. Human PDAC patients were also evaluated for levels of NETs and tumor-infiltrating T cells. Circulating NET markers correlated with intra-tumoral CD8+ cells in PDAC patients. Patients with high NET levels also experienced more post-operative complications. NET inhibition in mice reduced tumor growth and enhanced survival. Decreased expression of collagen and matrix metalloproteinase (MMP) genes, as well as reduced intra-tumoral collagen deposition were found in NET deficient mice. Additionally, an increase in TCF1+PD-1+CD44+CD8+ progenitor T cells, a subpopulation of T cells responsive to immunotherapy, were identified. These changes resulted in further tumor burden reduction and prolonged survival when anti-PD-1 therapy was given in conjunction with NET inhibition. NETs influence extracellular matrix remodeling and the T cell response to PDAC, allowing for a significant response to anti-PD-1 therapy. These findings support the combination therapy of immunotherapy and NET inhibition in patients with PDAC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8c46e4293b48b999ce9a40d9b92499a2b9823b8d" target='_blank'>
              Neutrophil extracellular trap inhibition revitalizes PDAC immunotherapy responsiveness via reduced fibrosis and TCF1+CD8+ progenitor T-cell expansion
              </a>
            </td>
          <td>
            Britney Niemann, Abby D Ivey, Quinn Hopen, Duaa Dakhlallah, Kathleen Brundage, Nicole E Mihalik, Timothy D Eubank, Brian A. Boone
          </td>
          <td>2025-12-01</td>
          <td>OncoImmunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/236386a7fa1ba2562148eaf357471660c9fc4c08" target='_blank'>
              Suppression of CD4 T cells by Tregs dictates metabolic remodeling of CD8 T cells during effector to memory transition
              </a>
            </td>
          <td>
            Adithya Vegaraju, V. Kalia, S. Sarkar
          </td>
          <td>2026-02-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="Simple Summary Glioblastoma is an aggressive brain tumor that evades the immune system; this study asked whether tiny particles released by glioblastoma cells (extracellular vesicles, or EVs) can influence a specific type of immune cell called a γδ T lymphocyte. For that purpose, we first characterize EVs from the U251 glioblastoma cell line and test whether they bind to, enter, and activate γδ T cells, and which molecules on EVs drive that effect. We found that the isolated EVs were enriched in medium/large sizes, contained tumor markers including EGFR and the stress ligands MICA/B, and were taken up by γδ T cells. Exposure to these EVs increased an early activation marker (CD69), raised production of inflammatory proteins TNF-α and IFN-γ, and enhanced the T cells’ ability to kill tumor cells. Blocking MICA/B on EVs reduced activation. These results suggest U251-derived EVs can stimulate antitumor γδ T-cell responses via MICA/B, offering a potential avenue to boost immune therapies and improve outcomes for patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/571080b94359e8e0eaf5f5df062df21ea630bc90" target='_blank'>
              Small Messengers: Glioblastoma-Derived Extracellular Vesicles Modulate γδ T Lymphocytes Through a MIC-Dependent Mechanism
              </a>
            </td>
          <td>
            Micaela Rosato, Paula Saibene Vélez, Alejandra Infante Cruz, M. Pibuel, Federico Fuentes, Mónica Vermeulen, Juan Iturrizaga, Pablo E. Espil, Silvia Berner, G. Salamone, C. Jancic
          </td>
          <td>2026-02-01</td>
          <td>Biology</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/496c0377801d80b550476f4860ba808c84291b11" target='_blank'>
              Coxsackievirus B Escapes Antiviral CD8⁺ T Cells but Triggers Robust CD4⁺ Memory Responses
              </a>
            </td>
          <td>
            Orlando Burgos-Morales, Federica Vecchio, Fatoumata Samassa, Margot Petit, Zhicheng Zhou, Barbara Brandao, A. Carré, Annalisa Nicastri, Valeriia Dotsenko, Chloe Shepherd, K. Viiri, Robert Parker, Amelia K. Linnemann, Sylvaine You, Malin Flodstrom-Tullberg, Nicola Ternette, Roberto Mallone
          </td>
          <td>2026-01-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="The pathogenesis of rheumatoid arthritis (RA) involves an aberrant number and/or activation of dendritic cells (DCs) within the synovial microenvironment. Targeting synovial DCs represents an attractive approach for the treatment of RA. Spleen tyrosine kinase (SYK), a pivotal molecule in immune cell receptor signaling pathways, is known to play a critical role in RA progression. However, the impact of SYK on DC biology under RA-specific pathological conditions remains incompletely understood. In this study, we employed a spontaneous RA mouse model carrying a gain-of-function SYK variant (SYKS544Y) to investigate the effects of SYK activation on DCs. Our findings demonstrate that SYK activation promotes the expansion of the DCs population (CD11C+MHCII+), particularly the CD11C+MHCII+CD11B+CD8a− subtype, in blood, spleen, and ankle. Furthermore, SYK activation enhances DC maturation and endocytosis by upregulating CD40 and CD86. Additionally, bone-marrow-derived DCs from SYKS544Y mice exhibit increased T-cell proliferative activity. Collectively, these results suggest that gain-of-function SYK may contribute to RA pathogenesis by promoting DC expansion and maturation, thereby modulating immune responses in the synovial environment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/90d45bd28b2a8c3fdbadb028c0f87f36c8d6fc15" target='_blank'>
              SYK Activation Enhances Dendritic Cell Functions in Spontaneous Rheumatoid Arthritis
              </a>
            </td>
          <td>
            Zhiyang Zeng, Xiya Cao, Haozhe Guo, Yuxuan Lai, Weihua Yang, Youyuan He, Jialiang Sun, Zhenliang Sun, Dali Li, Yamin Tan
          </td>
          <td>2025-12-30</td>
          <td>Inflammation</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Immunotherapies have transformed cancer treatment by harnessing the immune system to recognize and eliminate malignant cells, offering durable clinical benefit across diverse tumor types. Despite successes with immune checkpoint inhibitors (ICIs) and other strategies like cytokines, oncolytic viruses, cancer vaccines, bispecific antibodies, and adoptive cell therapies, substantial fractions of patients still fail to respond or develop resistance. The oncogene MYC, deregulated in ~70% of human cancers, has emerged as a central driver of immune evasion and a key contributor to immunotherapy failure. MYC regulates broad transcriptional networks controlling proliferation, metabolism, angiogenesis, and cell survival, while also orchestrating profound remodeling of the tumor microenvironment (TME). Mechanistically, oncogenic MYC suppresses antigen processing and presentation, attenuates interferon signaling, and upregulates immune checkpoints such as PD-L1 and CD47. Concurrently, MYC stimulates secretion of immunosuppressive cytokines and chemokines that recruit regulatory T cells, myeloid-derived suppressor cells, and M2 macrophages, while driving metabolic reprogramming that fosters nutrient competition, hypoxia, and acidosis, impairing effector T- and NK-cell function. Through these pathways, MYC promotes primary, adaptive, and acquired resistance to immunotherapy. Targeting MYC, directly or indirectly, holds promise to restore immune surveillance and potentiate immunotherapeutic efficacy. This review highlights MYC as a master regulator of tumor–immune interactions and underscores the therapeutic potential of MYC inhibition to overcome resistance and expand the clinical impact of cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/437ab7ab32dc49430fcd2b151a4005d089060a97" target='_blank'>
              MYC at the tumor–immune interface: mechanisms of immune escape and immunotherapy resistance
              </a>
            </td>
          <td>
            Íñigo González-Larreategui, Manrique Valdés-Bango Martín, S. Casacuberta-Serra, Laura Soucek
          </td>
          <td>2026-01-23</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Objectives CD79B is a key component of the B-cell receptor complex, but its relevance in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) remains unclear. Methods We screened immune-related genes in public MDS microarray datasets, prioritized CD79B, and validated its expression in an independent MDS cohort, an AML cohort, and peripheral blood samples from patients with MDS or AML transformed from MDS. Functional effects of CD79B overexpression were examined in HL-60 cells, and gene set enrichment and immune-infiltration analyses were used to explore CD79B-associated pathways. Results CD79B expression was consistently reduced in MDS and AML compared with normal controls in public datasets and clinical samples. In HL-60 cells, enforced CD79B expression modestly altered cell-cycle distribution and increased apoptosis. Transcriptomic analyses linked higher CD79B expression to immune response and T-cell activation pathways and to global patterns of immune-cell infiltration. Conclusion These exploratory data suggest that CD79B downregulation is a recurrent feature of MDS and AML and that CD79B may influence leukemic cell behavior and immune microenvironmental signals. The findings generate hypotheses for future mechanistic studies and evaluation of CD79B as a potential biomarker in myeloid malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c76dd1404117abb948eccddba91b587ad4db86ea" target='_blank'>
              CD79B in myelodysplastic syndromes and acute myeloid leukemia: an integrative computational and in vitro study
              </a>
            </td>
          <td>
            Xiangjing Kong, Yongfu Wei, Shengjuan Zhang, Xiaoya Lu, Rui Luo, Bo Liang, Yongsheng Chen
          </td>
          <td>2026-01-16</td>
          <td>Frontiers in Medicine</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Background Plasmodium infection has been proven to activate antitumor immune responses. This study comprehensively analyzes the immune cell populations in peripheral blood and tumor microenvironment to elucidate the potential immunological mechanisms by which Plasmodium infection inhibits tumor growth. Methods We established a subcutaneous Lewis lung cancer model in C57BL/6J mice and treated them with intraperitoneal injection of Plasmodium yoelii. The long and short diameters of tumors were measured. Then, high-dimensional flow cytometry was used to analyze the T cell subsets, macrophages and myeloid-derived suppressor cells (MDSCs) in peripheral blood and tumor tissues. Immunosuppression-related phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and TGFβ in tumor tissues were also measured through Western blotting assay. Results Plasmodium infection inhibited the growth of Lewis lung cancer in mice. The infection increased in the numbers of CD3+ T cells, including CD4+ and CD8+ T, CD4+ central memory T (Tcm), CD4+ effector memory T (Tem), CD8+ Tcm, CD8+ Tem, CD8+ virtual memory T (Tvm), CD8+ short-lived effector cells (SLEC), and CD8+ memory precursor effector cells (CD8+ MPEC) in peripheral blood. Concurrently, the infection also increased the numbers of CD3+ T cells, including CD4+ and CD8+ T, CD4+ Tcm, CD4+ Tem, CD4+ tissue resident memory T (Trm), CD8+ Tcm, CD8+ Tem, CD8+ Trm and CD8+ SLEC in tumor tissues. In addition, Plasmodium infection reduced the expression levels of PD-1 on CD4+ and CD8+ T, the number of polymorphonuclear MDSCs, and increased the ratio of M1/M2 macrophages in the tumor tissues. The initial mechanism study revealed that Plasmodium infection significantly reduced the expression levels of pSTAT3 and TGFβ in tumor tissues, providing direct evidence that Plasmodium infection activated the antitumor immune responses. Conclusion Based on our past and current studies, we can draw the following conclusion: Plasmodium infection fully remodels and activates the immune system, targets and inhibits the entire tumor ecosystem through the key signals of pSTAT3 and TGFβ. This is completely different from the mechanisms of action of the current immune checkpoint blockade therapies, representing a new form of cancer immunotherapy, namely, the immune ecotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cd7f210288e33ea28f813138a60cfcc73b611c1f" target='_blank'>
              Plasmodium infection fully activates the immune system in peripheral blood and tumor microenvironment in a murine Lewis lung cancer model
              </a>
            </td>
          <td>
            Qunfeng Huang, Dongheng Yang, Zhu Tao, Zhaoqing Yu, Wenting Ding, Na Tao, Xiulin Liao, Haoxin Lin, Zhipeng Cheng, Susu Gao, Zhongkui Kang, Jianming Xie, Wen Hu, Li Qin, Xiaoping Chen, Guifang Yu
          </td>
          <td>2026-01-28</td>
          <td>Frontiers in Molecular Biosciences</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Colorectal cancer (CRC) exhibits a striking dichotomy in response to immune checkpoint inhibitors (ICIs), with durable benefit largely restricted to dMMR/MSI-H disease while most pMMR/MSS tumors remain refractory. Central to this resistance is an immunosuppressive myeloid ecosystem—dominated by SPP1high tumor-associated macrophages, neutrophils/PMN-MDSCs, and LAMP3+ mregDCs—that enforces chemokine-driven exclusion, attenuates antigen presentation, and sustains metabolite-mediated T-cell suppression. Despite advances in checkpoint blockade and biomarker stratification, these microenvironmental circuits constitute a major therapeutic hurdle. Moreover, single-cell and spatial proteomic platforms (e.g., CITE-seq, CODEX, imaging mass cytometry) now resolve the composition and topology of suppressive neighborhoods and highlight their utility for patient stratification and pharmacodynamic monitoring. This mini review summarizes cellular and spatial mechanisms by which myeloid states drive ICI non-response in CRC, emphasizing stromal TGF-β–coupled SPP1+ TAM programs, granulocytic chemokine axes (CXCL1/2–CXCR2; IL-8–CXCR1/2), and mregDC-mediated co-inhibition. We outline current and emerging myeloid-reprogramming strategies—including PI3Kγ and CSF1–CSF1R targeting, TREM2 antagonism, COX-2–PGE2 blockade, and adenosine-axis inhibition—and their integration with PD-(L)1 therapy, alongside single-cell/spatial endpoints to quantify on-treatment remodeling. The purpose of this mini-review is to provide a mechanistic and technology-informed framework to reference rational trial design and clinical translation for overcoming checkpoint resistance in CRC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9edfc8b67748eb23273fb2effc39b0c690cbbf02" target='_blank'>
              Roles of immunosuppressive myeloid states in colorectal cancer checkpoint inhibitor non-response: single-cell and spatial proteomics, and reprogramming approaches
              </a>
            </td>
          <td>
            Yu Dai, Xinyu Luo, Li Zhang, Jin Yan
          </td>
          <td>2026-01-06</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that strongly suppress immunity and expand during tumor progression. Various antitumor chemotherapy agents can induce MDSC accumulation, reducing treatment effectiveness. We investigated the impact of the CHOP regimen and its components (cyclophosphamide (CTX), doxorubicin, vincristine, and prednisolone) on the dynamics of MDSC accumulation and the associated changes in immune cell profiles in the peripheral blood and spleen of healthy and lymphosarcoma RLS40-bearing CBA mice. CHOP induced significant thymic atrophy and splenomegaly, T-cell depletion, and robust accumulation of MDSCs, primarily polymorphonuclear MDSCs. Kinetic analysis in healthy mice revealed splenic MDSC expansion and T-cell depletion peaked 10-day post-CHOP, driven mainly by CTX; whereas doxorubicin, vincristine, and prednisolone exerted minimal immunological effects. To mitigate CTX-induced MDSCs, glycyrrhizic acid (GLZ), a natural triterpenoid with known immunomodulatory properties, and febroxolone methyl (FM), its novel cyano enone derivative, were administered to CTX-treated mice. GLZ significantly attenuated splenic MDSC accumulation, partially restored T-cell function, and improved immune organ morphology. Conversely, FM exacerbated immunosuppression by expanding MDSCs, enhancing their function by upregulation of Nos1 and Ido1 in vivo, and promoting the generation of highly immunosuppressive bone marrow-derived MDSCs in vitro. Thus, our results highlight CTX’s central role in CHOP-induced MDSC expansion. The structure-dependent duality of triterpenoids, countering (GLZ) or promoting (FM) MDSC expansion, offers therapeutic potential for pathologies ranging from chemotherapy-induced side effects to autoimmunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7552027a881146da8a9871bda6ded9bf7a0d48b5" target='_blank'>
              Cyclophosphamide-Mediated Induction of Myeloid-Derived Suppressor Cells In Vivo: Kinetics of Accumulation, Immune Profile, and Immunomodulation by Oleanane-Type Triterpenoids
              </a>
            </td>
          <td>
            M. Awad, A. Sen’kova, A. Markov, O. Salomatina, M. Zenkova, O. Markov
          </td>
          <td>2026-01-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Regulatory B cells (Bregs) are integral to the tumor microenvironment (TME) and influence immune responses through the secretion of immunosuppressive cytokines such as IL-10, IL-35, and TGF-β. This review highlights recent findings on the phenotype and mechanisms of Bregs, emphasizing their dual role in regulating immune responses within the TME. Importantly, we further explored the latest advances in Breg regulatory mechanisms from the novel perspectives of epigenetics and metabolic remodeling, including the effects of DNA methylation, histone acetylation, glycolysis, and oxidative phosphorylation on Bregs. We also investigate the therapeutic targeting of Bregs, with a focus on STAT3 inhibitors such as lipoxin A4, cucurbitacins, and resveratrol, which show promising potential in mitigating the suppressive function of Bregs. Furthermore, this review provides a detailed analysis of the impact of Bregs on tumorigenesis and metastasis, emphasizing the importance of inhibiting specific immune pathways to prevent tumor escape. Finally, this review offers a prospective outlook on immunotherapy strategies based on Bregs, foreseeing a more nuanced understanding of their TME function and the evolution of targeted treatments with enhanced therapeutic efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/89845b10942cf1fb9d00d8bf5893d8221d0e0a22" target='_blank'>
              Regulatory B Cells in Tumor Microenvironment
              </a>
            </td>
          <td>
            Zhuoyan Cai, Lin Xie
          </td>
          <td>2026-01-01</td>
          <td>Current Issues in Molecular Biology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/954805b24a989a5a800c8a228d8a6b54b8ed322d" target='_blank'>
              Cooperative Interaction Between IL-4 Signaling and FLT3 in Multipotent Progenitors Restore Lymphopoiesis in Inflammation and Aging
              </a>
            </td>
          <td>
            Jingfei Yao, Yuting Wang, Yi Zhang
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Background/Objectives: Adjuvants, added to vaccines to enhance immune responses, are central to shaping the magnitude and durability of immunity, yet their precise mechanisms remain incompletely defined. This study evaluated how diverse adjuvant combinations influence HPV vaccine immunogenicity in non-human primates, with a particular focus on impacts on hematopoietic biology—megakaryocytes and platelets—and broader innate and adaptive pathways. Methods: Eight adjuvanted formulations, each incorporating distinct immunomodulatory components and delivery platforms, were compared against an alum-only control in non-human primates. Longitudinal antibody titers (HPV16-specific) were measured up to 54 weeks, and blood transcriptomes were profiled at Day 1 and Day 7 after both prime and boost doses to assess pathway-level enrichment and gene-expression patterns. Results: Several adjuvant combinations significantly increased antibody titers at 54 weeks compared with alum alone. Formulations containing cationic lipid or monophosphoryl lipid A (MPL) were associated with enhanced antibody responses. Early upregulation of immune-related genes across innate and adaptive pathways was also observed, with some combinations (e.g., inclusion of QS21 or ISCOMs) showing similar trends. Distinct group- and time-dependent transcriptional signatures were observed, with higher-responding formulations exhibiting stronger enrichment in pathogen-influenced signaling and cellular/humoral immune programs. Conclusions: Adjuvant selection and formulation strategy substantially modulate vaccine immunogenicity and early transcriptional programs, including innate, adaptive, and hematopoietic pathways. While individual adjuvants differentially regulate immune and platelet-associated genes, common pathway-level patterns emerge across formulations. These findings suggest candidate mechanisms for prolonged vaccine efficacy and provide actionable insights to guide rational adjuvant design for sustained immune protection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b4d0762b16b24bdacde8573865bc4b685fb51de" target='_blank'>
              Exploring the Impact of Adjuvants on Vaccine Immunity Through Hematopoietic Cells
              </a>
            </td>
          <td>
            Yuhyun Ji, K. Bekkari, Mohammed Shardar, Geoffrey A. Walford, SamMoon Kim, Yaping Liu, Willis Read-Button, Kristina Tracy, Jennifer Kriss, Colleen Barr, Marissa Wolfle, Shailaa Kummar, Celia LaPorta, Rachel Graham, Lorenzo Chen, William J. Smith, Kunal Bakshi, Nicholas Murgolo, Nicole L. Sullivan
          </td>
          <td>2026-02-05</td>
          <td>Vaccines</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Glucocorticoids (GCs), such as dexamethasone (Dex), are widely used in breast cancer treatment to alleviate chemotherapy-induced side effects. However, their immunomodulatory effects on the tumor microenvironment (TME) exhibit a dual nature. On one hand, Dex may delay tumor progression by suppressing pro-inflammatory cytokine release, modulating T-cell function, and inhibiting angiogenesis. On the other hand, Dex can promote the formation of an immunosuppressive TME by activating the glucocorticoid receptor (GR) signaling pathway, thereby accelerating breast cancer metastasis. This review summarizes the molecular mechanisms by which Dex influences breast cancer lung metastasis through its regulation of immune cells (e.g., T cells, B cells, myeloid cells), cytokine networks, and metabolic reprogramming in the TME. Additionally, potential strategies targeting GR or combining immunotherapy are discussed.Therefore, this mini review aims to elucidate the complex mechanisms of Dex in the breast cancer TME and ultimately guide the translation of mechanistic discoveries into clinical breakthroughs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c149f170ee7affa8af0416cce619204ab0fcf62f" target='_blank'>
              The dual role of glucocorticoids in the breast cancer immune microenvironment: mechanisms and therapeutic implications
              </a>
            </td>
          <td>
            Bianping Liang, Xinglan Wang, Yunrui Fu, Mingxue Wang
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="The regulation of T cell exhaustion within the tumor microenvironment plays a pivotal role in shaping the immune response to cancer and determining the efficacy of immunotherapy. However, the molecular factors governing this process in colon cancer remain poorly understood. This study investigates the expression characteristics and functional significance of the transmembrane protein CD82 in the colon cancer immune microenvironment, with emphasis on its regulatory role in CD8+ T cell exhaustion and clinical outcomes. Publicly available transcriptomic datasets were integrated with multiplex immunohistochemistry on colon cancer tissue microarrays to characterize the cell–type–specific distribution of CD82 and its associations with key markers of T cell dysfunction. CD82 expression was markedly increased in tumor-infiltrating immune and epithelial cells compared with normal tissues, particularly within exhausted CD8+ T cells. Elevated CD82 levels showed strong positive correlations with canonical exhaustion markers such as programmed cell death protein 1 and T cell immunoglobulin and mucin domain-containing protein 3. Multiplex immunohistochemical analysis further revealed that enrichment of CD82-positive epithelial regions and expansion of the CD82+TIM-3+PD-1+CD8+ T cell subset were associated with poor prognosis and were confirmed by multivariate Cox regression as independent risk factors for unfavorable survival. In patients who failed to achieve a complete pathological response following immunotherapy, exhausted CD8+ T cells exhibited significantly higher CD82 expression. Single-cell regulatory network analysis identified BATF and BHLHE40 as potential transcriptional regulators of CD82. Collectively, these findings demonstrate that CD82 promotes CD8+ T cell exhaustion, contributing to tumor progression and immunotherapy resistance in colon cancer. This study provides novel insight into the molecular mechanisms underlying immune dysfunction and offers a potential therapeutic target for reversing immunosuppression and improving immunotherapy efficacy in colon malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/254f481971ba1782bc6c638ef396c6a18b14c937" target='_blank'>
              CD82-associated exhausted CD8+ T cells define prognosis and immunotherapy resistance in colon cancer
              </a>
            </td>
          <td>
            Jingfeng Zhang, Hengwei Cui, Shaoxian Wu, Hongwei Shi, Haitao Wang, Jingting Jiang
          </td>
          <td>2026-01-13</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Mesenchymal stem cells (MSCs) are multipotent stem cells with critical functions, including immunomodulation, multidirectional differentiation, anti-inflammatory activity, tissue repair, and regeneration. Recent studies demonstrate that MSCs can enhance hematopoietic stem cell engraftment, mitigate graft-versus-host disease (GVHD), address transplant-related complications, and treat conditions such as immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). These therapeutic effects are largely attributable to the immunomodulatory and anti-inflammatory properties of MSCs. However, in hematologic malignancies, MSCs can exert both pro-tumor and anti-tumor influences. Exosomes, which are extracellular vesicles derived from MSCs (MSC-EVs), not only replicate many MSC functions but also exhibit greater chemical stability and lower immunogenicity. These characteristics make MSC-EVs particularly significant in the context of hematopoietic stem cell transplantation (HSCT). This review provides a detailed overview of the roles and clinical applications of MSCs in hematologic diseases, the properties of MSC-EVs, and their emerging significance in HSCT.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/675b5fd2d3e02a458f9686f5c030ba7046442481" target='_blank'>
              The roles and clinical applications of mesenchymal stem cells and their exosomes in hematologic diseases
              </a>
            </td>
          <td>
            Mengxue Deng, Xiaoying Zhang, Yicheng Zhang
          </td>
          <td>2025-12-24</td>
          <td>Stem Cell Research & Therapy</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Ovarian cancer remains one of the most lethal gynecologic malignancies, largely due to its late-stage diagnosis and the establishment of an immunosuppressive tumor microenvironment (TME). Natural killer (NK) cells, key effectors of innate immunity, exhibit impaired cytotoxicity within this hostile niche. The dysfunction arises from multiple mechanisms, including suppression by immunosuppressive cytokines (TGF-β, MUC16), shedding of activating ligands (MICA/B, B7-H6, CD155), overexpression of inhibitory immune checkpoints (PD-1, TIGIT), and metabolic reprogramming shaped by glucose and lipid competition. Recent advances in NK cell–based immunotherapies—such as cytokine modulation, adoptive NK transfer, and checkpoint blockade—have demonstrated potential to reverse NK exhaustion and enhance antitumor efficacy. In this review, we systematically dissect the molecular and cellular pathways underlying NK cell suppression in ovarian cancer and evaluate emerging strategies to reinvigorate NK-mediated immunosurveillance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0c24208516b5c52a573a3fe8e8a63ee815d757d8" target='_blank'>
              Natural killer cell exhaustion in ovarian cancer: from molecular suppression to therapeutic revival
              </a>
            </td>
          <td>
            Jun Ning, Lan Yao
          </td>
          <td>2026-01-06</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="This research elucidates a novel strategy wherein CD8⁺ T cells overcome tumor immune evasion by initiating ferroptosis and establishing a self-sustaining positive feedback loop. Unlike traditional cytolytic pathways employed by CD8⁺ T cells (e.g., Fas-L/Fas and perforin/ granzyme mechanisms), the interferon-gamma (IFN- γ)-facilitated ferroptosis pathway unveils a distinct immunoregulatory role. Ferroptosis is an iron-dependent, non-apoptotic form of cell death driven by excessive lipid peroxidation, loss of mitochondrial membrane integrity, and eventual plasma membrane disruption. Crucially, beyond direct tumor cell killing, the process leads to emission of damage-associated molecular patterns (DAMPs), which potently stimulate dendritic cell maturation and enhance antigen-specific T cell responses. This establishes a cyclic “immune activation--ferroptosis- -immune reactivation” cascade, effectively alleviating immunosuppression within the tumor microenvironment (TME). Our comprehensive analysis demonstrates that CD8⁺ T cell-secreted IFN-γ downregulates SLC7A11, limiting cystine uptake and impairing glutathione (GSH) biosynthesis, thereby inactivating GPX4. Concurrently, IFN-γ upregulates ACSL4, promoting esterification of polyunsaturated fatty acids (PUFAs) into phospholipids and increasing susceptibility to lipid peroxidation. Together, these synergistic changes induce robust ferroptosis. This mechanism offers a transformative therapeutic perspective for tackling resistance to immune checkpoint inhibitors, with considerable theoretical and clinical implications for next-generation cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc592830024c2ef74ca04dbb64f75f144610d41c" target='_blank'>
              CD8⁺ T Cell-Induced Ferr optosis via a Positive Feedback Mechanism to Overcome Immune Resistance
              </a>
            </td>
          <td>
            Jiaqi Mou
          </td>
          <td>2025-12-19</td>
          <td>MedScien</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="The tumor microenvironment (TME) plays an important role in the development, progression, and treatment response of pediatric cancers, yet remains less elucidated compared to adult malignancies. Pediatric tumors are unique with a low mutational burden, an immature immune landscape, and unique stromal interactions. The resultant “cold” immune microenvironments limits the effectiveness of conventional immunotherapies. This review summarizes the key cellular and non-cellular components of the pediatric TME—including T cells, NK cells, tumor-associated macrophages, cancer-associated fibroblasts, extracellular matrix remodeling, angiogenesis, and hypoxia—and describes how these elements shape tumor behavior and therapy resistance. The role of TME in common pediatric cancers like leukemia, lymphoma, neuroblastoma, brain tumors, renal tumors, and sarcomas is discussed. Emerging therapeutic strategies targeting immune checkpoints, macrophage polarization, angiogenic pathways, and stromal barriers are discussed.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d34cc7bfcda14da44bca02f277e5096c55bbdde0" target='_blank'>
              Tumor Microenvironment: Current Understanding and Therapeutic Implications in Adult and Pediatric Cancers
              </a>
            </td>
          <td>
            Satyendra Batra, Prashant Prabhakar, Debabrata Mohapatra, Noreen Grace George, Neha Goel, Bhavika Rishi, Aroonima Misra, Amitabh Singh
          </td>
          <td>2025-12-25</td>
          <td>Onco</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5c799df3937abf8d305af852f267e2c53cc6190a" target='_blank'>
              Targeting autocrine retinoic acid signaling by ALDH1A2 inhibition enhances antitumor dendritic cell vaccine efficacy
              </a>
            </td>
          <td>
            Cao Fang, M. Esposito, Ulrike Hars, Robert T Byrne, Bokai Song, Jian Huang, A. Roichman, Lawrence Shue, Xiaobing Cheng, John Proudfoot, Demin Zhao, Yong Wei, I. Cristea, Joshua D. Rabinowitz, Yibin Kang
          </td>
          <td>2026-01-05</td>
          <td>Nature Immunology</td>
          <td>2</td>
          <td>18</td>
        </tr>

        <tr id="Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the leading cause of cancer-related deaths. Immune checkpoint inhibitors (ICIs) of programmed death-1 (PD-1)/programmed death ligand-1 signaling induce tumor regression in some patients with NSCLC, but most patients with NSCLC exhibit resistance to ICIs therapy. NSCLC shapes the potent tumor immunosuppressive microenvironment (TIME) that underlies tumor immune tolerance and acquired resistance. Therefore, elucidating the cellular and molecular mechanisms by which NSCLC establishes and sustains the TIME is essential for developing novel strategies to overcome immune resistance and enhance the clinical benefit of ICIs. Methods The correlation between sterile alpha motif domain and histidine-aspartate domain-containing protein 1 (SAMHD1) expression and ICIs was analyzed via immunohistochemistry. Cell migration assay was performed to assess the effect of SAMHD1 on macrophage recruitment. Multicolor flow cytometry was performed to analyze the effect of SAMHD1 knockdown on the tumor microenvironment. SAMHD1 regulation of the dual specificity phosphatase 6-extracellular regulated protein kinases 1/2 (DUSP6-ERK1/2) pathway was verified by RNA sequencing and western blotting. Results Here, we identify the SAMHD1 as a potential therapeutic target and a major determinant of poor response to ICIs in patients with NSCLC. Tumors with high SAMHD1 expression show resistance to anti-PD-1 antibody (αPD-1) treatment, whereas tumors with low SAMHD1 expression are highly sensitive. SAMHD1-dependent resistance to αPD-1 is characterized by increased tumor-associated macrophages (TAMs) infiltration and reduced CD8+T cell numbers. Mechanistically, SAMHD1 regulates the expression of macrophage-associated chemokines by influencing the activation of the DUSP6-ERK1/2 pathway, which contributes to TAMs aggregation within NSCLC tumors to shape an immunosuppressive microenvironment. The HIV accessory protein viral protein-x (VPX) specifically degrades SAMHD1 to promote HIV replication. Similarly, the vpx-engineered oncolytic adenovirus (oAd-vpx) targets SAMDH1 degradation to enhance oncolytic adenovirus replication and weaken the hostile immune microenvironment shaped by TAMs, thereby triggering a CD8+T-cell-dependent antitumor immune response. The combination of oAd-vpx and αPD-1 inhibits tumor growth and enhances sensitivity to ICIs in both mouse and human NSCLC. Conclusions This research identifies a key mechanism of SAMHD1-driven immunosuppression and highlights its important role in oncolytic adenovirus therapy. This study provides a theoretical basis for targeting SAMHD1 as a drug therapy strategy in patients with NSCLC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/372d10aa91d60fc17880ac962111bea4e207ee3b" target='_blank'>
              SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication
              </a>
            </td>
          <td>
            Shichuan Hu, Jian Xu, Zhiwu Wang, Yong Zhang, C. Zhao, Yu Liu, Feng Luo, Pi-Yun Cheng, Jiantao Wang, Jing Zhao
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Macrophages are innate immune cells that extensively infiltrate and play a key role in the tumor microenvironment (TME). Tumor cell–secreted factors recruit monocytes into the TME, where they differentiate into tumor‐associated macrophages (TAMs), which can polarize into distinct phenotypes: M1 and M2. M1 TAMs promote antitumor immunity through cytokine secretion and antigen presentation, whereas M2 TAMs support tumor progression by facilitating angiogenesis, invasion, and immune escape. Despite these dual roles, the specific mechanisms governing macrophage plasticity and polarization remain insufficiently understood. This review comprehensively summarizes the origin, polarization, and functional diversity of macrophages in the TME, with emphasis on pathways that regulate TAM‐mediated immune responses. Furthermore, this article examines current TAM‐targeted therapeutic strategies, including recruitment inhibition, phenotypic reprogramming, and the development of chimeric antigen receptor macrophages (CAR‐Ms), as well as macrophage‐based drug delivery and exosome therapy. By integrating recent advances in cell engineering and immunometabolism, this review highlights the translational potential of TAM‐targeted therapies and their value in reshaping the immunosuppressive TME to enhance cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7215a076e2ef0687c2a7e70ce9deca69722be237" target='_blank'>
              The Role of Macrophages in Cancer: From Basic Research to Clinical Applications
              </a>
            </td>
          <td>
            Zhimei Liu, Yan Li, Jingchao Cao, Yefeng Qiu, Kun Yu, Shoulong Deng
          </td>
          <td>2025-12-19</td>
          <td>MedComm</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Tumor‐associated macrophages (TAMs) represent the most abundant immune cell population within the tumor microenvironment and are central drivers of malignant progression and treatment resistance. High TAMs infiltration in solid tumors consistently correlates with poor clinical outcomes, largely due to their role in establishing an immunosuppressive milieu that supports tumor growth, metastasis, and undermines the efficacy of chemotherapy, radiotherapy (RT), and immune checkpoint inhibitors. Although TAMs are well‐recognized promoters of tumor progression, the development of effective strategies to therapeutically target them remains an unmet clinical need. In this review, we examine the multifaceted mechanisms through which TAMs contribute to malignancy, including phagocytic signaling modulation, metabolic reprogramming, exosomal communication, and crosstalk with other immune cells. We also evaluate three key therapeutic strategies: blocking TAMs recruitment and survival, reprogramming TAMs toward antitumor phenotypes, and the emerging approach of chimeric antigen receptor macrophage therapy. Furthermore, we highlight the synergistic potential of integrating TAMs‐targeted strategies with conventional chemotherapy, RT, and immunotherapeutic approaches. By synthesizing current clinical evidence, this review aims to inform the rational design of next‐generation TAMs‐targeted interventions and to propose novel strategies for overcoming treatment resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f8d44c15cdc93900836129bceb89040bd162694" target='_blank'>
              Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation
              </a>
            </td>
          <td>
            Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li
          </td>
          <td>2026-01-28</td>
          <td>MedComm</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Fibroblasts, once considered merely passive structural components of tissues, are now recognized as dynamic regulators of the immune microenvironment. Recent advances in single-cell and spatial multi-omics have revealed their profound heterogeneity, spatial organization, and functional plasticity, positioning them as a ‘ruler’ that measures, defines, and shapes local immune responses. In both homeostasis and disease contexts—such as cancer, autoimmune disorders, and fibrosis—distinct fibroblast subpopulations exhibit specialized roles: some drive immunosuppression via PD-L1 expression, TGF-β secretion, or metabolic reprogramming; others promote inflammation or fibrosis through cytokine and chemokine secretion; while a subset supports immune resolution and tissue repair. Spatially, fibroblasts organize immune territories by forming physical and chemical barriers, orchestrating tertiary lymphoid structures, and partitioning inflammatory zones. Their bidirectional crosstalk with immune cells—including T cells, macrophages, and B cells—further fine-tunes immune activation or suppression. The dysregulation of fibroblast subsets is a hallmark of disease progression and therapy resistance. Emerging therapeutic strategies aim to ‘recalibrate’ this dysfunctional ruler through targeted depletion, phenotypic reprogramming, or disruption of pathogenic signaling. Integrating fibroblast-centric metrics into clinical practice may enable precise assessment of the immune microenvironment and personalized interventions, heralding a new era in immunotherapy and fibrotic disease management.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a5b61a7cf749a3d3b53564921ffb11c2d17b261b" target='_blank'>
              Fibroblasts as a ruler of the immune microenvironment: measurement and modulation in tissue homeostasis and disease
              </a>
            </td>
          <td>
            Yanling Zhang, Xinyi Fang, Lian Yan, Lin Wang
          </td>
          <td>2026-01-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Antigen heterogeneity remains a major obstacle to the effective application of chimeric antigen receptor (CAR)-T cell therapy in solid tumors. We investigated the potential of epitope spreading as a strategy to overcome this limitation and examined whether CAR-T cells concomitantly producing IL-7 and CCL19 (7 × 19 CAR-T cells) could act as potent inducers of epitope spreading, as well as the underlying mechanisms. We used a murine model inoculated with a mixture of cancer cell lines—genetically modified to express the CAR target antigen—and their respective parental lines lacking target expression. Following administration of 7 × 19 CAR-T cells, flow cytometry and peptide stimulation assays were performed to evaluate the induction of tumor antigen-specific T cells and dendritic cells within tumor-draining lymph nodes and tumor tissues. We also evaluated the antitumor efficacy of 7 × 19 CAR-T cells derived from an allogeneic donor and their capacity to induce epitope spreading in vivo and ex vivo. In multiple tumor mixture models, 7 × 19 CAR-T cells demonstrated marked antitumor activity and promoted epitope spreading in murine solid tumor models, enabling endogenous T cells to recognize and target tumor-associated antigens. This response was dependent on cross-presentation by defined dendritic cell subsets in both the tumor microenvironment and tumor-draining lymph nodes within 2 weeks of 7 × 19 CAR-T cell administration. Notably, 7 × 19 CAR-T cells derived from allogeneic donors also induced epitope spreading in tumor-bearing hosts, thereby increasing survival. The 7 × 19 CAR system is a promising strategy for overcoming antigen heterogeneity in solid tumors by promoting epitope spreading.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5eb8bd306e6e5dbd3124364a88065920c203761" target='_blank'>
              CAR-T cells co-expressing IL-7 and CCL19 promote epitope spreading to enhance antitumor immunity
              </a>
            </td>
          <td>
            K. Adachi, Yukimi Sakoda, Tsuneyasu Kaisho, Koji Tamada
          </td>
          <td>2026-02-07</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="CD19-specific CAR T cells engineered to secrete a constitutively active form of the pro-inflammatory cytokine, interleukin (IL)-18 have demonstrated impressive efficacy in a recent clinical trial involving subjects who had failed prior CAR T cell therapy. Corroborating these clinical data, preclinical studies of IL-18-armored CAR and T cell receptor-engineered T cells have demonstrated enhanced anti-tumor activity in several xenograft and syngeneic mouse cancer models. Interleukin-18 improves tumor clearance via direct effects on CAR T cells and indirect actions on cells on a variety of host immune cells, including natural killer, macrophage and dendritic cells. Compared to unarmored CAR T cells, IL-18-secreting CAR T cells are less exhausted, expand more efficiently and produce greater quantities of interferon (IFN)-γ. However, upregulated circulating IL-18 and its downstream mediator, IFN-γ, are also associated with systemic toxicities which have proven to be severe on occasions. In light of this, several groups have developed strategies that set out to restrict IL-18 release or biological activity to the tumor microenvironment. Among these, CAR T cells armored with NFAT-inducible IL-18 are now undergoing clinical testing. The evaluation of inducible or tumor-selective IL-18 deployment will show whether it is possible to minimize IL-18 related systemic toxicities while preserving localized amplification of anti-tumor activity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b7e27cde3fbe958298583f915c452b76c82c37b2" target='_blank'>
              How can we balance risk and benefit of interleukin-18 armored T cell therapies?
              </a>
            </td>
          <td>
            Paulina Vicenova, John Maher
          </td>
          <td>2026-02-06</td>
          <td>Experimental Biology and Medicine</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Simple Summary Natural killer (NK) cells are innate immune cells with a critical role in the recognition and elimination of malignant cells and have therefore attracted considerable interest as targets for cancer immunotherapy. Despite encouraging results in experimental settings, the clinical performance of NK cell-based approaches can be improved. One of the major limitations is the inability of conventional animal models to accurately reproduce human NK cell development, persistence, and functional regulation within the tumor microenvironment. This review discusses the need for more advanced preclinical models and examines recent progress in the development of humanized mouse systems that more faithfully recapitulate key traits of human NK cells. By outlining both the advantages and the remaining limitations of these models, this work aims to inform the research community and support the design of more predictive preclinical studies, ultimately facilitating the translation of NK cell-based therapies into effective cancer treatments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/99723995636f7bdcf1c827b7360596d145f95c93" target='_blank'>
              Advancements and Challenges in Mouse Models for NK Cell-Based Cancer Immunotherapy
              </a>
            </td>
          <td>
            Chiara Vitale, Alessia Ruiba, A. Dondero, Martina Serra, Alice Tassistro, Cristina Bottino, R. Castriconi
          </td>
          <td>2026-01-26</td>
          <td>Cancers</td>
          <td>0</td>
          <td>42</td>
        </tr>

        <tr id="Gastric cancer (GC) is a highly heterogeneous malignancy and the formation of an immunotolerant tumor microenvironment (TME) is an important promoter of tumor progression, treatment resistance and a poor prognosis. The TME is composed of cellular components including immune cells as well as non-cellular elements (such as the extracellular matrix) which induce immune tolerance through numerous mechanisms. Comprehensive exploration of TME regulatory pathways in GC has established the theoretical foundation for targeted immunomodulatory strategies. TME-targeted immunotherapies have demonstrated efficacy in reversing immune tolerance and enhancing antitumor immunity. Additionally, when combined with chemotherapy, radiotherapy and/or targeted agents, these therapies notably improve response rates in patients with GC. The present review evaluates the impact of the TME on the development of immune tolerance in GC and the therapeutic implications of immunomodulation. The components of the GC TME were systematically characterized, and the present review discusses the contributions of cellular components to establishing an immunosuppressive microenvironment, investigates the molecular mechanisms underlying immune tolerance in GC, identifies key immune cells and their crosstalk within the TME and summarizes current treatments targeting TME-mediated immune tolerance, all with the aim to provide insights into optimized immunotherapeutic strategies and improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a552cdba1e0fda5662c793b6d423a20532cde08d" target='_blank'>
              Tumor microenvironment in gastric cancer immune tolerance and its therapeutic relevance in immunomodulation (Review)
              </a>
            </td>
          <td>
            Zihe Guan, Lichao Han, Baojiang Chen, Yijia Ma, Qianyue Ni, Zijian Wang, Jingyu Yang, Zheng Liu
          </td>
          <td>2026-01-13</td>
          <td>Oncology Letters</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Microsatellite-stable (MSS)/proficient mismatch-repair (pMMR) colorectal cancer (CRC) accounts for more than 85% of cases but responds poorly to single-agent immune checkpoint inhibitors (ICIs), with objective response rates remaining below 5%. A principal barrier to effective immunotherapy in these tumors is a durable immunosuppressive axis formed by myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) within the tumor microenvironment. This axis impedes antitumor immunity through multilayered mechanisms including bidirectional chemotactic recruitment, reciprocal cytokine signaling, metabolic suppression and exosome-mediated communication. CRC is uniquely influenced by the gut microbiota: Fusobacterium nucleatum promotes MDSC/Treg enrichment via TLR4–NF-κB and Fap2–TIGIT pathways; Peptostreptococcus anaerobius acts through integrin–PI3K–NF-κB signaling; and microbial metabolites such as 4-HPA activate JAK2/STAT3–CXCL3 signaling to expand MDSC populations. Concurrently, a hypoxia–lactate–HIF-1α–CD73/A2AR circuit further stabilizes suppressive phenotypes, forming a “microbiota–metabolism–hypoxia–MDSC–Treg” cascade. Emerging clinical and translational data indicate that disrupting this axis can sensitize MSS-CRC to ICIs: for example, Zanzalintinib combined with Atezolizumab reported survival benefit in the STELLAR-303 trial, and dual blockade of novel checkpoints with PD-(L)1 has been associated with enhanced immune activation in solid tumors. Targeting the MDSC–Treg axis therefore represents a promising strategy to overcome immunotherapy resistance in MSS/pMMR CRC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/97fa30aa6624c2b83fedbc0f9bce06bbb67408e2" target='_blank'>
              Myeloid-derived suppressor cells and regulatory T cells in colorectal cancer: a synergistic immunosuppressive axis and emerging therapeutic opportunities
              </a>
            </td>
          <td>
            Wenxing Zhang, Chenrui Jin, Shuyuan Liu, Xing Wan, Yu Li, Jifeng Liu, Zhijun Duan, Jingyuan Ma, Yunhai Gao
          </td>
          <td>2026-01-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="The distinctive feature of the adaptive immune system is its ability to generate immunological memory that can provide defense against subsequent infections. In the case of antibody-mediated immune responses, this memory comes in two cellular forms: plasma cells (PCs) and memory B cells (MBCs). PCs protect against reinfection by constitutively producing antibodies. The presence of a diverse pool of MBCs, which can expand and differentiate into PCs in secondary immune responses, is thought to be particularly important for defense against new pathogen variants. Recent studies have shown that the MBC compartment is far more heterogeneous than previously anticipated. This heterogeneity, among other factors, is shaped by their developmental pathway (germinal center (GC) vs non-GC-derived MBCs), the duration and strength of antigenic stimulation, anatomical and microanatomical localization, and the timing of generation in ontogeny. Combinations of these “layers” of MBC identities can define MBCs’ properties and their fate in recall responses. Here, we review the mechanisms underlying MBC differentiation, maintenance, and reactivation and explore how the layered identity of MBCs contributes to the functions of these cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b105568583e49e5af34fef32c4fcd5d99236420" target='_blank'>
              The multilayered identity of B cell memory
              </a>
            </td>
          <td>
            Vassilis Glaros, Nimmy Francis, Taras Kreslavsky
          </td>
          <td>2026-01-06</td>
          <td>Cellular and Molecular Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Background: Radiotherapy (RT) remodels the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) are key mediators of TME, yet how RT reprograms TAMs toward a programmed death ligand- 1(PD-L1)⁺ immunosuppressive phenotype remains unclear. Materials and Methods: Esophageal squamous cell carcinoma (ESCC) subcutaneous xenografts in immunodeficient mice received localized RT or sham treatment. Tumor-infiltrating PD-L1⁺ TAMs were quantified via multiplex immunofluorescence and flow cytometry. Extracellular vesicles (EVs) derived from irradiated ESCC cells (IR-EVs) were isolated and characterized by nanoparticle tracking analysis and transmission electron microscopy. Functional assays included co-culture of IR-EVs-educated macrophages with autologous CD8⁺ T cells. RNA sequencing identified DYNLL1-AS1 as the most upregulated lncRNA in IR-EVs. Mechanistic studies employed RNA pull-down, mass spectrometry, RNA immunoprecipitation, and dual-luciferase reporter assays. Clinical validation utilized ESCC specimens for RNA in situ hybridization. Prognostic significance was assessed via Kaplan-Meier and Cox regression analyses. Results: RT triggered ESCC cells to secrete DYNLL1-AS1-enriched EVs, which reprogrammed macrophages into PD-L1⁺ immunosuppressive TAMs. IR-EVs-educated macrophages suppressed CD8⁺ T cell proliferation and IFN-γ/ Granzyme B secretion. Mechanistically, DYNLL1-AS1 bound SEC22B, enabling its interaction with FOXP1 to activate PD-L1 transcription via promoter binding. In vivo, EVs carrying DYNLL1-AS1 counteract anti-PD-L1 therapy by suppressing CD8+ T cell function and promoting tumor growth. In ESCC patients, high DYNLL1-AS1 expression correlated with PD-L1⁺ TAM density, poor immunotherapy response, and reduced survival. Multivariate analysis confirmed DYNLL1-AS1 as an independent prognostic factor. Conclusions: Radiation-induced DYNLL1-AS1 in ESCC EVs drives PD-L1⁺ TAMs immunosuppression via SEC22B/ FOXP1 signaling. Combining DYNLL1-AS1 inhibition with PD-L1 blockade may reverse RT-induced immunosuppression, offering a transformative strategy for ESCC radio-immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/62c9c29a3e6d1b11c8904cf92b1d7f9e8f201bd1" target='_blank'>
              Extracellular vesicles derived from irradiated tumor cells foster immunosuppressive macrophages formation to promote esophageal squamous cell carcinoma immune evasion
              </a>
            </td>
          <td>
            Shanshan Jiang, Y. Pang, Yue Zhou, J. Ni, L. Chu, X. Chu, Jianghong Zhang, Yan Pan, Yida Li, R. Ye, Hongru Chen, Silai Yu, T. Guo, Chunlin Shao, Xi Yang, Zhengfei Zhu
          </td>
          <td>2026-01-01</td>
          <td>International Journal of Biological Sciences</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Decorin (DCN) predominantly produced by fibroblasts is a small leucine-rich proteoglycan with tumor-suppressive property. However, whether DCN has a role in shaping the tumor immune microenvironment remains elusive. The TCGA and GEO databases were analyzed to identify fibroblast-specific secretory proteins that are downregulated in most types of human tumors, positively correlate with CD8⁺ T cell infiltration, and associate with improved response to immune checkpoint blockade (ICB) therapy. The function of DCN in vivo was assessed using cell lines with stable DCN overexpression in both immunocompetent and immunodeficient mice. The changes in the composition and function of immune cell subpopulations in tumors were analyzed by flow cytometry analysis (FCM) and immunofluorescence staining. The role of CD8⁺ T cells in the DCN-mediated tumor suppression was further elucidated by utilizing B2m-knockout tumor cells and CD8⁺ T cell depletion assays. The in vitro co-culture system of tumor cells and T cells was applied to dissect the effects of DCN on CD8+ T lymphocyte activation and functions. Finally, the therapeutic efficacy of DCN in combination with anti-PD1 antibody was evaluated in mouse tumor model. DCN-mediated tumor suppression was present in immunocompetent mice, wherein either depletion of CD8⁺ T cells in mice or ablation of β2M in tumor cells abrogated the tumor-inhibitory effects mediated by DCN, indicating the importance of CD8⁺ T cells in the DCN-antitumor activities. DCN overexpression promoted CD8⁺ T cell infiltration into tumors and increased the production of TNF-α, IFN-γ, and perforin in infiltrating T cells, and DCN expression substantially enhanced the tumor-suppressive efficacy of anti-PD1 therapy. More importantly, integrative analyses of clinical data indicated that DCN expression is downregulated in multiple types of human tumors and positively associated with the presence of CD8⁺ T cells and their expression of cytotoxic genes. Furthermore, high DCN levels were correlated with favorable prognosis in certain types of cancer patients with ICB therapy. Our study reveals that DCN functions as a tumor-suppressive factor by enhancing T cell response, and proposes the potential of exogenous DCN as a supplement to cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1d5b6eb80a5279f1cd41ac2e3910968815e0cfd4" target='_blank'>
              Decorin facilitates T cell-mediated antitumor immunity and augments the efficacy of anti-PD1 immunotherapy
              </a>
            </td>
          <td>
            Ningqian Zheng, Lvzhu Xiang, Guiqin Xu, Yun Liu, Chengming Xu, Li Zhang, You Zuo, Zhiqian Ye, Yongzhong Liu, Zhaojuan Yang
          </td>
          <td>2026-01-27</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Despite effective antiretroviral therapy (ART), many people with HIV (PWH) exhibit persistent immune activation (IA) and suffer metabolic comorbidities. We investigated whether residual HIV production in lymphoid tissues drives IA. Among 20 ART-suppressed PWH, HIV RNA+ cells were detected in lymph nodes and correlated directly with markers of pyroptosis, assessed via cleaved gasdermin D positivity, but not with most plasma cytokines or IA markers. Notably, glucagon-like peptide 1 (GLP-1), an enteroendocrine hormone with anti-inflammatory roles, was upregulated in the ileum of PWH and correlated directly with systemic cytokines but inversely with lymph node pyroptosis. These findings suggest that chronic occult inflammation in people with successfully suppressed HIV infection is mediated by persistent virus production in lymph nodes leading to pyroptosis, which may trigger compensatory anti-inflammatory enteroendocrine activation that may dampen pyroptosis. Targeting pyroptosis or enhancing GLP-1 signaling represent potential therapeutic strategies for modulating IA and managing metabolic comorbidities in PWH. Graphical abstract">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b172fff8b9ac2a2d6503296bac6111b9948e7f2" target='_blank'>
              Ongoing lymphoid HIV production drives pyroptosis and GLP-1 counter-regulation in ART-suppressed infection
              </a>
            </td>
          <td>
            Peter A. Crawford, Joshua Rhein, Jeffrey G. Chipman, Gregory J. Beilman, Ross Cromarty, Kevin Escandón, Jodi L. Anderson, Garritt Wieking, Andrew Johnston, Afeefa Ahmed, Jarrett Reichel, Alexander Khoruts, Christopher M. Basting, Nataliia Kuchma, Jason V. Baker, Nichole R. Klatt, A. T. Haase, T. Schacker
          </td>
          <td>2026-01-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Liver fibrosis, characterized by the excessive deposition of extracellular matrix (ECM) driven by hepatic stellate cells (HSCs) activation, remains a critical challenge due to its progression to cirrhosis and hepatocellular carcinoma (HCC). This review clarifies the complex crosstalk between the immune system and HSCs, highlighting key cellular players including macrophages, natural killer (NK) cells, regulatory T cells (Tregs), and their cytokine‐mediated signaling pathways that regulate fibrogenesis and fibrosis resolution. We describe pivotal molecular mechanisms such as transforming growth factor (TGF)‐β, platelet‐derived growth factor (PDGF), Wnt/β‐catenin, and NF‐κB signaling in HSCs modulation, emphasizing their interplay with immune responses. Novel therapeutic strategies targeting this complex immune–HSCs interaction, ranging from immunomodulatory agents, macrophage polarization, and NK cell‐based therapies, to stem cell‐derived exosomes, offer promising opportunities for preventing and reversing fibrosis. We further discuss innovative combination therapies integrating immunotherapies with antifibrotic agents, personalized strategies based on immune profiling, and the challenges of immune heterogeneity in fibrosis management. This review discusses recent advances in molecular interplay of immune system and HSCs, highlighting novel therapeutic targets, and future perspectives for managing chronic liver diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5022b23a68cf2c2cfdfb9468e2f2ae355d75f27a" target='_blank'>
              Immune System and Hepatic Stellate Cells’ Crosstalk in Liver Fibrosis: Pathways and Therapeutic Potential
              </a>
            </td>
          <td>
            Wahyu Widowati, Adilah Hafizha Nur Sabrina, Annisa Firdaus Sutendi, F. H. Zahiroh, Aris Muhammad Nurjamil, T. Wargasetia, I. M. Nainggolan, Rizal Azis, Elham Rismani, Dr. Massoud Vosough
          </td>
          <td>2026-01-01</td>
          <td>Journal of Immunology Research</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Cancer is a disease with a very high fatality rate. immunotherapy is a promising way to treating cancers, of which CTLs are important for the host immune system against tumor, directly killing tumor cells. However, the relative immunotherapy is limited by many factors that suppress the function and activity of CD8+ CTLs. This review aims to study the mechanisms by which CD8+ CTLs are suppressed in the tumor microenvironment. By collecting preclinical and clinical studies, this paper summarized the main factors that suppress CD8+ CTLs including the following factors: immune cells like regulatory T cell (Tregs), tumor-associated macrophage (TAM), myeloid-derived suppressor cells (MDSCs); metabolic factors like hypoxia, lactic acid accumulation, glucose competition, and immune checkpoints molecules (ICM) PD-1 and CTLA-4. The complex mechanisms of suppressing CD8+ CTLs in the tumor microenvironment are discussed in these findings, which may give clues to the relative treatment and help overcome these suppression effects on CD8+ CTLs in tumorigenesis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e0a3c8667fb5c07636fc20ce12f9301e91ee0bab" target='_blank'>
              Suppressed Factors to CD8+ Cytotoxic T Lymphocytes in Cancer Immunotherapy
              </a>
            </td>
          <td>
            Zeyu Zhou
          </td>
          <td>2025-12-19</td>
          <td>MedScien</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with poor overall survival. Understanding how dysregulated immunity contributes to the development and progression of AML is an active area of investigation. Prior work has demonstrated functional defects in natural killer (NK) cells; however, the role of non-NK innate lymphoid cells (ILCs) in AML is incompletely understood. Conventional ILC3s are non-cytotoxic and regulate mucosal immunity through cytokine secretion. In this study, we discovered an expansion of ILC3s in both a murine model of AML and in AML patients. The transcription factor, aryl hydrocarbon receptor (AHR) is required for ILC3 development and function, and AML blasts have been shown to secrete AHR ligands. Modeling studies demonstrated ILC3 expansion was mediated by AHR activation in ILC precursors. ILC3s developed in leukemic settings had increased cytokine production, and co-culture of ILC3s significantly increased AML colony formation, which was mediated by ILC3-derived TNFα and GM-CSF. Furthermore, co-transfer of ILC3s with AML led to more rapid disease progression in vivo and human ILC3 frequency was associated with adverse risk stratification in AML patients. These data support a model in which AML promotes ILC3 expansion and function via an AHR-dependent mechanism to aid AML growth and survival.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9a83a3f8e625be3b71c4e7fbb7f5ebf620217514" target='_blank'>
              Leukemia-driven expansion of type 3 innate lymphoid cell facilitates a pro-tumoral microenvironment in acute myeloid leukemia
              </a>
            </td>
          <td>
            T. T. Dinh, Matthew R. Lordo, Amy Y Zhang, C. Goda, Nikolas Shilo, Ekaterina Altynova, Michael Ruesch, Parker Kronen, Megan Broughton, Erin Jeremy, Victoria L Sellers, Xiaoli Zhang, Karilyn T. Larkin, Patrick L Collins, Adrienne M Dorrance, A. Freud, Christopher C Oakes, Bethany L. Mundy- Bosse
          </td>
          <td>2025-12-22</td>
          <td>Leukemia</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Background & Aims: Colorectal cancer (CRC) represents a major global health burden due to its high incidence and mortality, particularly in the advanced stages, with limited treatment options. While therapies that block the PD-1/PD-L1 pathway have demonstrated clinical benefit, their success in CRC is largely confined to patients with high microsatellite instability (MSI-H) tumors. Innovative immunotherapeutic solutions are critically needed for the majority of CRC cases. CD276 (B7-H3), a B7 family immune checkpoint molecule, is overexpressed in many cancers including CRC. Significant CD276 upregulation in CRC cell lines compared to benign tissues has been previously demonstrated. In this study, the potential of an Fc-optimized anti-CD276 monoclonal antibody to enhance natural killer (NK) cell activity in CRC was evaluated. Methods: An Fc-optimized monoclonal antibody, 8H8_SDIE, was developed to enhance NK cell activity by increasing CD16 binding. In vitro experiments were conducted using human CRC cell lines and peripheral blood mononuclear cells (PBMCs) from healthy adult donors to evaluate the binding specificity of 8H8_SDIE to CD276. NK cell activation was assessed by measuring the upregulation of activation markers (CD69, CD25, and CD107a) and secretion of cytotoxic mediators (IFNγ, granzyme B, and perforin). Cytotoxicity assays were performed to determine NK cell-mediated tumor cell lysis. Results: 8H8_SDIE specifically bound to CD276-positive CRC cells and significantly enhanced NK cell activation. These effects included increased levels of activation and cytotoxic mediators. In cytotoxicity assays, 8H8_SDIE demonstrated potent NK cell-mediated lysis of CRC cells. Conclusion: The Fc-optimized anti-CD276 antibody 8H8_SDIE effectively enhanced NK cell reactivity against CD276-positive CRC cells and induced tumor cell lysis in vitro. These findings suggest that 8H8_SDIE holds potential as a novel">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/90a04f582dadd28f5912b9afe672146ee43a1cd0" target='_blank'>
              Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3)
              </a>
            </td>
          <td>
            Sylwia A. Stefańczyk, Xenija Kaiser, I. Hagelstein, M. Lutz, Samuel J. Holzmayer, L. Zekri, M. Märklin, Susanne Jung
          </td>
          <td>2026-02-01</td>
          <td>ImmunoTargets and Therapy</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC), the most common primary liver cancer, continues to rank among the leading causes of cancer-related death despite improvements in early detection and systemic therapies. Therapeutic advances, including immune checkpoint blockade, cancer vaccines, and adoptive cell therapies, have broadened treatment possibilities. However, their efficacy and durability are often limited by immune evasion within a metabolically challenging tumor microenvironment (TME). This review consolidates current knowledge on how metabolic reprogramming in immune cells influences HCC progression, therapy resistance, and clinical outcomes. We discuss the roles of glycolysis, oxidative phosphorylation, fatty acid oxidation, and amino acid metabolism kynurenine pathways—in regulating the differentiation and function of T cells, regulatory T cells, macrophages, dendritic cells, natural killer cells, and B cells. Environmental factors such as hypoxia, lactate accumulation, adenosine signaling, and lipid remodeling act as key TME cues that suppress antigen presentation, impair cytotoxic responses, and promote immunosuppressive myeloid phenotypes. Building on these mechanisms, current strategies focus on targeting metabolic checkpoints in immune cells, reshaping the TME, and integrating metabolic modulation with checkpoint inhibitors to enhance therapeutic efficacy. In addition, candidate biomarkers (including circulating metabolites, multi-omics profiles, and liquid-biopsy indicators of immune metabolism) offer opportunities for patient stratification and dynamic monitoring. Together, these insights provide a conceptual framework in which precise modulation of immune metabolism can potentiate existing immunotherapies and guide rational combination strategies, warranting further clinical investigation to achieve sustained benefit in HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3e43a3cd7e997e6b0d1b868223afcfca36efc08" target='_blank'>
              Immune cell metabolic reprogramming in hepatocellular carcinoma: mechanisms, tumor microenvironment, and future immunotherapeutic directions
              </a>
            </td>
          <td>
            Lichen Zhou, Wenjie Zhang, Zhuoran Liu, Yaming Xie, Kangyi Jiang
          </td>
          <td>2026-01-12</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Macrophages play a key role in immunity against solid tumors. However, their development and clinical applications are limited by their difficult-to-transfect nature, low proliferative capacity, and easily changing polarization states. The combination of chimeric antigen receptor (CAR) technology with macrophages to form chimeric antigen receptor macrophages (CAR-Ms) is an emerging strategy for adoptive cell therapy. In our previous study, we confirmed that anti-CD47 CAR-Ms have potential for ovarian cancer treatment. Here, we demonstrated that the introduction of IL-21 significantly increases the tumor-suppressive effect of anti-CD47 CAR-Ms against ovarian cancer. Specifically, IL-21-modified CAR-Ms with second-generation CARs targeting CD47 showed potent tumor cell-killing activity, both in vitro and in vivo, through direct and indirect pathways (direct phagocytosis and activation of cytotoxic T lymphocytes). In addition, an IL-21 modification significantly enhanced the tumor microenvironmental regulation of immunosuppression mediated by anti-CD47 CAR-Ms in vivo, thereby improving their therapeutic efficacy in a mouse model of ovarian cancer, without any obvious adverse effects. Taken together, these results suggest that anti-CD47 CAR-Ms combined with IL-21 is a promising treatment strategy for ovarian cancer. The anti-tumor effects of a co-expression strategy of chimeric antigen receptor macrophages with IL-21 was validated in both in vitro and in vivo models of ovarian cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1287e633e565f0f44deb23e07481a37084e0b41a" target='_blank'>
              IL-21 promotes the anti-tumor effect of anti-CD47 chimeric antigen receptor macrophages in ovarian cancer
              </a>
            </td>
          <td>
            Yizhao Chen, Xiangling Zhu, Yu Chen, Zhaoyi Yang, Zhaolei Shen, Mengchen Chen, Chong Liu, Yuanyuan Zhou, Huihui Wang, Mengjuan Zhu, Jiaqi Qiu, Jinhua Huang, Xintong Han, Wei Wei, Ruilin Li, Wenming Hong, Jiajie Tu
          </td>
          <td>2025-12-23</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Basal plasmacytosis is a histopathological hallmark of ulcerative colitis (UC). However, the precise roles of plasma cells in UC pathogenesis remain unknown. In this study, we investigated the effects of a proteasome inhibitor, which depletes plasma cells, on chronic colitis progression in mice to clarify their contribution to disease pathogenesis. Chronic colitis was induced in female C57BL/6 mice by three cycles of ad libitum dextran sulfate sodium (DSS) feeding followed by distilled water (DW), each cycle lasting seven days. The proteasome inhibitor bortezomib was administered intravenously twice weekly for three weeks after the second DSS/DW cycle. Elevated plasma IgG and perinuclear anti-neutrophil cytoplasmic antibody (pANCA) levels, as well as infiltration of IgG-producing plasma cells into the colon, were observed after the second DSS/DW cycle in chronic DSS-induced colitis model mice. Plasma cells in the colon exhibited an immature CD19⁺CD138⁺ phenotype. Bortezomib significantly ameliorated colitis and intestinal fibrosis by reducing plasma IgG and pANCA levels and the number of IgG-producing plasma cells in the colon. In conclusion, IgG-producing plasma cells were involved in colitis pathogenesis, and their depletion ameliorated colitis. Thus, IgG-producing plasma cells are associated with colitis pathogenesis and potential therapeutic targets for UC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1bceb071c658615aec0661ef9ead3acadcc004cf" target='_blank'>
              Depletion of IgG-producing plasma cells in the colon by treatment of proteasome inhibitor ameliorates chronic DSS-induced colitis in mice
              </a>
            </td>
          <td>
            Shin Ebihara, Yukari Kimoto, R. Katsumoto, Noriko Konishi
          </td>
          <td>2026-01-08</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Myeloid-derived suppressor cells (MDSCs) are recognized as a key mediator of immunosuppression in aging, which induce immunosenescence and increase elderly people’s susceptibility to infections, cancers, autoimmune diseases, and degenerative diseases. However, the commonly used MDSC markers overlap with those defining healthy and normal neutrophils or monocytes, which makes it challenging to distinguish MDSCs from their myeloid counterparts, and hampers deeper understanding of the pathophysiological functions of MDSCs. In this study, we compared MDSCs from aged mice to young controls using single-cell RNA sequencing. We established MDSC-specific gene signature, which revealed the general characteristics of MDSCs during aging, and thus facilitating distinguishing them from normal myeloid cells. Experimental study revealed that CD300c may serve as a specific marker for improved detection and enrichment of MDSCs in aging. CD11b+Gr1+CD300c+ cells demonstrated a robust ability of T cell suppression. The universality and applicability of MDSC-specific gene signature have also been demonstrated in human myeloid cells. We also found that MDSCs from aged individuals shared the similar developmental trajectory with their myeloid counterparts, and may develop from mature myeloid cells, both in mice and human beings, which has been reported by a limited number of studies. Overall, our work extends the understanding of MDSCs in aging process.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a7343d247742e2514c816d82197f3a4e427bbbd1" target='_blank'>
              Defining the marker and developmental trajectory of myeloid-derived suppressor cells in aging by single-cell transcriptomics
              </a>
            </td>
          <td>
            Yaru Su, Ruimin Wu, Haochen Ai, Zhaoming Zhong, Lin Zou, Zihan Wang, Kewu Tu, Lingzheng Tang, Jiawen Gao, Yusheng Huang, Congrui Liao, Guanhai Zeng, Hongyang Zhang, Jian Jin, Siyuan Zhu
          </td>
          <td>2025-12-24</td>
          <td>NPJ Aging</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Parvovirus B19 (B19V) is a human ssDNA virus with ample pathogenic potential. It is characterized by a selective tropism for erythroid progenitor cells (EPC), exerting a cytotoxic effect with blockade of erythropoiesis. In our work, we investigated both viral and cellular expression profile in the course of infection of EPCs cultures via mRNA high throughput sequencing technology (HTS) and a dedicated bioinformatic pipeline, reconstructing both the viral and cellular transcriptome and their variations. A productive infection was confirmed as restricted to EPCs expressing mature differentiation markers and the specific receptor for virus VP1u region. mRNA HTS reconstructed the viral transcriptome in terms of localization and abundance of the different mRNA species, detailing the differential expression profile of B19V among early or late times in the course of infection. Analysis of cellular transcriptome indicated that variation was mainly driven by the cellular differentiation process, with the virus impacting to a lesser level, but still clearly separating infected vs. non-infected profiles. At early times post-infection, variations were typical of cellular sensing of viral infection and aimed at the induction of an antiviral state. At later times in the course of infection, the cellular population showed induction of an inflammatory response, related to TNF and IL-10, and a transition to adaptive immunity with evidence of upregulation of genes involved in MHC-II presentation. This dual-transcriptome analysis on infected EPCs population can lay the ground for future research aimed at a better definition of the pathogenetic mechanisms of B19V.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/806a7298c7cd4fe24f376dba0f2979efac7935a0" target='_blank'>
              Parvovirus B19 and Cellular Transcriptome Dynamics in Differentiating Erythroid Progenitor Cells
              </a>
            </td>
          <td>
            Erika Fasano, Niccolò Guglietta, Federica Bichicchi, Ilaria Gasperini, E. Manaresi, Giorgio Gallinella
          </td>
          <td>2025-12-25</td>
          <td>Viruses</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Exhaustion of T cells, characterized by their compromised function and cytokine production, was first discovered in chronic infections and later redefined in the context of immunosuppressed tumor microenvironment (TME). Exhaustion markers include the immune checkpoints PD-1, TIM-3, LAG-3, and TIGIT. Colorectal cancer (CRC), which ranks among the highest in global prevalence, has been associated with exhaustion of T cells. While many trials have focused on anti-PD1 therapeutics in clinical trials, results indicate suboptimal efficacy. A robust approach involved dual blockade of other immune checkpoints together with PD-1. Interestingly, novel exhaustion markers could be used as prognostic markers for the development and progression of CRC. The present work discusses the basics of T cell exhaustion markers and their signaling in CRC. Also, novel combination therapy approaches and challenges in the field are discussed.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a02631f965c15b2749164cf5ae55f1cc2908741" target='_blank'>
              Targeting T cell exhaustion in colorectal cancer: emerging roles of LAG-3, TIM-3, and TIGIT signaling in overcoming immunotherapy resistance
              </a>
            </td>
          <td>
            Pardis Zamani, Erfan Barootchi, Ayda Firouzabadi, Maryam Sadat Tonekaboni, Kiarash Saleki, Niloufar Yazdanpanah, N. Rezaei
          </td>
          <td>2026-01-05</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Phage therapy (PT) is a promising alternative for antibiotic-resistant infections, but its immunomodulatory effects in clinical settings remain poorly understood. This exploratory observational study aimed to characterize pro- and anti-inflammatory gene response patterns in ten patients undergoing personalized PT at the Phage Therapy Unit in Wrocław. Peripheral blood mononuclear cells (PBMCs) and granulocytes were analyzed to assess changes in the expression of 22 selected immune-related genes associated with innate and adaptive immune signaling pathways. While no uniform pattern of immune gene expression was observed across the cohort, individual cases exhibited significant up- or downregulation of specific genes. Interestingly, we identified biological age as a potential determinant of the host response. Specifically, older patients showed higher activation of the innate sensing machinery in PBMCs, characterized by a higher TLR4 fold change which may reflect the “inflammaging” phenomenon. These findings suggest that chronic exposure to bacterial viruses (bacteriophages), unlike many viral infections, does not trigger a predictable, significant systemic immune activation and that immune responses to PT are highly individualized by host- and phage-related biological factors. By documenting this spectrum of real-world responses, our work provides baseline data and hypotheses to guide the rational design of future preclinical and clinical investigations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5ab2b289866cbc1eb0a98219b4968f109c16e453" target='_blank'>
              Analysis of Pro- and Anti-Inflammatory Gene Response Patterns in Patients Receiving Phage Therapy
              </a>
            </td>
          <td>
            Hubert Kasprzak, Maciej Przybylski, W. Fortuna, Sławomir Letkiewicz, Paweł Rogóż, B. Bubak, Andrzej Górski, R. Międzybrodzki
          </td>
          <td>2025-12-23</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="The tumor microenvironment (TME) is a key factor influencing carcinogenesis, disease progression, and therapeutic outcomes. Tumor-associated endothelial cells (TECs), integral components of the TME, form the structural and functional foundation of the vasculature, while also modulating tumor immune responses. TECs regulate immune cell activity and distribution through multiple molecular mechanisms, thereby influencing tumor immunity. Recent evidence highlights TEC-targeted interventions as a promising strategy to enhance immunotherapy efficacy. This review examines the mechanisms through which TECs drive tumorigenesis, progression, and metastasis, and explores the therapeutic potential of TEC-targeted approaches in cancer treatment. It also provides a systematic analysis of TECs’ impact on the immune microenvironment, assessing the potential of TEC-directed therapies to overcome chemoresistance and immunotherapy resistance, thus offering new perspectives for drug development targeting TECs. Finally, the review critically evaluates potential molecular targets within TECs and recent advancements in genetic research for cancer therapy, emphasizing key research priorities and pressing clinical challenges that require urgent focus.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cd5e2322afb5c6ffa7a0363f83b269479ee8db97" target='_blank'>
              Tumor-associated endothelial cells in tumor immune escape and immunotherapy: multifaceted roles and treatment approaches
              </a>
            </td>
          <td>
            Tianyu Zheng, Xinran Yu, Caihong Yu, Wangting Xu, Zhuoyang Fan, Yongjie Zhou, Changyu Li, Juncheng Wan, Chaoqiao Jin, Xuran Jin, Wen Zhang, Zhiping Yan, Peng Luo, Bufu Tang, Xudong Qu
          </td>
          <td>2025-12-24</td>
          <td>Biomarker Research</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Rationale Tuberculosis vaccines aim to elicit protective immunity, with IFNγ-producing CD4⁺ T cells considered central mediators of host defense. In murine models, IFNγ activates macrophages to induce inducible nitric oxide synthase (iNOS), resulting in nitric oxide–dependent control of Mycobacterium tuberculosis (Mtb). Objective To define the relevance of IFNγ-induced iNOS activity in humans and other natural host of virulent mycobacterial species. Methods We systematically compared IFNγ-induced effector responses in Mtb-infected myeloid cells across species. Using bulk RNA sequencing, functional infection assays, and nitric oxide measurements, we assessed IFNγ responsiveness in human and mouse macrophages. These analyses were extended to monocytes from seven mammalian species and complemented by reanalysis of publicly available single-cell RNA-sequencing datasets and spatial proteomic imaging of tuberculous granulomas. Measurements and Main Results Single-cell transcriptomic reanalysis revealed minimal NOS2 expression in myeloid cells from human and non-human primate granulomas. In vitro, IFNγ pretreatment failed to induce NOS2 transcription, iNOS activity, or Mtb growth restriction in human macrophages, in stark contrast to murine cells. Across species, iNOS activity was largely restricted to mice, with limited induction in cattle monocytes. Instead, human respiratory epithelial cells consistently expressed NOS2, and multiplexed ion beam imaging localized iNOS protein to epithelial compartments adjacent to granulomatous lesions. Conclusion IFNγ signaling is uncoupled from iNOS induction in primate myeloid cells and epithelial compartments represent dominant sources of iNOS in human tuberculosis. These findings, challenge murine macrophage–centric paradigms and IFNγ-based correlates used in TB vaccine development and central to pathophysiology of tuberculosis and other pneumonias.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/28994b7df14a803a7e0314e91e0dbcfa85973adc" target='_blank'>
              Species-specific iNOS expression distinguishes epithelial and myeloid IFNγ responses in tuberculosis
              </a>
            </td>
          <td>
            Fabian Stei, Erin F. McCaffrey, Björn Zessin, Jonathan Pioch, S. Simm, B. Stubbe, Ralf Ewert, Frank Verreck, B. Schneider, A. Dorhoi, Bryan D. Bryson, Björn Corleis
          </td>
          <td>2026-01-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/72f3e3fb83d6da5da12fbd024325e0282875f616" target='_blank'>
              Single-cell analysis identifies monocyte signatures of disease activity and clinical subtypes in Behcet disease
              </a>
            </td>
          <td>
            E. Carmona, R. Deniz, C. Bes, H. Direskeneli, A. Gul, A. H. Sawalha
          </td>
          <td>2025-12-27</td>
          <td>None</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Background Hematologic malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma (MM), are characterized by high relapse rates due to intrinsic and acquired drug resistance. Resistance mechanisms often involve dysregulation of apoptosis pathways, such as B-cell lymphoma 2 (BCL2) family overexpression, and immune evasion through microenvironment modulation. Purpose This review synthesizes recent advances (2020–2025) in therapeutic strategies targeting these mechanisms, focusing on BCL2 inhibition and immunomodulatory approaches to overcome resistance and improve outcomes. Methods We systematically reviewed literature from PubMed, Nature, and other databases, emphasizing clinical trials, mechanistic studies, and emerging combinations published between 2020 and 2025. Main Findings: BCL2 inhibitors like venetoclax have achieved high response rates (ORR >70%) in CLL and AML but face resistance via MCL1/BCL-XL upregulation. Next-generation agents (e.g., sonrotoclax) and combinations address this. Immunomodulatory therapies, including immunomodulatory imide drugs (IMiDs) and chimeric antigen receptor T-Cell immunotherapy (CAR-T cells), enhance T/NK cell activity, with objective response rate (ORR) up to 90% in relapsed MM. Integrated strategies combining BCL2 inhibition with immunotherapy show synergistic effects, improving progression-free survival (PFS) by 30%–40%. Conclusion These strategies represent a paradigm shift toward precision medicine, but challenges like toxicity and biomarker-driven resistance persist. Future directions include AI-guided predictions and novel degraders like proteolysis-targeting chimeras (PROTACs).">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3c5cb2617d14710c4cd3eb706ea797aedb7b33bb" target='_blank'>
              Novel therapeutic strategies targeting resistance mechanisms in hematologic malignancies: from BCL2 inhibition to immunomodulatory approaches
              </a>
            </td>
          <td>
            Qianyu Han, Shasha Jiang, Jirui Chen, Lei Xue
          </td>
          <td>2026-01-22</td>
          <td>Frontiers in Pharmacology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with limited responsiveness to immune checkpoint inhibitors (ICIs). Accumulating evidence indicates that tumor-associated macrophages (TAMs) are central regulators of the immunosuppressive tumor microenvironment (TME) and major contributors to immune escape and therapeutic resistance in HCC. TAMs arise from both circulating monocytes and tissue-resident macrophages and exhibit remarkable plasticity, adopting diverse polarization states in response to microenvironmental cues. Beyond the classical M1/M2 paradigm, single-cell and spatial technologies have revealed a continuum of TAM phenotypes with distinct transcriptional, metabolic, and functional properties. These heterogeneous TAM subsets orchestrate angiogenesis, fibrosis, immune suppression, and resistance to immunotherapy. Consequently, TAMs have emerged as attractive therapeutic targets. Strategies aimed at limiting monocyte recruitment, reprogramming M2-like TAMs toward antitumoral phenotypes, exploiting TAMs as drug delivery vehicles, and combining TAM-targeted interventions with ICIs, radiotherapy, anti-angiogenic agents, or nanobiotechnology have shown promising preclinical and early clinical efficacy. This review summarizes current advances in understanding TAM origin, polarization heterogeneity, and functional roles in HCC, and highlights emerging TAM-centered therapeutic strategies that may improve immunotherapy outcomes and enable more precise, durable treatment responses.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a5cb02bcc1ce59f3581a08c421f69f954a98a78b" target='_blank'>
              Rewiring tumor-associated macrophages in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Xue Han, Rui Jin
          </td>
          <td>2026-01-27</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="A recent publication by Qin et al. in Cell reported on the ﬁ rst-in-human application of anti-BCMA chimeric antigen receptor (CAR)- T cell therapy in patients with treatment-refractory progressive multiple sclerosis (MS) with a good tolerability and ef ﬁ cacy. 1 CAR-T cells rank among the breakthrough therapeutic approaches, transforming the ﬁ eld of cancer and autoimmune conditions including neuroimmunological disorders. B-cell maturation antigen (BCMA) and CD19 antigen are B-cell target antigens frequently used in CAR constructs for autoimmune diseases. 1,2 In addition to the B-cell depletion in the peripheral blood, CAR-T cells allow deep depletion of tissue-resident B cells e.g., in lymphoid tissues and hard-to-reach compartments such as the central nervous system (CNS), an effect that has not been observed with antibody-based B-cell depletion therapies. However, little is known about direct and indirect effects of CAR-T cells on microglia, even though CNS-resident microglial cells are involved as one of the key drivers and maintainers of the compartmentalized neuroin ﬂ ammation and neurodegeneration during MS progression. This is con ﬁ rmed by emerging evidence that smoldering neurodegenerative processes are hallmarked by chronic microglia-mediated neuroin ﬂ ammation with progressive axonal injury, resulting in disability progression independent of relapse activity (PIRA) and brain atrophy. 1 To date, none of the available therapies for MS are fully effective at preventing disease progression and PIRA. The emerging study by Qin et al. showed, for the ﬁ rst time, signi ﬁ cant functional improvement during a 9-month">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aadbe175bb178ba56f15991ba7d572d20c6623b1" target='_blank'>
              Anti-BCMA CAR-T cells attenuate microglial activation in progressive multiple sclerosis: indicating a plasma cell-microglia crosstalk
              </a>
            </td>
          <td>
            F. Ismail, Hans-Peter Hartung, Nico Melzer
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Abstract Introduction The cytokine CD137 (TNFRSF9, 4-1BB) is best known as a T cell costimulatory molecule. However, CD137 is also part of a negative feedback mechanism that limits T cell activation, and that is employed by regulatory T cells (Tregs) to prevent an overstimulation of T cells and subsequent autoimmune damage. CD137 has been identified as the gene that most significantly distinguishes intra- from extratumoral Tregs. CD137+ Tregs are more immunosuppressive than CD137− ones, and CD137 levels on intratumoral Tregs correlate with a poor prognosis for cancer patients. In addition, CD137 is also ectopically expressed on several types of malignant cells that usurp this physiological feedback mechanism to evade immune surveillance. This suggests CD137 as a target for eliminating or changing intratumoral Tregs. Here we demonstrate that a murine CD137-specific aptamer can bind to CD137 on malignant cells and T cells and be internalized. Methods and Results We fused the aptamer to short hairpin (sh) RNAs that are specific for Enhancer of zeste homolog 2 (EzH2) or neuropilin-1 (Nrp1), and demonstrated their uptake into CD137+ malignant cells and Tregs, and the subsequent downregulation or EzH2 and Nrp1. Conclusion This study confirms CD137 as a target for tumor immunotherapy and introduces CD137 aptamer-shRNA chimeras as novel tools to be evaluated for their usefulness in cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1541323ab972d605301367d616f74090104c8314" target='_blank'>
              Targeting intratumoral regulatory T cells by CD137 aptamer-shRNA chimeras
              </a>
            </td>
          <td>
            Kang Yi Lee, Yu Mei, Haiyan Liu, Herbert Schwarz
          </td>
          <td>2025-12-22</td>
          <td>Immunotherapy Advances</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="The blood-brain barrier (BBB) is a dynamic, multicellular interface that preserves central nervous system (CNS) homeostasis by restricting entry of pathogens and circulating cells. Cytotoxic T lymphocytes (CTLs), comprising both CD8⁺ and CD4⁺ subsets, are central to adaptive immunity through targeted elimination of infected or transformed cells. However, in immune-mediated neurological disorders, including viral encephalitis, multiple sclerosis, Parkinson’s disease, and glioma, CTLs effector functions can inadvertently compromise BBB integrity. Here, we integrate findings from primary research to delineate three principal mechanisms by which CTLs modulate the BBB: (1) direct cytotoxicity, in which perforin/granzyme release and FasL-Fas interactions induce endothelial cell apoptosis; (2) proinflammatory cytokine signaling, notably IFN‑γ and TNF‑α activation of JAK/STAT and NF‑κB pathways in brain microvascular endothelial cells; and (3) chemokine‑driven leukocyte trafficking, wherein CXCL10 and CCL5 gradients promote CTLs and bystander immune cell migration across the barrier. We further review evidence from in vitro and in vivo models that illustrate both protective and deleterious roles of CTLs at the neurovascular interface. By clearly specifying these mechanisms and their disease‑specific contexts, this review establishes a unified framework for future investigations aimed at preserving BBB function while maintaining effective CTL‑mediated immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ed4112f7eae80c222adb588e38d2d80e2868fcd" target='_blank'>
              Cytotoxic T lymphocytes and their dual role in modulating blood-brain barrier integrity in immune-mediated neurological pathologies
              </a>
            </td>
          <td>
            Bin Li, Wen Xi, Ping Li
          </td>
          <td>2025-12-23</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b364384029e8332616bd3d0f1e05609ce0723cb3" target='_blank'>
              [Research progress of Type II immune responses in cancer therapy].
              </a>
            </td>
          <td>
            Yunfei Dong, Ying Sun, Hongqian Guo, Ke Zeng, Rong Yang
          </td>
          <td>2026-02-01</td>
          <td>Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="ABSTRACT Introduction The immunosuppressive microenvironment of hepatocellular carcinoma (HCC) is shaped by multiple oncogenic pathways, but howosteopontin (OPN), a molecule frequently overexpressed in HCC, regulates anti-tumor immunity remains unclear. Methods To define the mechanism by which OPN modulates the HCC immune microenvironment, with a focus on its regulation of CD155 and its impact on CD8+ T-cell – mediated anti-tumor responses. Results We identified that OPN activates the p65/NF-κB – c-Myc/CD155 signaling axis, leading to robust upregulation of CD155 and impaired intratumoral CD8+ T-cell infiltration and effector activity. These immunosuppressive effects occurred independently of changes in tumor stemness markers or Treg accumulation. Genetic suppression of p65 abrogated OPN-induced CD155 expression and mitigated tumor progression in vivo, demonstrating the pathway’s functional requirement. Discussion OPN drives HCC progression by suppressing CD8+ T-cell immunity through the NF-κB (p65)/c-Myc/CD155 axis. Targeting this pathway may enhance anti-tumor immunity and represents a promising therapeutic strategy for HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/241c4fb9ee39fefaef3e7ced0898ca89a09ca3d0" target='_blank'>
              OPN Promotes Hepatocellular Carcinoma Progression Through the p65/c-Myc/CD155 Axis by Suppressing CD8+ T Cell Infiltration and Activation
              </a>
            </td>
          <td>
            Jincun Fang, Liwei Liu, Zhiying He, Mingqiang Ling, Jiajun Liang, Yingying Lei, Zhenzhen Wen, Jingfeng Guo
          </td>
          <td>2025-12-19</td>
          <td>Immunological Investigations</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Cell-based immunotherapy utilizing regulatory T cells (Tregs) has recently advanced into clinical applications, demonstrating promising results in phase I/II trials to prevent transplant rejection and treat autoimmune diseases. We have completed a clinical trial in renal transplant patients in which the significant biological effect was the increase of B cells with a regulatory phenotype in the blood of kidney transplant patients. The mechanisms by which Tregs regulate B cells and the specific molecules involved in this process remained poorly understood. In this study, we employed an in vitro system of co-culture of peripherally purified B cells and expanded Tregs to show that Tregs can induce a population of memory B cells that express IL-10 and CD25. This subset of B cells has been previously identified as one of humans’ regulatory B cell populations. Notably, these expanded Tregs’ regulation of B cells was found to be independent of IL-10 and reliant on direct cell contact. We established that TIM3 expression by Tregs was crucial for the induction of IL-10-producing CD25+ memory B cells. Our findings suggest that TIM3 is a critical molecule for the induction of regulatory B cells by Tregs, indicating that TIM3 expression by adoptively transferred Tregs is vital in diseases where B cells play a pathogenic role. Expanded Tregs induce IL-10+ CD25+ B cells. TIM3 expression on Tregs is crucial for IL-10+ B cell induction. Tregs require direct cell contact to regulate B cells. Blocking TIM3 reduces IL-10+ B cells but increases IFN-γ, TNF-α, IL-17. Tregs enhance regulatory B cell differentiation, promoting tolerance. Expanded Tregs induce IL-10+ CD25+ B cells. TIM3 expression on Tregs is crucial for IL-10+ B cell induction. Tregs require direct cell contact to regulate B cells. Blocking TIM3 reduces IL-10+ B cells but increases IFN-γ, TNF-α, IL-17. Tregs enhance regulatory B cell differentiation, promoting tolerance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/36e08ef76b3627c90f60b98b669f2c6ed9aaccd5" target='_blank'>
              TIM3-mediated differentiation of IL-10-producing CD25+ B cells by expanded regulatory T cells
              </a>
            </td>
          <td>
            R. Alhabbab, Daniela Mastronicola, Giovanna Lombardi, C. Scottà
          </td>
          <td>2025-12-27</td>
          <td>Journal of Molecular Medicine (Berlin, Germany)</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Bispecific T-cell Engagers (BITEs) are a novel form of immunotherapy that overcome a deficiency of immune checkpoint inhibitors (ICI) by targeting a preidentified tumor associated antigen and redirecting a polyclonal population of effector T-cells against the tumor. High grade serous ovarian cancer is a lethal disease in the recurrent setting and has not been amenable to ICI therapy. MUC16/CA125 is overexpressed in high grade serous ovarian cancer. BITEs targeting the tumor-retained portion of MUC16/CA125 have recently been described and are in early-phase clinical trials. To identify mechanisms of resistance to BITEs, we collected serum, peripheral blood mononuclear cells, and ascites samples from patients with disease progression on MUC16-directed bispecific antibodies. Analysis of these samples showed downregulation of MUC16/CA125, elevated secretion of VEGF, and epithelial-to-mesenchymal transition in tumor cells. Interestingly, hypoxia was determined to be a driver of these changes. These findings were prospectively validated in ovarian cancer cell lines with CRISPR/Cas9 knockout of MUC16/CA125 and VEGF. Peripheral blood mononuclear cells from patients with disease progression were capable of effective cytolysis ex vivo, suggesting that resistance to therapy was primarily tumor driven. Restoration of MUC16/CA125 expression did not restore cytotoxicity in the presence of increased VEGF secretion. Combination treatment with a VEGF inhibitor rescued cytotoxicity in hypoxia-conditioned ovarian cancer cell lines with preserved target antigen expression. Collectively, these data outline a link between hypoxia and the development of resistance to BITEs and posits inhibition of VEGF inhibition as a potentially important therapeutic intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/50276863592076e01725c57fe1f33a7b17e06d98" target='_blank'>
              Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers
              </a>
            </td>
          <td>
            Mengyao Xu, S. Barakzai, Raj Kumar, Irva E Veillard, Eugene Kim, Amy Bregar, Eric Eisenhauer, Richard Penson, S. Bouberhan, Jennifer Filipi, T. Colella, Timothy S. Bond, Caroline Clark, Lawrence H Lin, Jinpeng Ruan, Cheng Wang, Xing-Lei Qin, K. Sarosiek, Bo R Rueda, Cesar M Castro, David R. Spriggs, O. Yeku
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Acute myeloid leukemia (AML) continues to pose significant therapeutic challenges, with high relapse rates driven largely by leukemic stem cells (LSCs), a rare, therapy-resistant population with self-renewal capacity, niche adaptation, and the ability to re-initiate disease. In this state-of-the-art review, we synthesize recent advances in LSC biology, addressing (i) how LSCs differ functionally and phenotypically from normal hematopoietic stem cells (HSCs), (ii) practical approaches for LSC quantification using multiparameter flow cytometry and LSC-enriched marker panels, (iii) the dysregulated signaling, metabolic and epigenetic programs that enable LSC persistence under chemotherapy and contribute to measurable residual disease, and (iv) current therapeutic strategies targeting LSC eradication, including antibody-based therapies, apoptosis and metabolic inhibitors, and emerging epigenetic agents. We also examine the key translational barriers, particularly antigen overlap with normal progenitors, microenvironmental protection, and the need for assay harmonization, while proposing a practical framework for integrating LSC assessment into risk stratification and therapeutic development.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3cd1cbd5980c8002b0d9b3730098739618a3c127" target='_blank'>
              Decoding Leukemic Stem Cells in AML: From Identification to Targeted Eradication
              </a>
            </td>
          <td>
            E. Apostolidou, Vasileios Georgoulis, Dimitrios Leonardos, Leonidas Benetatos, Eleni Kapsali, E. Hatzimichael
          </td>
          <td>2026-01-30</td>
          <td>Diseases</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Glucocorticoids (GCs) are known for their anti-inflammatory potential, which includes the macrophage polarization into an anti-inflammatory and tissue remodeling state. GCs are routinely co-administered to cancer patients to alleviate the side effects of chemotherapy. However, it is not well known if GCs can modulate tumor-associated macrophages (TAMs) to promote tumor progression. Here, we show that dexamethasone (DEX) induces dose-dependent differentiation of THP-1 monocyte-derived anti-tumorigenic (M1) macrophages into pro-tumorigenic (M2-like) macrophages, even in the presence of M1 cues, and that DEX can repolarize fully differentiated M1 macrophages into an M2-like state. These macrophages have a cytokine profile similar to the pro-tumorigenic (M2) macrophages and can stimulate the proliferation and invasion of triple-negative breast cancer (TNBC) cells in vitro. DEX treatment of an orthotopic mouse model of TNBC attenuated paclitaxel-mediated tumor growth inhibition, increased M2-like TAMs in primary tumors, and enhanced lung metastasis. Transcriptomic analysis of DEX-treated M1 macrophages revealed not only transcriptomic overlap with M2 macrophages, but also with human breast cancer TAM transcriptomic data, and further to a specific TAM signature associated with aggressive estrogen receptor-negative breast cancer. Our study illustrates a remarkable macrophage repolarization plasticity upon DEX exposure that can promote tumorigenesis, warranting care in prescribing high doses of GCs to breast cancer patients, especially to those considered for chemotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/13ba2aca7a65c995d23e6a0cfbaa06b3762a101f" target='_blank'>
              Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness
              </a>
            </td>
          <td>
            Mohamed M. Shamekh, Birgitta Lindqvist, I. Nalvarte
          </td>
          <td>2025-12-19</td>
          <td>Cell Death & Disease</td>
          <td>1</td>
          <td>22</td>
        </tr>

        <tr id="Beyond their traditional role as short-lived antimicrobial cells, neutrophils are increasingly recognized as key regulators of adaptive immunity and tumor progression. This AI-assisted integrative review investigated the neutrophil–T-cell axis, particularly the role of Galectin-9 (Gal-9), across adult T-cell leukemia/lymphoma (ATL), Sézary syndrome (SS), coronavirus disease 2019 (COVID-19), and psoriasis. Leveraging AI tools (GPT-5 and Adobe Acrobat AI Assistant) for literature synthesis (2000–2025) and expert validation, we aimed to identify common immunological mechanisms. Across all conditions, neutrophils displayed persistent activation, elevated Gal-9 expression, and modulated T-cell interactions. In ATL and SS, neutrophilia correlated with poor survival and TCR signaling dysregulation, suggesting Gal-9-mediated immune modulation. In COVID-19 and psoriasis, neutrophil-derived Gal-9-linked innate hyperactivation to T-cell exhaustion and IL-17-driven inflammation. These findings define a recurring neutrophil–Gal-9 regulatory module connecting innate and adaptive immune responses. This study underscores the feasibility of combining AI-driven literature synthesis with expert review to identify unifying immunological mechanisms and therapeutic targets across malignancy and inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6f09c2cd18cebd70f857746a605633d6065276e4" target='_blank'>
              Neutrophil–Galectin-9 Axis Linking Innate and Adaptive Immunity in ATL, Sézary Syndrome, COVID-19, and Psoriasis: An AI-Assisted Integrative Review
              </a>
            </td>
          <td>
            Toshio Hattori
          </td>
          <td>2025-12-31</td>
          <td>Reports - Clinical Practice and Surgical Cases</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Immunotherapy often fails in solid tumors due to an immunosuppressive tumor microenvironment, driven in part by dysfunctional dendritic cells impairing antigen presentation, and suppressive neutrophils. Recent studies revealed a non-canonical role for neutrophils in antigen presentation (nAPC), whose frequency in tumors correlates with improved prognosis in several human cancers. Here, we show that an intravenously delivered antibody-antigen-conjugate (AAC) targeting neutrophil FcγRIIIB reprograms neutrophils into nAPCs that drive robust CD8⁺ T cell activation. This response requires neutrophils and their expression of MHC-I and occurs independently of conventional type-1 dendritic cells (cDC1), demonstrating that nAPCs can compensate for cDC1 deficiencies. In a mouse melanoma model, AAC therapy promotes durable immunity limiting metastases of Ova-negative tumors in the lung and contralateral skin, with tumor burden inversely correlating with intratumoral nAPC frequency. AAC treatment efficacy is attributed to tumor infiltration by antigen-specific CD8⁺ T cells, NK cells, and memory TSCM and TRM cells recognizing both the target antigen and melanocyte-lineage antigens, consistent with effective epitope spreading, which could overcome tumor heterogeneity and antigen loss. Mechanistically, the spleen is required for T cell priming and tumor infiltration, suggesting AAC engages a cancer-spleen axis that bypasses the dysfunctional tumor-draining lymph node (LN). Both CD8⁺ T cells and NK cells are essential for tumor control. Co-treatment with anti-PD-1 enhances tumor regression and metastasis control, while anti-PD-1 alone is ineffective. In summary, AAC therapy reprograms neutrophils to initiate potent T cell immunity, offering a novel strategy to break immune exclusion and enhance anti-PD1 therapy in solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/56237fa16d9e6e3926a34a6b0c6bbd5ad6612198" target='_blank'>
              Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Anti-Tumor Immunity.
              </a>
            </td>
          <td>
            Huan Wang, Qi Meng, Yoshimasa Ito, Kanupriya Kusumakar, Tanya Mayadas
          </td>
          <td>2026-02-09</td>
          <td>Cancer research communications</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Multiple myeloma (MM) develops in the hypoxic bone marrow (BM) microenvironment, which alters tumor behavior and immune responses. While hypoxia is known to directly suppress immune function, its effect on immunotherapy-relevant antigen expression and the MM secretome remains underexplored. Here, we investigated how hypoxia affects BCMA expression and BCMA-targeted CAR T cell responses. MM cells were cultured under normoxia (21% O₂) or hypoxia (1% O₂). BCMA surface and total expression were analyzed. Anti-BCMA CAR T cells were co-cultured with normoxic or hypoxic MM cells to assess cytotoxicity and cytokine release. Conditioned media and small extracellular vesicles (sEVs) were isolated, quantified, and RNA-profiled. MM cells cultured in hypoxia showed reduced BCMA surface and total protein expression, resulting in reduced CAR-mediated signaling. Importantly, the hypoxic tumor secretome further reduced BCMA levels and significantly impaired CAR T cell killing and cytokine production, which was partially reversible by γ-secretase inhibition. To dissect the suppressive nature of the hypoxic secretome, we identified an increase in small extracellular vesicle (sEV) release under hypoxia. RNA profiling of sEVs revealed a hypoxia-induced RNA signature with potential immunomodulatory roles. This study shows that hypoxia diminishes BCMA expression and enhances secretion of immunosuppressive factors, including sEVs, thereby limiting the efficacy of BCMA CAR T cell therapy in MM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/32804a5eae759659f84b5610dc79fafee9f0e914" target='_blank'>
              Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
              </a>
            </td>
          <td>
            Chenggong Tu, A. Van der Vreken, Fien Meeus, Lauren van den Broecke, Jack Brons, K. De Veirman, K. Vanderkerken, E. De Bruyne, Karine Breckpot, E. Menu
          </td>
          <td>2026-01-08</td>
          <td>Experimental Hematology & Oncology</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="CD38 is a transmembrane glycoprotein involved in NAD+ metabolism, calcium signaling, and immune cell activation. Its role in the inflammatory response has been studied extensively in innate immune cells; however, its contribution to the activation of memory T lymphocytes under inflammatory conditions is less understood. Additionally, recent studies have shown an age-related increase in the expression of the protein CD38 in various human and murine tissues. Moreover, CD8+ bystander T cells have been shown to contribute to inflammation during the aging process. Given the importance of its potential role in age-related pathologies, we examined the effect of CD38 on bystander activation of CD8+ memory T cells in aged mice following lipopolysaccharide challenge. CD38-deficient mice exhibited attenuated serum cytokine responses (IL-1β, IL-6, IFN-γ, and IL-10) and a distinct CD8+ T cell profile, characterized by a decrease in activated T cells. Wild-type mice displayed a significant expansion of CD69+TCM cells after LPS inoculation, an effect that was absent in CD38-deficient animals. LPS also promoted the expression of CD69 and CD38 in TEM/EFF subsets. Thus, our findings reveal a CD38-dependent mechanism underlying bystander activation of memory CD8+ T cells in aging. Highlighting the potential contribution of CD38 to age-related diseases, such as autoimmunity, and in the face of inflammatory conditions in aged people.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c2543f635ae92595d3f140c2ea47a35fc4eab9dd" target='_blank'>
              CD38 promotes LPS-induced innate-like activation and proliferation of CD8+ T lymphocytes in aged mice
              </a>
            </td>
          <td>
            Wendolaine Santiago-Cruz, Enrique Espinosa, Jocelyn C Pérez-Lara, Héctor Romero‐Ramírez, Priyadharshini Devarajan, Fabio García-García, J. C. Rodríguez-Alba
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Aging</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bcaf29e7d36c896ae0340a15249e26f5fa8f55aa" target='_blank'>
              Extracellular vesicles in colorectal cancer: immunomodulation, diagnostics, and therapeutic perspectives
              </a>
            </td>
          <td>
            Ridhiksha Kumra, Rohit Rai, Raman Thakur
          </td>
          <td>2026-02-05</td>
          <td>Medical Oncology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Hypoxic tumor microenvironment (TME) is a common occurrence in the development of solid tumors, which activates hypoxia-inducible factors (HIFs) and their downstream signaling pathways in cancer cells to facilitate tumor progression and immune escape. However, among the various immune cells that constitute innate and adaptive immune systems, HIFs have a more intricate function; moreover, different isoforms of HIFs play different functions under spatial and temporal conditions. HIFs are conducive to the adaptation of various immune cells to the hypoxic TME. The stability of HIF-α can regulate metabolism and directly regulate the expression of immune genes. Additionally, the activation of HIF signaling may also inhibit the development of immune cells in some tumor environments, affecting the antigen recognition and killing processes to assist cancer cells in immune escape. Therefore, understanding the relationship between HIF signaling and immune cells more comprehensively may yield substantial benefits for the immunotherapy of various types of cancer. The present study reviewed the role of HIFs in immunity, including their role in T cells, B cells, macrophages, neutrophils, dendritic cells and natural killer cells. It also discussed the effectiveness of HIF targeted therapy in clinical application, the challenges associated with it and the development of a precise targeting drug delivery system. The present review may help researchers comprehend the tumor immune process in a hypoxic microenvironment. It aimed to offer novel strategies for cancer immunotherapy and prolonging the overall survival of patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2f2959e24720a9bfcd6ba812398c12fc625e1637" target='_blank'>
              Regulatory networks of HIFs in tumor-infiltrating immune cells: From molecular mechanisms to therapeutic implications (Review)
              </a>
            </td>
          <td>
            Chaoqun Li, Chenge Qin, Xingchen Li, Jinzhu Wang, Yang Li, Qin Sun
          </td>
          <td>2026-01-12</td>
          <td>International Journal of Oncology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Bacteria-based cancer immunotherapies are regaining attention due to recent advances in understanding the mechanisms underlying their efficacy, making them promising tools for cancer treatment. Among these, Salmonella stands out as one of the most extensively studied microorganisms in this field. Its ability to directly induce tumor cell death while stimulating the immune system offers unique therapeutic advantages, as cell death within an inflammatory environment may enhance the release of tumor antigens and promote effective antitumor immune responses. Although multiple studies have addressed Salmonella-induced cell death, the nomenclature and classification of death modalities are often inconsistent—either because earlier reports predate the formalization of certain death pathways, or due to overlapping criteria between different types of cell death. This review aims to comprehensively analyze the available evidence on Salmonella-induced apoptosis, pyroptosis and autophagy, as well as other less characterized death modalities. Given that most mechanistics evidence on Salmonella-induced cell death has been generated in myeloid cells, we primarily focus on the myeloid compartment while integrating available observations from tumor cells and other immune populations when relevant, organizing the existing data under current definitions and concepts, and highlighting the challenges of manipulating these pathways to optimize bacterial-based immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/069ad99e795c93842bb8c408455bb719ffbb2405" target='_blank'>
              Salmonella-Induced Cell Death in Cancer Immunotherapy: What Lies Beneath?
              </a>
            </td>
          <td>
            A. Mónaco, Sofía Chilibroste, María Clara Plata, J. Chabalgoity, María Moreno
          </td>
          <td>2025-12-20</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Glycolysis, commonly used by malignant tumors for energy production, results in acidification of the tumor microenvironment (TME) through the secretion and accumulation of lactic acid. Acidosis is a potent inhibitor of immune cell function and may therefore affect T-cell infiltration and the efficacy of immunotherapy. This study aimed to characterize the metabolic tumor microenvironment and its association with lymphocyte distribution in patients with advanced melanoma treated with immune checkpoint blockade (ICB) therapies. Pre-treatment formalin-fixed, paraffin-embedded metastatic melanoma specimens from 45 patients treated with anti-PD-1 ± anti-CTLA-4 ICB were included in this study. Patients with progression-free survival (PFS) ≥ 6mo were categorized as responders (n = 23), while non-responders had a PFS < 6mo (n = 22). Two custom multiplex immunofluorescence panels were developed to evaluate the expression and distribution of markers of a hypoxic microenvironment (CA9 and HIF1α), glycolysis (GLUT1 and GLUT3) and vessels (CD31) in relation to melanocytes (SOX10) and T lymphocytes (CD3). GLUT1 + melanoma regions contained significantly lower proportions of CD3+ T-cells than GLUT1- regions (p < 0.0001). Responders displayed significantly higher proportions of intratumoral T-cells expressing GLUT1 (p = 0.049) and GLUT3 (p = 0.043) compared to non-responders. CD3+ T-cells co-expressing hypoxia-associated markers were present in higher proportions significantly closer to GLUT1+ melanoma cells in responders compared to non-responders (p < 0.05). Patients with higher proportions of CD3+ T-cells and CD3+CA9+ T-cells within the 20 µm distance to GLUT1+ melanoma cells had significantly longer progression-free survival (p = 0.0133 and p = 0.0378, respectively). Together, these findings support the hypothesis that the presence of glycolysis in melanoma (as inferred by increased GLUT expression) may affect the ability of T-cells to infiltrate tumors and function effectively. The results also suggest that the overall proportion and spatial distribution of GLUT+ T-cells, including those displaying evidence of adaptation to a hypoxic/acidic TME, may be relevant for responses to ICB therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cd8fd44ca9137efe21b148f0b54536a64d278319" target='_blank'>
              GLUT1 expression, lymphocyte distribution and CD3+ T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma
              </a>
            </td>
          <td>
            E. Paver, T. N. Gide, Zarwa Yaseen, Paola Cornejo-Páramo, Peter Ferguson, Nigel G. Maher, A. Menzies, Matteo S. Carlino, I. D. da Silva, Jeff Holst, G. Long, R. Scolyer, J. Wilmott
          </td>
          <td>2026-01-20</td>
          <td>Journal of Experimental & Clinical Cancer Research : CR</td>
          <td>0</td>
          <td>58</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a85afdff22ae96afa7e975dddb2b63ea9aa9cd29" target='_blank'>
              Microbiota-induced T cell plasticity enables immune-mediated tumour control.
              </a>
            </td>
          <td>
            T. Najar, Yuan Hao, Yuhan Hao, Gabriela Romero-Meza, Alexandra Dolynuk, Emma Almo, Dan R. Littman
          </td>
          <td>2026-01-14</td>
          <td>Nature</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="ABSTRACT Gammaherpesviruses are ubiquitous pathogens that establish lifelong infection and are associated with the development of cancer and multiple sclerosis. Unlike other viral families, gammaherpesviruses selectively target B cells to establish chronic infection. Specifically, gammaherpesvirus-driven differentiation of latently infected cells through the germinal center supports chronic infection and seeds viral lymphomagenesis. CD11c+ B cells are induced by most viral infections and are also observed in aged individuals and autoimmune diseases. Classically, CD11c+ B cells differentiate via an extrafollicular pathway that does not involve germinal center response, generating antibodies of beneficial (antiviral) or pathogenic (self-reactive) nature. While CD11c+ B cells are induced during B cell-tropic gammaherpesvirus infection, their role in chronic infection remains poorly defined. Here, we demonstrate that infection of the CD11c+ B cells, including those expressing germinal center markers, contributes to the overall latent gammaherpesvirus reservoir during natural infection. Both T-bet+ and T-betneg CD11c+ B cell subsets expanded and underwent germinal center differentiation during chronic gammaherpesvirus infection. Furthermore, B cell-intrinsic T-bet expression attenuated the long-term latent viral reservoir, gammaherpesvirus-driven germinal center responses, and differentiation of self-reactive B cells. In summary, our study for the first time defines CD11c+ splenic B cells as a reservoir of latent gammaherpesvirus during mucosal chronic infection and reveals an important role of T-bet+ B cells in controlling long-term infection and gammaherpesvirus-driven pathogenic host processes. IMPORTANCE Gammaherpesviruses are ubiquitous pathogens that are associated with cancer and multiple sclerosis. These viruses selectively infect B cells and drive their differentiation through the germinal center response to establish chronic infection. Here, we demonstrate that gammaherpesvirus infection drives expansion and germinal center-based differentiation of CD11c+ B cells that host the latent viral reservoir. We also show that B-cell-intrinsic T-bet expression is important for control of long-term gammaherpesvirus infection and pathogenesis. Gammaherpesviruses are ubiquitous pathogens that are associated with cancer and multiple sclerosis. These viruses selectively infect B cells and drive their differentiation through the germinal center response to establish chronic infection. Here, we demonstrate that gammaherpesvirus infection drives expansion and germinal center-based differentiation of CD11c+ B cells that host the latent viral reservoir. We also show that B-cell-intrinsic T-bet expression is important for control of long-term gammaherpesvirus infection and pathogenesis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fda0daf287e8f1845c7b1577feccd843195e7ec0" target='_blank'>
              A combination of proviral and antiviral roles of CD11c- and T-bet-expressing B cells defines parameters of chronic murine gammaherpesvirus infection
              </a>
            </td>
          <td>
            Erika R. Johansen, Xander G. Bradeen, Emily V. Xie, Bonnie N. Dittel, Elizabeth A. Leadbetter, V. Tarakanova
          </td>
          <td>2026-01-30</td>
          <td>mBio</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Multiple myeloma (MM) is a hematologic malignancy driven by clonal expansion of malignant plasma cells. Despite the long-term disease control achieved with immunotherapies in some patients, treatment resistance remains a major cause of disease relapse. Accumulating evidence highlights the tumor immune microenvironment, especially macrophages, as a key contributor to immunotherapy failure in MM. Herein, we identified a subset of MM-associated macrophages with high expression of fibroblast activation protein alpha (FAPα), defined as FAPα+ macrophages. Clinical data showed that FAPα+ macrophages were enriched in the bone marrow versus peripheral blood of MM patients, and their abundance positively correlated with tumor burden. In MM mouse models, depletion of FAPα+ macrophages significantly boosted the efficacy of anti-PD-1/PD-L1 antibody therapy but not anti-CTLA-4 therapy; this combinatorial strategy also exerted enhanced anti-tumor effects in EL4 lymphoma and CT26 colorectal carcinoma models. Mechanistically, FAPα stabilized PD-L1 expression by maintaining its N-glycosylation and inhibiting proteasomal degradation, and induced PD-L1 synthesis via promoting vimentin (VIM) phosphorylation at the S72 residue. Additionally, FAPα+ macrophages accelerated T cell senescence by secreting soluble FAPα. Collectively, our findings demonstrate that FAPα+ macrophages mediate MM immune evasion via dual mechanisms, positioning them as promising therapeutic targets to potentiate anti-tumor immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4fdd98a62af104734c7d9ca3e69d0c38a4399f57" target='_blank'>
              FAPα+ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence.
              </a>
            </td>
          <td>
            Huiyao Gu, Zhenfeng Dai, Xi Huang, E. Zhang, Xinyuan Dai, Haoguang Chen, Wen Cao, Jinna Zhang, Yifan Hou, Haimeng Yan, Yang Yang, Li Yang, Yi Li, Wenlong Lin, Zhen Cai, Jingsong He
          </td>
          <td>2026-01-30</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="T cells are central mediators of adaptive immunity, playing a pivotal role in eliminating pathogens and tumor cells. In the context of chronic infections and cancer, however, persistent antigenic stimulation drives T cells into a state of exhaustion characterized by diminished effector function, sustained expression of inhibitory receptors, and profound metabolic reprogramming. Emerging evidence indicates that T cell exhaustion is not irreversible and can be alleviated through immune checkpoint blockade, such as targeting PD-1. Moreover, increasing attention has been directed toward the role of intracellular metabolic pathways in shaping T cell fate and function. Strategies aimed at enhancing nutrient availability and metabolic fitness offer an additional avenue to restore T cell activity. This review highlights recent advances in reversing T cell exhaustion through immune checkpoint inhibitors and nutritional interventions, providing novel insights into the precision and personalization of cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/27a9b0dc0b8ecdaf2d6b4f7e25bb9f887a5b8086" target='_blank'>
              Nutritional intervention alleviates T cell exhaustion and empowers anti-tumor immunity
              </a>
            </td>
          <td>
            Yuqi Xu, Wenhui Yuan, Ke Li, Peng Li
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Colorectal cancer (CRC) exhibits limited responsiveness to immune checkpoint inhibitors (ICIs), largely due to its immunosuppressive tumor microenvironment (TME) and poor baseline immunogenicity. Here, we report that Pseudomonas aeruginosa (P. aeruginosa) triggers caspase-3–dependent pyroptosis in murine CRC MC38 cells, characterized by GSDME cleavage, intracellular reactive oxygen species (ROS) accumulation, and the release of damage-associated molecular patterns (DAMPs). This form of immunogenic cell death promotes robust inflammatory cytokine secretion, upregulation of PD-L1 on tumor cells, and functional maturation of bone marrow–derived dendritic cells (BMDCs) in vitro. In vivo, intratumoral injection of P. aeruginosa leads to significant reprogramming of the TME, including increased expression of proinflammatory genes, DC maturation, and enhanced infiltration of CD8+ T lymphocytes. Notably, combination therapy with P. aeruginosa and an anti-PD-L1 antibody results in synergistic tumor regression, markedly outperforming either monotherapy, without inducing detectable systemic toxicity. Together, our findings reveal that P. aeruginosa-induced pyroptosis serves as a potent immunogenic stimulus that reshapes the CRC tumor microenvironment and overcomes resistance to immune checkpoint blockade. This strategy represents a promising approach to enhance immunotherapy efficacy in poorly immunogenic solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/14d2a753150ca0c9ea9da3203e435c6eae383d87" target='_blank'>
              Pseudomonas aeruginosa induces tumor pyroptosis and immune activation to enhance checkpoint blockade in colorectal cancer
              </a>
            </td>
          <td>
            Yanan Hu, Rong Li, Jiaxi Feng, Ningyi Sun, Wei Zheng, Xin Jin, Guodong Wang, Yi He, Yiwei Hao, Jun Zhang, Ke Ren, Xin Wu
          </td>
          <td>2026-01-01</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>2</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2025', '2026'],
    y: [5, 7],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>